|
|
·|û¡GCliff10135274 µoªí®É¶¡:2017/5/7 ¤U¤È 11:02:30
|
¡u¤ß®®¥ÍÂå¥H¯f±wªº»Ýn¬°Àu¥ý¦Ò量¡A±Mª`©ó¤¤¼Ï¯«¸g¯e¯f»â°ì¡AÂåÀø»Ý¨D©|¥¼³Qº¡¨¬ªº³¡¥÷¶i¦æ·sÃĬãµo¡C¡v ´Á³\ª©¤W½Ñ½å¡A¥H¤ß®®²£«~ªº°ò¥»±¡B¥«³õÄvª§¹ï¤â°ÊºAµ¥°T®§´£¨Ñ±´°Q¡A»P¥t¤@Ó¡u¤ß®®¥ÍÂåÄw½X°lÂÜ©«¡vª©°µ¥X°Ï¹j¡A¤]Åwªï¥t¶}¡u§Þ³N¤ÀªRª©¡v»P¡u²á¤Ñª©¡v¡AÅý¦Uª©Äݩʧó©ú½T¡A¥H«Kª©¤ÍŪ¨ú¡C Ų©ó¥i¯à¹ï¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¹B§@·P¨ì¯¥Í¡A«Øij¥ý¨ã³Æ¬ÛÃö°ò¥»»{ÃÑ«á¸û¯àº¥¤J¨Î¹Ò¡C ¥Bê©ó¥»ª©µLªkÅã¥Ü¹Ï«¬¸Ñ»¡¡A«Øij¥ý°Ñ¦Ò¥H¤U¸ê®Æ¡C ¡uliaw6575¡v¡G¡uhttp://liawbf.pixnet.net/blog¡v¡C·PÁ»·¦b«n¥xÆWµoÁnªº¹ù¤j¤j¨¯¶Ôªº¯Ñ¯Ð¡C ¡uSNOOPYÁ¿¥j¡v¡G¡]ì§}¤wÃö³¬¡F¦ýºô§}«O¯d¦b¦¹¤£§R°£¡A¬O¬°¤F·PÁ¦ѥv¤j¤j´¿¸gµL¨pªº¥I¥X¡C¡^¡umychannel.pchome.com.tw/channels/s/n/snoopychiang/content.htm?page=1&ord=v&vol=100¡v |
|
·|û¡G³¯ÀR10141886 µoªí®É¶¡:2018/6/30 ¤U¤È 05:50:05²Ä 349 ½g¦^À³
|
³o¨Ç·Q¹³¥¼¨Óªº°Q½×¹ê¦b¨S¦³¥²n¡B¨S¦³¯q³B¡B±Ð±Â説ªº²M·¡¡B¤£©y綫¤W¤½¶}°Q½×¡C·R¤§¾A¨¬¥H®`¤§¡A¯E¹©®×¤£¤]¬O¼ö¤ß¹L«×¡B±Àªi§UÄi¡B°Q½×ªº¸¤W¤Ñªºµ²ªG |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/30 ¤U¤È 03:24:36²Ä 348 ½g¦^À³
|
liaw6575¤j¤j ªºªÑªF·|¤ß±o ¼Wª©¦h¦¸ ½Ð¦³¿³½ì¥B¥u¬Ý¤@¦¸ªº¤j¹ÙÌ ¦A°Ñ¦Ò liawbf.pixnet.net/blog/post/48002196 ÁÂÁ ¤p³ì¤jªº¦A»¡©ú ¤pªº¤F¸Ñ ÁÂÁ kim ¤j §d¨ÎÀM ¤j ¥t¦³¬ü°ê©M»´äªºÃÒ©Òµ|¨î ´£½Ð°Ñ¦Ò©Î°Q½× ©Î½ÐÀ´µ|ªkªº¤j¤j±Ð¾Ç»¡©ú ÁÂÁÂ! ºK¦Û ù©ú±Ó ¥ý¥Í¡]Ming-Ming Lo¡^ ªº¤j¤å ( ´Â¶§¬ì§Þ¤j¾Ç°]°Èª÷¿Ä¨tÁ¿®v ) www.cyut.edu.tw/~finance/10/download/2014-12/2014v2-4.pdf ¬ü°ê¦a°Ï ÃÒú³¥æ©ö©Ò±oµ|¡]2013 ¦~ªk®×1¡^ (1)Ó¤H ¨Ö¤J¤@¯ë©Ò±o½Òµ|¡A°Ï¤Àµu´Á(12 Ó¤ë¥H¤º)»Pªø´Á(12 Ó¤ë¥H¤W)¸ê¥»§Q±o¡C a.µu´Áµ|²v¡G10%~35%(2013 ¦~«e)¡F15%~39.6% (2013 ¦~«á) b.ªø´ÁÀu´fµ|²v¡G0%~15%(2013 ¦~«e)¡F10%~20%(2013 ¦~«á) ¸ê¥»·l¥¢¥i©è´î¸ê¥»§Q±o¡A±©¨C¦~³Ì°ª¤£¶W¹L 3,000 ¬ü¤¸¡C·í¦~«×¥¼©è´î§¹²¦ªÌ¡A¥i»¼©µ©ó¥H«á¦~«×Ä~Äò¦©©è¡C (2)ªk¤H ¨Ö¤J¤½¥q©Ò±o½Òµ|¡A³Ì°ªµ|²v 35%¡C ·í¦~«×¸ê¥»·l¥¢±o»P·í¦~«×¸ê¥»§Q±o©è´î¡C·í¦~¥¼©è´î§¹²¦ªÌ¡A¥i©¹«e¦^·¹ 3 ¦~¡A©Î«O¯d©ó¤§«á 5 ¦~©è´î¡A¦pÁÙ¤£¯à©è´î§¹²¦¡A«h¤£±o¦A©è´î¡C (3)¥~°êÓ¤H ¦p²Å¦X¥~°ê¤H¸ê®æ(¤@¦~¤º©~¦í¤Ñ¼Æ¤£¨ì 183 ¤Ñ¡A«D©~¥Á)¡A«h§K½Ò¸ê¥»§Q±oµ|¡C (4)¥~°êªk¤H¡G¤@¯ë§Kµ|¡C »´ä¦a°Ï(ì«h¤W§Kµ|¡A¹ï±M·~§ë¸êªÌ½Ò¼x) ÃÒú³¥æ©ö©Ò±oµ| (1)Ó¤H ì«h¤W§Kµ|¡C ¦ý¹ï¥X°â¦³»ùÃÒ¨éºc¦¨¦b»´ä¦a°Ï±q¨Æ·~°È¬¡°ÊªÌ½Ò¼x¸ê¥»§Q±oµ|¡C¤@¯ë«D±q¨Æ·~°È¬°¥DªºÓ¤H¡Aì«h¤W¹ï¸ê¥»§Q±o¤£¼xµ|¡A¦ý¹ïµu½u¥æ©ö³¡¤À¡A¦pªG§ë¸êªÌ¦bµu´Á¤ºÀWÁcª£§@¦ÓÀò§Q¡A¨Ì¨ä¥æ©ö¦æ¬°²£¥Í¤§©Ò±o¥i³Qµ|°È§½µô©w¬°¨ãÀç§Q©Ê¤§¸gÀç©Ò±o¡A¨Ö¤J¨ä¥L©Ò±op徴¡C ¸ê¥»§Q±oµ|µ|²v¡G±M·~§ë¸êÓ¤H 15%¡C (2)ªk¤H ì«h¤W§Kµ|¡C ¦ý¹ï¥X°â¦³»ùÃÒ¨éºc¦¨¦b»´ä¦a°Ï±q¨Æ·~°È¬¡°ÊªÌ½Ò¼x¸ê¥»§Q±oµ|¡C¤@¯ë«D±q¨Æ·~°È¬°¥Dªºªk¤H¡Aì«h¤W¹ï¸ê¥»§Q±o¤£¼xµ|¡A¦ý°w¹ïµu½u¥æ©ö³¡¤À¡A¦pªG§ë¸êªÌ¦bµu´Á¤ºÀWÁcª£§@¦ÓÀò§Q¡A¨Ì¨ä¥æ©ö¦æ¬°²£¥Í¤§©Ò±o¥i³Qµ|°È§½µô©w¬°¨ãÀç§Q©Ê¤§¸gÀç©Ò±o¡A¨Ö¤J¨ä¥L©Ò±op¼x¡C ¸ê¥»§Q±oµ|µ|²v¡A±M·~§ë¸êªk¤H 16.5%¡C (3)¥~°êÓ¤H»Pªk¤H a.¥X°â¦³»ùÃÒ¨éºc¦¨¦b»´ä¦a°Ï±q¨Æ·~°È¬¡°ÊªÌ¡A¥B¦b»´ä¦a°ÏªºÃÒ¥æ©Ò¶i行¶R½æ¡A¶·½Ò¼x利±oµ|¡C b.¥X°â¦³»ùÃÒ¨é不ºc¦¨¦b»´ä¦a°Ï±q¨Æ·~°È¬¡°ÊªÌ¡A¨Ìµ|°È±ø例²Ä 14 ±ø¤§³W©w¡A§K¼x利±oµ|¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G§d¨ÎÀM10141531 µoªí®É¶¡:2018/6/30 ¤U¤È 12:04:55²Ä 347 ½g¦^À³
|
²q·Q¤j¡CÁÂÁÂÀ°¦£¡C¤p§Ì¯u¬O¤ÓºF·\¤F¡C°Ó¼Ð³£¤£ª¾¹D¡C·PÁ¡C |
|
|
·|û¡G¤p³ì10135960 µoªí®É¶¡:2018/6/29 ¤U¤È 05:36:46²Ä 346 ½g¦^À³
|
²q·Q¤j,±z»~·|§Úªº·N«ä¤F §Ú¬O«ü±Ð±Â¹ï¤½¥q¥¼¨Ó¤è¦V¤wÁ¿ªº«Ü²M·¡¥¼¨Ón°µªº¨Æ ³Ì«n¬OªÑÁ{·|ªºÄ³®×,¦p¦¹¦Ó¤w |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/29 ¤W¤È 10:50:38²Ä 345 ½g¦^À³
|
¹ï¤£°_! ¤p³ì¤j ¹ï¤£°_! ¤j¹ÙÌ ¤pªº²VµM§Ñ¤F½²±Ð±Âªº©ú¥Ü ½Ð¤j®a´N¦¹¥´¦í ¤£n¦A°Q½× ÁÂÁ¤j®aªº¦X§@! ÁÂÁ¤j®a! |
|
|
·|û¡Gkim10134548 µoªí®É¶¡:2018/6/29 ¤W¤È 10:16:24²Ä 344 ½g¦^À³
|
¦p¦ó¯à¦¨¬°°ê»Ú¤Æªº¤½¥q¡H ³Ì¦nªº¤èªk´N¬O§ä¬ÛÃöªº°ê»Ú¤jÃļt¤JªÑ¡q¨p¶Ò¡r¦¨¬°¤jªÑªFÅo¡I ´N¥Ø«e¤½¥q©Ò³Ñ²{ª÷µL´X¡A¥[¤W«Ü¦h¤G¡B¤T´ÁÁ{§Én³°Äò±Ò°Ê¡A ¦~©³«eªÑªFÁ{®É·|¡A¥²µM±o¼W¸ê¡A¦Ó¼W¸ên¯à¦¨¥\¡A ¥[¤WSND13´Á¤¤¤ÀªR¥XÄl¡AªÑ»ù¦ÛµM¤£·|¤ÓÃø¬Ý¡A·Q¥²ºë±m¥i´Á¡I ¥H¤W¬°¤p§ÌÓ¤H·Qªk¡A¤Å·í§@§ë¸ê°Ñ¦Ò |
|
|
·|û¡G¤p³ì10135960 µoªí®É¶¡:2018/6/29 ¤W¤È 09:46:14²Ä 343 ½g¦^À³
|
²q·Q¤j ±Ð±Â¤£¬O©ú¥Ü¤F¶Ü? Àn¤l¦E¤ô,Á{ªÑ·|¨£¯u³¹ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/29 ¤W¤È 09:31:21²Ä 342 ½g¦^À³
|
¤£¯à¥u¦³±µy°ê»Ú ¦Ó¬On¯à¦¨¬°°ê»Ú¤Æªº¤½¥q ³o¥y¸Üªº·N²[¬O¬Æ»ò©O? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/29 ¤W¤È 06:22:43²Ä 341 ½g¦^À³
|
ÁÂÁ liaw6575¤j¤j ªºªÑªF·|¤ß±o liawbf.pixnet.net/blog/post/48002196 §d¨ÎÀM¤j SNG-12°Ó«~¦W¬° Synapsine ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/29 ¤W¤È 06:15:53²Ä 340 ½g¦^À³
|
®¥³ß¤ß®® ½²±Ð±Â ¼z²´^¶¯ ¦Ñ¥v¤j¤j ^¶¯¼z²´ ÁÂÁÂCliff¤j®¦¼w ¡AÀ°¤pªº¸Ñ´b ¤×¨ä¨º¥y¡u ªmªm´´¥ú¥ú«G«G ¡v¡A¤@»y¥Í°Ê¤F¤º¤~¥~¬Û ¡A¤]¤Ó¶Ç¯« ¦A¦¸®¥³ß¤ß®®±o«G¤~ ¤ß®®¥[ªo¡I ¦Ñ¥v¤j¤j¥[ªo! ÁÂÁ¤j®a¡I |
|
|
·|û¡G§d¨ÎÀM10141531 µoªí®É¶¡:2018/6/29 ¤W¤È 01:53:11²Ä 339 ½g¦^À³
|
²q·Q¤j ¤p§Ì¯uªº¤£ª¾¹D¡C¡Csng-12ªº°Ó¼Ð¦W¡CÀµ¨D±Ð¾Ç¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/6/28 ¤U¤È 11:57:42²Ä 338 ½g¦^À³
|
°ª¯ª¼z²´ÃѤl©Ð¡A¤Ñ¤U¤@²Îº~«Ç¿³¡C ½²¸³®®¤ß¯Ç¥v¥S¡A¸£¦å«Ì»Ù¦Û¥Ñ¦æ¡C Ä´½ÑÃö¦ÐÀò¨ª¨ß¡A¤S¦p¼B³Æ³X¤Õ©ú¡C ´Á«Ý°{Ä£ªF¤è¯]¡A½AÀö¥ú¨~¤@Áû¬P¡C ¤½¥q¦h¤F¤@¦ì½Ñ¸¯«G¡Aªmªm´´¥ú¥ú«G«G¡C §ë¸ê¤Ö¤F¤@¥÷¹q¤l³ø¡AÃjÃjÀ´À´¶^¶^¼²¼²¡C ¤Ö¤F¤@¦ì¢Ù®Ñ¦ñ¡A ¦h¤F´X³\¤p±¨±£¡C ¯¬ºÖ ¥[ªo |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/20 ¤W¤È 06:29:20²Ä 337 ½g¦^À³
|
liaw6575¤j¤j ¬°§Ú̵ûªR ¦Û±þ·N©Àªº«e¥Í¤µ¥@ ©M SNG-12 ªº¤µ¥@¨Ó¥Í ÁÂÁÂliaw¤j¤j ªººë±m¤j¤å liawbf.pixnet.net/blog/post/47988894 ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/14 ¤U¤È 11:50:29²Ä 336 ½g¦^À³
|
¥»Äæ²Ä339½g¡A¤p§Ì¦³ÃöSND-13¸ÕÅç²Îpªº³]©w°ÝÃD¡AÀò±o liaw6575¤j¤jªº«ü¾É¸ÑªR ¤p§Ì«D±`·PÁÂliaw6575¤j¤j¨â¤Ñ¨Óªº«ä¦Ò¤ÀªRºc«ä¤Î¬°¤å¸Ñ»¡ ÁöµM¬Ý¤F¶W¹L10¦¸ ¡AÁÙ¬O¥d¥dªº¡A§Æ±æ¦A±µ¦AÀy¦AÅé·| ·íµM¤j®aY¦³¿³½ì¡A¤]½Ð«e©¹¸£¤O¿EÀú liawbf.pixnet.net/blog/post/47981739 Y¦³¨ô¨£¡A¥ç½Ð¤£§[¤À¨É ¦A¤@¦¸ÁÂÁÂliaw6575¤j¤j ¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/13 ¤W¤È 11:16:37²Ä 335 ½g¦^À³
|
Sage Therapeutics±N¥[³t§íÆ{¯g·sÃÄSAGE-217¬ãµop¹º ¨Ó·½¡GÃÄ©ú±d¼w¡@2018-06-13 med.sina.com/article_detail_100_2_47371.html ¤µ¤é¡ASage Therapeutics¦b»P¬ü°êFDA¶i¦æ¬ð¯}©ÊÀøªk·|ij«á«Å¥¬¡A±N¥[³t¨ä·sÃÄSAGE-217ªº¬ãµop¹º¡C¸Óp¹º¦®¦b¤ä«ùSAGE-217¥Î©óªvÀø««×§íÆ{¯g¡]MDD¡^©M²£«á§íÆ{¯g¡]PPD¡^¦b¬ü°êªºÀò§å¡C SAGE-217¬O¤U¤@¥N¥¿¦V§Oºc½Õ¸`¾¯¡A¦³±æ¬°MDD©MPPD±wªÌ±a¨ÓªvÀø§Æ±æ¡C¥¦°w¹ï¬ðIJ©M¬ðIJ¥~GABA¨üÅ骺¿ï¾Ü©Ê¡A¥H¤Î¨C¤é¤fªAµ¹ÃĪºÃÄ¥N°Ê¤O¾Ç¯S¼x¶i¦æ¤FÀu¤Æ¡CGABA¨t²Î¬O¤j¸£©M¤¤¼Ï¯«¸g¨t²Îªº¥Dn§í¨î«H¸¹³q¸ô¡A¹ï½Õ¸`¤¤¼Ï¯«¸g¨t²Î¥\¯à¨ã¦³«n·N¸q¡C¸ÓÃĪ«©ó¤µ¦~2¤ëÀò±oFDA¹{¥¬ªº¬ð¯}©ÊÀøªk»{©w¡AªvÀøMDD¡C Sage°w¹ïSAGE-217ªº§Ö³t¬ãµop¹º¥]¬A¤@¶µ¦bMDD±wªÌ¤¤¶i¦æªº³æ¤@ÃB¥~¦w¼¢¾¯¹ï·Ó3´ÁÃöÁä©Ê¸ÕÅç¡A¥H¤Î¥¿¦bPPD¤k©Ê¤¤¶i¦æªº¦w¼¢¾¯¹ï·Ó¸ÕÅç¡]²{¦b³Q«ü©w¬°ÃöÁä©Ê¸ÕÅç¡^¡C³o¨â¶µÁ{§É¸ÕÅç³£¦®¦bµû¦ô»P¦w¼¢¾¯¬Û¤ñ¡ASAGE-217°¸µo©Êµ¹ÃÄ¡]episodic dosing¡^©Îµu´ÁÀøµ{¹ï´î»´§íÆ{¯gª¬ªº¼vÅT¡C¤@¶µ¶}©ñ¼ÐÅÒ¬ã¨s±Nµû¦ô°¸µo©ÊªvÀø¹ï·sµo©Î½ÆµoMDDªºÀø®Ä¡A¨Ã´£¨ÑÃB¥~ªº¦w¥þ©Ê¼Æ¾Ú¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/12 ¤U¤È 05:12:22²Ä 334 ½g¦^À³
|
liaw6575¤j¤j¤SÀ°§Ṳ́W¤F¤@°ó²Îp½Ò ®ÄªG¶q , ³q«U»¡ªk liawbf.pixnet.net/blog/post/47976792 ¤µ¤Ñ¬Ý¤F²³øÀÉ ¦¬Ã¬¨}¦h ¦ý¬O P. 23 ªº²Îp»¡©ú ¯uªº¤£À´ ¥»·Q¦bliaw6575¤j¤jªººô¶¤W , ª½±µ½Ð±Ðliaw6575¤j¤j µM¦Ó [ ¯d¨¥³B ] ¨ÃµLªk¨Ï¥Î [ ½Æ»s¶K¤W ] ¥\¯à ©Ò¥H¶K©ó¦¹ , ½Ð±Ð¤j®a¥¦ªº²Îp·N¸q , ·íµMÁ|¨Ò»¡©ú§ó¦n©úÁA P. 23 ªº»¡©ú [[ • Phase II/III registrational trial is designed to detect an ES >= 0.5 with 85% power • A sample size reassessment and adjustment will be performed prior to enrolling the remaining patients to be able to detect an ES >= 0.2* with 80% power on the entire trial ( * ES=0.2 is the minimally clinical meaningful treatment effect. ) ]] ÁÂÁÂliaw6575¤j¤j ÁÂÁ¤Ӻò±i¤j ÁÂÁ¤j®a! |
|
|
·|û¡G¤Óºò±i10135421 µoªí®É¶¡:2018/6/12 ¤W¤È 08:33:34²Ä 333 ½g¦^À³
|
·PÁ²q·Q¤j¤@ª½ÀqÀq¤À¨É¬ÛÃö¸ê°T. ¤ß®®CNS»â°ì¯u¬O¼ç¤OµL½a, 1/2´ÁPȳ£¬Û·í¤£¿ù. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/12 ¤W¤È 06:43:45²Ä 332 ½g¦^À³
|
·PÁ Mengcun Lin ¤j¤j ´£¨Ñ¤ß®®ªºÂ²³ø¸ê®Æ ( 2018/04 ) ¤À¨É www.bplifescience.com/SyneuRxPresentationApril2018.pdf ùر¦³¤£¤Ö¤p§Ì¥H«e¤£ª¾ªº°T®§ ¤@¨Ö´£½Ð¤j®a°Ñ¦Ò ¦A¦¸ÁÂÁ Mengcun Lin ¤j¤j ÁÂÁ¤j®a! |
|
|
·|û¡G´M³V10132258 µoªí®É¶¡:2018/6/7 ¤W¤È 11:03:57²Ä 331 ½g¦^À³
|
ÁÂÁÂCliff¤j~ ¤§«e¦Ñ¥v¤j¤]»¡¹L~ §Ú·N«ä¬O¤µ¦~¦b¯q¦wªº®×¨Ò¤U~»¡¤£©w¤ß®®¤]·|¶}ªáµ²ªG~³o¼Ë¤½¥q¸êª÷§ó¥R¨K¦n¹B¥Î~ ¥xÆWªÑ¥«ÁÙ¬O«Ü«Àò§Qªº~³oºØ¿N¿úªº¦æ·~~¹³§A̤º¦æªº§ë¸ê¤HÁÙ¬O¤£¦hªü! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/6/7 ¤W¤È 10:53:24²Ä 330 ½g¦^À³
|
¡u¡]¤G¡^«n²£¾P¬Fµ¦ ¥»¤½¥q¦U¶µ²£«~¶}µo§¹¦¨©Î§i¤@¬q¸¨«á¡A±N³z¹L»P°ê»Ú¤jÃļt¬¢½Í¦X§@¤è¦¡¡A³o¥i ¯à¥]¬Aµ²·ù¤Î±ÂÅv¨Æ©y¡A¨ú±o±ÂÅv¦¬¤J©ÎÅv§Qª÷¦¬¤Jµ¥¡C¡v ³o¬q¤å¦r¨Ã¤£¬O·sªº½×z¡A2016¡B2017¦~Àç·~³ø§i®Ñ¤¤¬Ò¤w§e²{¡C |
|
|
·|û¡G´M³V10132258 µoªí®É¶¡:2018/6/7 ¤W¤È 10:23:18²Ä 329 ½g¦^À³
|
¡]¤G¡^«n²£¾P¬Fµ¦ ¥»¤½¥q¦U¶µ²£«~¶}µo§¹¦¨©Î§i¤@¬q¸¨«á¡A±N³z¹L»P°ê»Ú¤jÃļt¬¢½Í¦X§@¤è¦¡¡A³o¥i ¯à¥]¬Aµ²·ù¤Î±ÂÅv¨Æ©y¡A¨ú±o±ÂÅv¦¬¤J©ÎÅv§Qª÷¦¬¤Jµ¥¡C ©Ò¥H¤ß®®¥Ø«e±b¤W²{ª÷¨¬°÷°µ§¹¤âÃ䪺¹êÅç~´Á«Ý¥ý±ÂÅv¤@ºØ¦¬¨úÅv§Qª÷¸ò¯q¦w¤@¼Ë,¦¬¨ú¤@¶µ²£«~ÁȧÖ3Ӫѥ», ¨Ó¼W¥[¦Û¤vªº¸êª÷¥H§§¤j¨ä¥L²£«~ªº¶}µo! ¥[ªo!ªÑªF·|©Î³\¥i¥Hťť½²³Õ¤hªº»¡ªk! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/7 ¤W¤È 09:35:45²Ä 328 ½g¦^À³
|
ÁÂÁ Cliff ¤j®¦¼w Àç·~³ø§i®Ñ³sµ² doc.twse.com.tw/pdf/2018_6575_20180628F02_20180607_090659.pdf ºKn : .«e¨¥ º¥ý·PÁ¦U¦ì¤@¦~¨Ó¹ï¤ß®®¥ÍÂ媺¤ä«ù»P«jÀy¡A106 ¦~«×¹ï©ó¥Í§Þ²£·~¦Ó¨¥¬O¬D¾ÔÄY®m ªº¤@¦~¡C§Y¨Ï¦p¦¹¡A¥»¤½¥q¤´«ùÄòªÃ«ùµÛ¥H¯f±wªº»Ýn¬°Àu¥ý¦Ò¶q¡A±Mª`©ó¤¤¼Ï¯«¸g¯e¯f»â °ì¡AÂåÀø»Ý¨D©|¥¼³Qº¡¨¬ªº³¡¥÷¶i¦æ·sÃĬãµo¡C¬°¨DªvÀø¤¤¼Ï¯«¸g¨t²Î¬ÛÃöªº¯e±w¡AP¤O©ó ¥H«e¤©Êªº¬ãµoµ¦²¤¡Aµo®i¨ã²©R©Ê¡B¦³§O©ó¥H©¹ªº¥þ·sºØÃþÃĪ«¡A¨Ã¥H¦h¹F¼ÆºØÃĪ«ªº¼ç ¤Oµ²¦X¦Û¥D¬ãµo¡B±M§Q§G§½¡Bªk³W¤ÀªR¡Bµ¦²¤¦X§@¡C¦¹¥~¡A³z¹L¬ð¯}©ÊÀøªk¤Î§Ö³t¼f¬dªº¤è ¦¡¡A§Æ±æµu®É¶¡¤º¬°¯f±w´£¨Ñ§ó¦w¥þ¦³®Äªº·sÃÄ¡A¦bºë¯«¯e¯f¬ÛÃö¥ÎÃĪº¥«³õ¹F¨ì¥D¾Éªº¦a ¦ì¡C .¬ã¨sµo®iª¬ªp ¥H³Ð¿ì¤H¬J¦³¤§±M§Q¤Æ¦Xª«¡B§@¥Î¾÷Âà¡B¤Æ¦Xª«¤§Á{§ÉÀø®Ä¬°°ò¦¡A¶i¦æÃĪ«¬ãµo¡A §Q¥Î¬ãµo¹Î¶¤¦bÃĪ«ªk³Wµ¦²¤¤W¤§±Mªø»PÃĪ«¶}µo¤§Â×´I¸gÅç¡A³z¹L«ùÄò³Ð³y·sªº±M§Q«O Å@¡A¦b¥@¬É¦U¥DnÃĪ«¥«³õ¶i¦æ±M§Q§G§½¡F¥Ñ©ó¬ãµo¼Ðªº¦h¬°¦w¥þ©Ê¼Æ¾Ú¥R¤À¤§¤Æ¦Xª«¡A ¦b¥Ó½Ð¤HÅé¸ÕÅ綥¬q®É¡A¦h¥i¸õ¹L¦w¥þ©Êµû¦ô¤§¤@´ÁÁ{§É(phase I)¦Ó¶i¤J¸û¬°ÃöÁ䤧Á{ §É¤G´Á(phase II)©ÎÁ{§É¤G/¤T´Á(phase II/phase III)¤§Á{§É¸ÕÅç¡A¤j´TÁYµu¶}µo®É µ{¡B¸`¬Ù¶}µo¶O¥Î¡A¬G¦Ó°§C§ë¸ê·ÀI¡C ¤ß®®¥ÍÂå§Q¥Î¤T¤j·s¿oªº¤¤¼Ï¯«¸g½Õ±±¾÷Âର°ò¦¡A¶}µo²[»\¤T¤j¥Dnºë¯«¬ÛÃö¯e ¯fÃþ§OÃĪ«¡Gºë¯«¤Àµõ¯g¡B¼~Æ{¯g¡B¥¢´¼¯g¥ÎÃÄ¡C .¥Á°ê 107 ¦~pµe·§n ¡]¤@¡^¸gÀ給²¤ 1.SND-11 ªº¾AÀ³¯g¬°«C¤Ö¦~ºë¯«¤Àµõ¯g¡A¥Ø«e¤w¨ú±o¬ü°ê FDA ®Öã²Å¦X©t¨àÃĸê®æ¡B ¥xÆW¤Î¬ü°ê FDA ®Öã¶i¦æ¤G(b)+¤T´Á¤HÅéÁ{§É¸ÕÅç¡C¬ü°ê¤Î¥xÆW³¡¤À§¡¤w¦¬®×¡A¥¼ ¨Ó±N«ùÄò¿n·¥±À¼sÁ{§É¸ÕÅ窺¸ê°T¯à¨£«×¡C 2.SND-12 ªº¾AÀ³¯g¬°Ãøªv«¬ºë¯«¤Àµõ¯g¤§¦X¨ÖªvÀø¡A¥Ø«e¤w¨ú±o¬ü°ê FDA ®Öã²Å¦X©t ¨àÃĸê®æ¤Î¬ð¯}©ÊÀøªk¡]breakthrough therapy designation¡^¤§»{©w¡B¬ü°ê FDA ®Öã¶i¦æ¤G(b)+¤T´Á¤HÅéÁ{§É¸ÕÅç¡C¬ü°ê¤w©ó 106 ¦~ 3 ¤ë¶}©l¶i¦æÁ{§É¸ÕÅ禬®×¡B9 ¤ëÀò±o¥[®³¤j½Ã¥Í³¡®Öã¶i¦æ·sÃÄÁ{§É¸ÕÅç¡A¥¼¨Ó±N«ùÄò¿n·¥±À¼sÁ{§É¸ÕÅ窺¸ê°T ¯à¨£«×¡C 3.SND-13 ªº¾AÀ³¯g¬°¦¨¤Hºë¯«¤Àµõ¯g¤§¥[¦¨ªvÀø¡A¥Ø«eÀò±o¬ü°ê FDA ¬ð¯}©ÊÀøªkªº»{ ©w¡B¨Ã¨ú±o¬ü°ê FDA ®Öã¶i¦æ¤G(b)+¤T´Á¤HÅéÁ{§É¸ÕÅç¡C¬ü°ê¤w©ó 106 ¦~ 3 ¤ë¶}©l ¶i¦æÁ{§É¸ÕÅ禬®×¡B9 ¤ëÀò±o¥[®³¤j½Ã¥Í³¡®Öã¶i¦æ·sÃÄÁ{§É¸ÕÅç¡A¥¼¨Ó±N«ùÄò¿n ·¥±À¼sÁ{§É¸ÕÅ窺¸ê°T¯à¨£«×¡C 4.SND-14 ªº¾AÀ³¯g¬°»´·L¥¢´¼¯g¡A¥Ø«e¤w¨ú±o¬ü°ê FDA ®Öã¶i¦æ¤G(b)+¤T´Á¤HÅéÁ{§É ¸ÕÅç¡C´Á±æ¦b 107 ¦~¤º¥i¥H¥¿¦¡¶i¦æÁ{§É¸ÕÅ禬®×¡C 5.SNG-12 ªº¾AÀ³¯g¬°«Æ{¯g¡A¥Ø«e·Ç³Æ¦V¬ü°ê FDA ¥Ó½Ð¶i¦æ¶i¦æ¤T´Á¤HÅéÁ{§É¸ÕÅç¡A ´Á±æ¦b 107 ¦~¤º¥i¥H¨ú±o IND ®Öã¡C 6.SNA-1 ªº¾AÀ³¯g¬°Ãøªv«¬«Æ{¯g¡A¥Ø«e·Ç³Æ¦V¬ü°ê FDA ¥Ó½Ð¶i¦æ¶i¦æ¤G´Á¤HÅéÁ{§É¸Õ Åç¡A´Á±æ¦b 107 ¦~¤º¥i¥H¨ú±o IND ®Öã¡C 7.SND-5 ªº¾AÀ³¯g¬°¥¢´¼«¬ÄY«ºë¯«¯f¯g¡A¥Ø«e·Ç³Æ¦V¬ü°ê FDA ¥Ó½Ð¶i¦æ¤G´Á¤HÅéÁ{§É ¹êÅç¡A´Á±æ¯à¦b 107 ¦~¤º¥i¥H¨ú±oªì¨B®Öã¡C ¡]¤G¡^«n²£¾P¬Fµ¦ ¥»¤½¥q¦U¶µ²£«~¶}µo§¹¦¨©Î§i¤@¬q¸¨«á¡A±N³z¹L»P°ê»Ú¤jÃļt¬¢½Í¦X§@¤è¦¡¡A³o¥i ¯à¥]¬Aµ²·ù¤Î±ÂÅv¨Æ©y¡A¨ú±o±ÂÅv¦¬¤J©ÎÅv§Qª÷¦¬¤Jµ¥¡C ·sÃĬãµo¨ã¦³§Þ³NªùÂe°ª¡B¬ãµo¶g´Áªø¡B±M·~§Þ³N»Ý¨D«×°ª¤Îªþ¥[»ùÈ°ªµ¥¯S ¦â¡A²£·~¶i¤JªùÂe¬Û¹ï¸û°ª¡A¤£©ö¦bµu®É¶¡¤º²£¥Í¼@¯PÅܤơA¥B¥»¤½¥q¸³¨Æªø¬°°ê»Ú ¤¤¼Ï¯«¸g³Ð·s¬ãµo¤§¾Ç³N¬É·N¨£»â³S¡AÀH®Éª`·N²£·~¤§§Þ³Nµo®iÁͶաA¨ÃµÛ¤âµû¦ô¥i ¯à¤§¼vÅT¥Bµø»Ýn±Ä¨ú¾A·í¦]À³±¹¬I¡C Patients & Families First ¥H¯f±wªº»Ý¨D¬°ºn¦Ò¶q¬O¥»¤½¥q¤@ª½¥H¨ÓªºÄ@´º¡A §ÚÌ´Á±æ³Ð³y¤@¨t¦C·s¿oªº²£«~¡A¥i¥H¼sªxªº¨Ï¥Î¦b¦UºØ¤¤¼Ï¯«¸g¯e±w¡A¤£ºÞ¬O«Ä¨à ̩άO¦~ªøªÌ³£¥i¥H¦w¥þ¦³®Äªº¨Ï¥Î¡C§Æ±æ§Ṳ́@°_§V¤O¡A«¬B¤ßÆFªº³ß®®¡C¤ß®®¥Í Âå¥ç«ùÄò§V¤O¶i¨B¡A³Ð³y³Ì¨Î§ë¸ê¦¬¯q¡A¥H¤£t´Á«Ý¡C ( ºK¦Û¤ß®®Àç·~³ø§i®Ñ ) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/6/7 ¤W¤È 08:54:08²Ä 327 ½g¦^À³
|
¤@〇¤»¦~«×Àç·~³ø§i®Ñ¤w¤W¬[¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/5 ¤W¤È 11:10:53²Ä 326 ½g¦^À³
|
¤ß®®ªñ´Á¥Ó½Ðªº¤TÓ°Ó¼Ð(TRADEMARK) : www.trademarks411.com/search?o=SyneuRx+International+%28Taiwan%29+Corp.&option=srearch_3&sub_option=sub_srearch_1 SYNAPSINAE TANNQUILYNNE CLOZABEN OWNER : SyneuRx International (Taiwan) Corp. FILING DATE : MAY 09, 2018 ½Ð°Ý¤j®a [ SYNAPSINAE ]¬O¬Æ»ò? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/31 ¤W¤È 10:28:42²Ä 325 ½g¦^À³
|
Sage Therapeutics ºÓ²£«á§íÆ{·sÃĥӽФW¥«ÀòFDAÀu¥ý¼fµû¸ê®æ ¨Ó·½¡GÂåÃÄÅ]¤è¼Æ¾Ú ¡@2018-05-31 med.sina.com/article_detail_103_2_46651.html Sage Therapeutics 5¤ë30¤é«Å¥¬¡AFDA¤w¸g¨ü²zbrexanolone (SAGE-547)ÀR¯ßª`®g²GªvÀø²£«á§íÆ{ªº·sÃĤW¥«¥Ó½Ð¡]NDA¡^¡A¨Ã±Â¤©Àu¥ý¼fµû¸ê®æ ; brexanolone¬O¤@ºØ£^-®ò°ò¤B»ÄA«¬¨üÅé¡]GABAA¨üÅé¡^ªº§Oºc½Õ¸`¾¯¡A¯à°÷¦P®É½Õ¸`¦ì©ó¯«¸g¬ðIJ¤º©M¬ðIJ¥~ªºGABAA¨üÅ骺¥\¯à¡A«ì´_¤j¸£¤ºGABAA¨üÅé©MNMDA¨üÅé¡]N-¥Ò°ò-D-¤Ñ¥V®ò»Ä¨üÅé¡^¬¡©Ê¤§¶¡ªº¥¿Å. ¸ÕÅçµ²ªGÅã¥Ü¡A¨â¶µ¬ã¨s¤¤©Ò¦³¾¯¶qbrexanolone¦bª`®gµ¹ÃÄ60h«áHAM-D¶qªíµû¤À¬Û¤ñ°ò½uªº¤U°µ{«×§¡¤ñ¦w¼¢¾¯²Õ§ó¬°©úÅã¡A@¨ü©Ê¨}¦n¥B¤£¨}¨Æ¥óµo¥Í²v¬Û¦ü¡C brexanoloneÀR¯ßª`®g²G¦b²£«á§íÆ{³oÓ¾AÀ³¯g¤W¤wÀò±oFDAªº¬ð¯}©ÊÃĪ«¸ê®æ©MEMAªºÀu¥ýÃĪ«»{©w¡C¦pªGÀò§å¡Abrexanolone±N¦¨¬°ºÓªvÀø²£«á§íÆ{ªºÃĪ«¡A¤]±N·|¬OSage TherapeuticsºÓ¹ê²{°Ó·~¤Æªº²£«~¡C ÁÂÁ·s®öÂåÀøºô ÁÂÁÂÂåÃÄÅ]¤è¼Æ¾Úºô |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/22 ¤U¤È 05:30:03²Ä 324 ½g¦^À³
|
ÁÂÁ¤p³ì¤jªº§Y®É°T®§ ¤]ÁÂÁ¤½¥qªº«ÂI»¡©ú 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡A¹wp©MÃøªv«¬««×¼~Æ{¯g(SNA1)¤@¨Ö ±Ò°Ê¦¬®×¡C (2)SNG12 ì®ÆÃĬ°¥Ò°ò¥Ì®ò»Ä¦@´¹¡A¬O¥Ì®ò»Ä¦^¦¬§í¨î¾÷¨îªº·s¾÷Âà·sÃÄ¡A ¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)½T»{¬°¡u·s¤Æ¾Ç¤À¤l¡v¡]New Chemical Entity¡^¨Ã¤w Àò±o¬ü°ê±M§Q¡C¤T´Á¸ÕÅ禳¨â¤jÁ{§É®Ä¥Î«ü¼Ð¡G¤@¬°¼~Æ{¯gª¬¥t¤@¬°¦Û±þ¯gª¬¡A ¥Ø«e¦Û±þ¯gª¬¨ÃµLÃĪ«ªvÀø¡C¥H¥xÆW¬°¨Ò¡A¨C¤Ñ¬ù¤Q¤H¦Û±þ¨¤`¡A¨ä¤¤µ´¤j³¡¤À ¿©¦³««×¼~Æ{¯g¡C ÁÙ¦³Åý§ÚÌ«·s½Æ²ßliaw6575¤j¤j¦³ÃöSNG-12ªº¨t¦C¤j§@ liawbf.pixnet.net/blog/category/2056471 ÁÂÁ¤j®a! |
|
|
·|û¡G¤p³ì10135960 µoªí®É¶¡:2018/5/22 ¤U¤È 03:30:46²Ä 323 ½g¦^À³
|
§Ç¸¹ 3 µo¨¥¤é´Á 107/05/22 µo¨¥®É¶¡ 15:21:39 µo¨¥¤H ½²¥É´@ µo¨¥¤H¾ºÙ °]·|¸g²z µo¨¥¤H¹q¸Ü 02-77422699 ¥D¦® ¤½§i¥»¤½¥q¬ãµo¤¤««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡A Àò±o¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)®Öã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç ²Å¦X±ø´Ú ¡@²Ä 43 ´Ú ¨Æ¹êµo¥Í¤é 107/05/22 »¡©ú 1.¨Æ¹êµo¥Í¤é:107/05/22 2.¤½¥q¦WºÙ:¤ß®®¥ÍÂåªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q¬ãµo¤¤««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡AÀò±o¬ü°ê¹«~ÃĪ«ºÞ²z§½ (FDA)®Öã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç¡C (1)¬ãµo·sÃĦWºÙ©Î¥N¸¹:SNG12¡C (2)¥Î³~¡G¼~Æ{¤Î¦Û±þ¯gª¬¡C (3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¤T´Á¤HÅéÁ{§É¸ÕÅç¡C (4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G A.´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G ««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡AÀò±o¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)®Öã°õ¦æ¡@ ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç¡C B.¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G ±N¨Ì¸ÕÅçpµe¶i¦æÁ{§É¸ÕÅç¡C C.¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G·s¥x¹ô43,303¥a¤¸¡C (5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G ±N®Ú¾Ú¥»´ÁÁ{§É¸ÕÅçµ²ªG¨M©w¬O§_»Ýn¶i¦æ¡C A.¹wp§¹¦¨®É¶¡¡G¹ê»Ú®Éµ{±N¨Ì°õ¦æ¶i«×¨M©w¡C B.¹wpÀ³t¾á¤§¸q°È¡GµL¡C 6.¦]À³±¹¬I:µL¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡A¹wp©MÃøªv«¬««×¼~Æ{¯g(SNA1)¤@¨Ö ±Ò°Ê¦¬®×¡C (2)SNG12 ì®ÆÃĬ°¥Ò°ò¥Ì®ò»Ä¦@´¹¡A¬O¥Ì®ò»Ä¦^¦¬§í¨î¾÷¨îªº·s¾÷Âà·sÃÄ¡A ¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)½T»{¬°¡u·s¤Æ¾Ç¤À¤l¡v¡]New Chemical Entity¡^¨Ã¤w Àò±o¬ü°ê±M§Q¡C¤T´Á¸ÕÅ禳¨â¤jÁ{§É®Ä¥Î«ü¼Ð¡G¤@¬°¼~Æ{¯gª¬¥t¤@¬°¦Û±þ¯gª¬¡A ¥Ø«e¦Û±þ¯gª¬¨ÃµLÃĪ«ªvÀø¡C¥H¥xÆW¬°¨Ò¡A¨C¤Ñ¬ù¤Q¤H¦Û±þ¨¤`¡A¨ä¤¤µ´¤j³¡¤À ¿©¦³««×¼~Æ{¯g¡C (3)·sÃĶ}µo¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥§ë¸ê·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/21 ¤U¤È 07:37:18²Ä 322 ½g¦^À³
|
ÁÂÁÂliaw6575¤j¤jªºÃ¸»s SND-13¸ÕÅç¬yµ{²¹Ï liawbf.pixnet.net/blog/post/47944689 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/21 ¤U¤È 05:08:35²Ä 321 ½g¦^À³
|
±j¥Í²×¤î¦´Áªüº¸¯ý®üÀq¯g¬ãµop¹º ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-05-21 med.sina.com/article_detail_100_2_46115.html ±j¥Í¤½¥qºX¤U¦è¦w·¨´Ë»sÃÄ«Å¥¬¨ä¤w¨M©w²×¤î¹ïªüº¸¯ý®üÀq¯f BACE §í¾¯atabacestatªº¬ãµop¹º¡C ¸Ó¤½¥qªí¥Ü¡A¥Ñ©óÃĪ«¦s¦b¦w¥þ°ÝÃD¡A¨M©wÃö³¬¸Ó¶µ¬ãµoµ{§Ç¡A¦ýÁnºÙÃĪ«¥\®Ä¤£¦s¦b¥ô¦ó°ÝÃD¡C®Ú¾Ú¬J©¹ªº¹êÅçµ²ªGÅã¥Ü¡A°Ñ¥[ÃĪ«¦´ÁIIb/III´ÁÁ{§É«eªüº¸¯ý®üÀq¯fÁ{§É¸ÕÅç¥H¤ÎII´Áªø´Á¦w¥þ©Ê¸ÕÅ窺±wªÌ¥X²{¤F¨x酶¤É°ªªº¯gª¬¡C¸ÓÃĪ«ªº¬ãµo©ó2015¦~¶}©l¡A¨Öp¹º¦b2024¦~¤W¥«¡C ¥Ø«e¤j¦h¼ÆªºÁ{§É¸ÕÅç¬O¥H£]-¾ý¯»¼Ë³J¥Õ¬°¹v¦V¡A¸Õ¹Ï¤À¸Ñ©Îªý¤î£]-¾ý¯»¼Ë³J¥Õ´³¶ôªº§Î¦¨¡C¦ý¬O¤j¶q¥H¾ý¯»¼Ë°²»¡¬°¹v¦VªºÃĪ«¬ãµo¥¢±Ñ¡A¨Ï¦U¤jÃļt¯É¯ÉÂà´««ä¸ô¡A¾ý¯»¼Ë°²»¡¦ü¥G¥¿¦b¨«¦V¦º¤`¡C½÷·ç§@¬°³Ì¦¶i¦æªüº¸¯ý®üÀq¯fÃĪ«¬ãµoªº¤½¥q¤§¤@¡A³Ìªñ¤]ªí¥Ü¤½¥q±N²×¤îªüº¸¯ý®üÀq¯f©M©¬ª÷´Ë¯g·sÃĪº¶}µo¤u§@¡C Àq¨FªF¤]¦b¤ÀªR¤FverubecestatªºÁ{§ÉII´Á¬ã¨s«á¡A¨M©w¼È°±¨äÁ{§ÉIII´Á¬ã¨sp¹º¡A¸ÓÃĪ«¥Î©óªvÀø»´«×¦Ü¤¤«×ªüº¸¯ý®üÀq¯f±wªÌ¡C ·í³o¨Ç»sÃÄ¥¨ÀY½ó÷]¤£«e®É¡A¤@¨Ç³Ð·~·s¾U«oªí²{¥X¤FµL©Ò¬ÈÄߪº«_ÀIºë¯«¡A©tª`¤@ÂY¡A¸Õ¹Ï±Ã¥X¤@¤ù¤Ñ¦a¡C1¤ë6¤é¡A¥Íª«¬ì§Þ¤½¥qDenali Therapeutics©MªZ¥Ð«Å¥¬¤w¹F¦¨¾Ô²¤¦X§@¡A¦@¦P¶}µo°w¹ï¯«¸g°h¦æ©Ê¯e¯fªºÃĪ«©MÀøªk¡C¨Ì·Ó¨óij¡AªZ¥Ð±N´£¨Ñ1.5»õ¬ü¤¸ªº¥ý´Á¥I´Ú¡A¥H¦b¦Ü¦h3ÓÁ{§É¶µ¥Ø¤WÀò±o¶}µo»P±À¼sªº³\¥i¡C |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/5/21 ¤U¤È 01:04:14²Ä 320 ½g¦^À³
|
¦pªG³æ´N¤ß®®»PÄvª§¹ï¤â¨Ó±´°Q... ³Ìªñ¤ß®®ÀòÁÜ°Ñ¥[ªº²Ä¤Q¤»©¡°ê»Ú·sÃĵo©ú¬ì§Þ¦~·|... ¤£§«¦A¬Ý¬Ý³oÓ¤j·|ªº»¡©ú...¨ä¤¤³Ì«á¤@¬q´£¨ì... ÁܽÐ40¦hÓ°ê®a©M¦a°Ï¤W¤d¦ìÃĪ«¬ãµo»â°ìªº¬ÛÃö±M·~¤H¤h...50®aµÛ¦W¥ø·~°Ñ®i... >>>¤ß®®ÀòÁܦb³o50®aµÛ¦Wªº¦U»â°ì·sÃĬãµo¥ø·~¸Ì±.. §Ú»{¬°³o¥Nªí¤F¤ß®®¦bCNS»â°ì¬O¥þ²y³Ì»â¥ýªº¥ø·~... ¤G¡A¤j·|¤¶²Ð ¥Ñª¾¦W°ê»Ú·|ij¤½¥q¦Ê¶ø®õ°ê»Ú·|ij¶°¹Î¥D¿ìªº²Ä¤Q¤»©¡°ê»Ú·sÃĵo©ú¬ì§Þ¦~·|¡]IDDST-2018¡^±N©ó2018¦~8¤ë16-18¤é¦b¬ü°êªi¤h¹y¥l¶}¡C °ê»Ú·sÃĵo©ú¬ì§Þ¦~·|2003¦~¥Ñ¦Ê¶ø®õ°ê»Ú·|ij¶°¹Îµo°_¡AP¤O©ó¬°¥þ²yÃĪ«¬ãµo»â°ìªº¬ì¾Ç®a©M¥ø·~®a·f«Ø¤@Ó¬Û¤¬¥æ¬y»P¦X§@ªº°ê»Ú¥¥x¡A¬°¦æ·~µo®i´£¨Ñ·s«ä¸ô¡A«ü¤Þ·s¤è¦V¡A¥H¦¹±À°Ê¥þ²yÃĪ«¬ãµoªº¶i®i¡C°ê»Ú·sÃĵo©ú¬ì§Þ¦~·|¤w¸g¦b¥_¨Ê¡A«n¨Ê¡A²`¦`¡A¤j¨Áµ¥¦a¦¨¥\Á|¿ì¤F¤Q¤©¡¡A¦¨¥\¦a§l¤Þ¤F¹O¸U¦W¥@¬ÉµÛ¦W±M®a¡A¾ÇªÌ¡A¥@¬É500±j»sÃÄ¥ø·~°ªºÞ¡A³Ð·s«¬»sÃÄ¥ø·~®a°Ñ»P¡A¬O·sÃĬãµo»â°ì«nªº«~µP©Ê·|ij¡C ¥»©¡¦~·|¦@³]¸m¤F26³õ±M·~§Þ³N½×¾Â¡A¥Dn¥]¬A¡GÃĪ«¬ãµoªº³Ì·s¶i®i¡A¥Î©óÃĪ«¬ãµoªº³Ì·s§Þ³N¡AÃIJz¤ô¥¤WªºÃĪ«µo²{¡Apºâ¾÷»²§UªºÃĪ«µo²{¡A¹v¦VÃĪ«¡A·s«¬¤p¤À¤l§í»s¾¯©M¿E°Ê¾¯¡A¥Íª«ªvÀø»â°ì·s¶i®i¡AÃĪ«»¼°eªº¬ì¾Ç»P§Þ³N¡A°w¹ï¥Dn¯e¯fªºÃĪ«¬ãµo·s¶i®iµ¥¡C¦¹¥~¡AÁÙ±NÁ|¿ì¤¤¬ü¥ø·~®a°ª®p½×¾Â¡A¥Íª«ÂåÃÄ°ªºÝ¤H¤~©M¶µ¥Ø¹ï±µ·|¡A¶é°Ï©Û°Ó±À¤¶·|¡A¤H¤~©Û¸u·|¡Aªi¤h¹y¥Íª«ÂåÃIJ£·~¶é°Ï¤Îª¾¦W¾÷ºc¦Ò¹îµ¥°Ó°È¬¡°Ê¡C ¥»©¡¦~·|±NÁܽХ@¬É500±j»sÃÄ¥ø·~°ªºÞ¡A°ê»ÚµÛ¦W±M®a¾ÇªÌ¡A¬ü°ê°ê¤º¬ÛÃö¾÷ºc¥Nªí¡Aª¾¦W¥ø·~®aµ¥»â»Î¥DÁ¿¡A¦@p200Ó³ø§i¡C±NÁܽШӦۥ@¬É40¦hÓ°ê®a©M¦a°Ïªº¤W¤d¦ìÃĪ«¬ãµo»â°ìªº¬ÛÃö±M·~¤H¤h°Ñ¥[·|ij¡A50®aµÛ¦W¥ø·~°Ñ¥[®iÄý¡A±N¦V¥@¬É®i¥Ü«¤j·sÃijШ«eªu§Þ³N©M¬ì§Þ¦¨ªG¡A¤Þ¾É°ê»Ú·sÃĬãµo»â°ìªºµo®iÁͶթM«eªu°Ê¦V¡A«P¶i¬ì¬ã¦¨ªG²£·~¤Æ¦X§@¡C ¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/20 ¤U¤È 04:35:11²Ä 319 ½g¦^À³
|
¤]³\¦]¬°¦¬®×¼Æ¶V¨Ó¶V¦h(?) ¤ß®®SND-12Á{§É¸ÕÅ窺[Central Contact Backup] ¥Ñì¨Óªº Elena Lin, MS Telephone: 886-2-77422699 Ext. 117 §ï¥Ñ Felicia Yao Telephone: 886-2-77422699 Ext. 136 t³d clinicaltrials.gov/ct2/history/NCT03094429?A=2&B=3&C=Side-by-Side#StudyPageTop ¦Ü©óSND-13Á{§É¸ÕÅ窺[Central Contact Backup] ¤´¥Ñì¨Óªº Elena Lin, MS Telephone: 886-2-77422699 Ext. 117 t³d clinicaltrials.gov/ct2/history/NCT02261519?A=3&B=4&C=Side-by-Side#StudyPageTop SND-11¤]¨S§ïÅÜ clinicaltrials.gov/ct2/history/NCT01908192?A=10&B=11&C=Side-by-Side#StudyPageTop ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/18 ¤U¤È 04:55:28²Ä 318 ½g¦^À³
|
¸É¥R: ¬Q¤Ñ¤½¶}ªþ¦³¹Ïªíªº±M§Q¤½§i (US20180133237) Enrichment Methods for Preparing Tannic Acid Compositions patentscope.wipo.int/search/en/detail.jsf?docId=US215882572&recNum=1&maxRec=30&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28TSAI%2C+Guochuan+Emil%29&tab=PCTDescription |
|
|
·|û¡Gbooli10146418 µoªí®É¶¡:2018/5/17 ¤U¤È 05:01:24²Ä 317 ½g¦^À³
|
PULSAR |
|
|
·|û¡Gbio man10142285 µoªí®É¶¡:2018/5/17 ¤U¤È 04:46:12²Ä 316 ½g¦^À³
|
²q·Q¤j~ ªiÄõªºpulsarpµe¦WºÙ µª®×¬O¬Æ»ò @@ ¥i¥H³Â·Ð§iª¾¶Ü ^^ ÁÂÁ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/17 ¤U¤È 03:47:14²Ä 315 ½g¦^À³
|
¤µ¤Ñè褽¶}ªº¬ü°ê±M§Q¥Ó½Ð¤½§i appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22TSAI,+Guochuan+Emil%22&OS=%22TSAI,+Guochuan+Emil%22&RS=%22TSAI,+Guochuan+Emil%22 Enrichment Methods for Preparing Tannic Acid Compositions Abstract ( Google ½Ķ ) »s³Æ§tÂý»Äªº²Õ¦Xª«¡]¨Ò¦pÃĪ«²Õ¦Xª«¡AÀç¾i»s«~²Õ¦Xª«©ÎÂåÃĹ«~²Õ¦Xª«¡^ªº¤èªk¡A¯S§O¬O¨º¨Ç¨ã¦³Àu²§®Ä¤O¡A¯Â«×©M¦w¥þ©Êªº´I§t³æ¹ç»Ä¸sªº¤èªk¡C¥»¤åÁÙ´£¨Ñ¤F¥Î©ó§í¨îD-®ò°ò»Ä®ñ¤Æ酶©M/©Î¥Î©óªvÀøCNS¯f¯g©M¥]¬A¿}§¿¯f¡A°ª¦å¿}¯g¡A°ª¯×¦å¯g©Î°ªÁx©T¾J¦å¯gªºªÎD¯gªº§tÂý»Ä²Õ¦Xª«¡C Example 10. The Acute Toxicity Study of Tannic Acid from Different Sources Results [ ªþµù:Tannic acids were purchased from Sigma (Sigma tannic acid) or made from Enrichment method 10 (Enrichment #10)] The maximum tolerated dose of Sigma tannic acid was 750 mg/kg. In Enrichment #10 tannic acid study, all mice received 2000 mg/kg tannic acid displayed decreased activity, arching back, and heavy breathe immediately after dosing, and recovered in 10 minutes. No adverse effects were observed and the gross autopsy gave no significant finding in all groups. The maximum tolerated dose of Enrichment #10 tannic acid was at least 2000 mg/kg. In conclusion, enrichment #10 tannic acid showed a much higher maximum tolerated dose than Sigma tannic acid and is safer to be used as treatment for CNS and obesity disorders. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/17 ¤U¤È 03:29:23²Ä 314 ½g¦^À³
|
liaw6575¤j¤jªº¤jÀ\ Back to Basic II , ¤G³¡¦± Sarcosine §ïµ½ºë¯«»P¼~Æ{¯gª¬ , ´£¤É»{ª¾¥\¯à liawbf.pixnet.net/blog/post/47918067 Sarcosine §Ü¼~Æ{®ÄªG , ±j¨ìÅý¤Hhigh ? liawbf.pixnet.net/blog/post/47933703 ES-K¥L©R , n§A©R ? liawbf.pixnet.net/blog/post/47937966 ÁÂÁÂliaw6575¤j¤jªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/4 ¤W¤È 08:29:34²Ä 313 ½g¦^À³
|
¬Q¤Ñ¤½¶}ªº°ê»Ú(©Î CN )±M§Q¥Ó½Ð¤½§i POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF f¥Ò»Ä¶uªº¦h´¹«¬¤Î¨ä¥Î³~ patentscope.wipo.int/search/en/detail.jsf?docId=WO2018077157&recNum=1&maxRec=29&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28TSAI%2C+Guochuan+Emil%29&tab=FullText [Claims]¦h¤F¦n´X±ø ¤]¦³¹Ï¥i¨Ñ¬ãŪ°Ñ¦Ò ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/4/30 ¤W¤È 09:23:14²Ä 312 ½g¦^À³
|
·PÁÂliaw6575¤j¤j»s§@SND-1±M§Q§G§½Â²¹Ï...²M·¡ªº»¡©ú...²³æ©öÀ´... ¤ß®®ªº·sÃĬÛÃö±M§Q¤£Â_¶i¦æ¥Ó½Ð...¥[¤W¤µ¦~¤jÁ|¼x¤~...«áÄòÁ{§É¼Æ¾Ú¥i¨£ºÝÙ... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/4/30 ¤W¤È 06:15:54²Ä 311 ½g¦^À³
|
·í¤pªºÁÙ¦b«ä¦Ò¡B®ø¤Æ¤ß®®ªº±M§Q§G§½¬O«ç¼ËªºÅ@«°ªe®É liaw6575¤j¤j´N¥H¤@±i²¹Ï²M·¡¦a§@¤F»¡©ú¡A½Ð¬Ý ¡u SND-1±M§Q§G§½ ¼h¼h«OÅ@ ¡v liawbf.pixnet.net/blog/post/47912079 ÁÂÁÂliaw6575¤j¤j ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/4/29 ¤W¤È 11:28:44²Ä 310 ½g¦^À³
|
¤ß®®Á٫ܼF®`ªº? ¨â¤j®Õªø¿î¿ï ³£©M¤ß®®ªº¸³¨Æ¦³³sµ²? ¶§©ú¤j¾Ç®Õªø¿î¿ï , ¨â¦ì¿W¥ß¸³¨Æ½ÐÃã ³o¦¸¥x¤j®Õªøª§Ä³ , ¤S²o§è¬ü°ê®v¨K®¦¥Í§Þ¤½¥q¡]SPIRANTHES BIOTECH¡^t³d¤H¥x¸Ç¬üÄy¬ì¾Ç®a ¼Ú¶§«Û°ó¡]James Y. Oyang¡^ ¤pªº·Q , ¦b³oӮɶ¡ÂI½ÐÃã , ¼Ú¶§¥ý¥Í¥i¯à¬O¤£·Q³y¦¨¤ß®®ªº§xÂZ§a? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/4/26 ¤U¤È 09:12:30²Ä 309 ½g¦^À³
|
¤µ¤Ñ¤½¶}ªº¬ü°ê±M§Q¥Ó½Ð¤½§i POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF f¥Ò»Ä¶uªº¦h´¹«¬¤Î¨ä¥Î³~ appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22TSAI,+Guochuan+Emil%22&OS=%22TSAI,+Guochuan+Emil%22&RS=%22TSAI,+Guochuan+Emil%22 .¦b°ªÀã«×±ø¥ó¤U·s¦h´¹«¬§Î¦¡¡4ªºÃ©w©Ê´ú¸Õ --- ªí©ú¦h´¹«¬¡4¦b°ªÀã«×±ø¥ó¤U¤ñ´ú¸Õªº¥«°â°Ó«~f¥Ò»Ä¶u§óéw .¦b°ªÀã«×±ø¥ó¤U·s¦h´¹«¬¡4»P´â´á¥Áp¦XªºÃ©w©Ê¸ÕÅç --- Æ[¹î¨ì·sªº¦h´¹«¬§Î¦¡¡4»P´â´á¥Áp¦XªºXRPD¼Ò¦¡¨S¦³§ïÅÜ .·s«¬¦h´¹«¬§Î¦¡¡4»P¨Ó¦ÛMerck©MSigma Aldrichªºf¥Ò»Ä¶uªº¶i¤@¨B¤ñ¸û¤ÀªR·sªº¦h´¹ --- µo²{·sªº¦h´¹«¬ª«¡4¬Of¥Ò»Ä¶uªº¼ö¤O¾Ç³Ìéwªº¦h´¹«¬ª« .·sªº¦h´¹«¬§Î¦¡¡4¦b¤ô¤¤ªº·»¸Ñ«× --- µ²ªGÅã¥Ü·s¦h´¹«¬ª«¡4 ªº³Ì¤j¤ô·»¸Ñ«×¡]666mg / ml¡^°ª©óMerck¡]500mg / ml¡^©MSigma Aldrich¡]454mg / ml¡^ªºf¥Ò»Ä¶u Y¦³¤£§´ , ½Ðª©¥D¤j¤j³w¤©§R°£ , ÁÂÁÂ! ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/4/18 ¤U¤È 04:07:12²Ä 308 ½g¦^À³
|
liaw6575¤j¤jªº¤ß±oµû½× 10704 ©Û§L¶R°¨ µ¦°¨¤¤ì liawbf.pixnet.net/blog/post/47889453 FDA 2018¦~2¤ëµo¥¬ ¦´ÁADÃĪ«¬ãµo¤§·~¬É«ü¤Þ(¯ó½Z) liawbf.pixnet.net/blog/post/47895075 µûªR SND-14 ¼g±oºë±m ÁÂÁÂliaw6575¤j¤jªº¥Î¤ß©M¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/4/14 ¤W¤È 09:24:26²Ä 307 ½g¦^À³
|
¤ß®®¦b¬ü°ê4/5¥Ó½Ðªº·s±M§Q...¤º®e¦n¦h...¦b°ê¥~ºô¯¸¦³¬Ý¨ì¤U¦C³o¬q... ¤£ª¾ª©¤WÂå¾Ç±M·~¯Åªº¤j¤jÌ...¬O§_¯à¤À¨É¤@¤U¹ï³oÓ±M§Qªº¥¼¨ÓÀ³¥Î¤Î¬Ýªk? --------------------------------------------------------------------------------------------------- Also within the scope of the present disclosure are (i) any of the tannic acid-containing compositions (e.g., pharmaceutical compositions, health food products, or medical food products) described herein for use in treating an DAAO- and/or glutamatergic neurotransmission-associated disease/disorder, such as those described herein, or for treating an obesity disorder, eating disorder, anorexia nervosa, bulimia nervosa, hyperlipidemia, hyperglycemia, diabetes, or an CNS disorder, and (ii) uses of such composition in manufacturing medicaments for use in treating any of the target diseases/disorders, including those described herein. |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/4/12 ¤W¤È 12:15:07²Ä 306 ½g¦^À³
|
²q·Q¤j... ·PÁ´£¨Ñ¸ê®Æ... ¤W¶g¬ü°ê¥Ó½Ðªº±M§Q...´Á¬ßª©¤W±M·~¤j¤j̪º¤ÀªR¤F...·P®¦! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/4/11 ¤U¤È 06:05:28²Ä 305 ½g¦^À³
|
¤p©¯¹B¤j ¬Oªº ¥Ó½Ð¬ü°êªº±M§Q ¤½¶}¤é : 2018/04/05 Compositions Containing Tannic Acids and Uses Thereof appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22Tsai+Guochuan+Emil%22&OS=%22Tsai+Guochuan+Emil%22&RS=%22Tsai+Guochuan+Emil%22 ¥Ó½Ð¤¤°êªº±M§Q 2017/10/05 ´N¤½¶}¤F WO/2017/167168 COMPOSITIONS CONTAINING TANNIC ACIDS AND USES THEREOF patentscope.wipo.int/search/en/detail.jsf?docId=WO2017167168&recNum=7&office=&queryString=FP%3A%28TSAI%2C+Guochuan+Emil%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=26 ¤p§Ì¤£²M·¡¤º®e¬O§_¤@¼Ë? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/4/11 ¤U¤È 05:51:32²Ä 304 ½g¦^À³
|
2018¦~³Ì·s©¬ª÷´Ë¯f¬ãµoÃĪ«¦³þ¨Ç ¨Ó·½¡GÃÄ©ú±d¼w¡@2018-04-11 med.sina.com/article_detail_103_2_44098.html ©¬ª÷´Ë¯f¡]Parkinson¡¦s Disease¡APD¡^¬O¤@ºØºC©Ê¶i¦æ©Ê¯«¸g°h¦æ©Ê¯e¯f¡C³oºØ¯e¯f¬O¥Ñ^°êÂå¥Í¸â©i´µ•©¬ª÷´Ë¡]James Parkinson¡^©R¦Wªº¡A¥L¦b1817¦~º¦¸´yz¡CPD¬O¶È¦¸©óªü¯÷®üÀq¯fªº²Ä¤G¤j±`¨£¯«¸g°h¦æ©Ê¯e¯f ¦b©¬ª÷´Ë¯f¤¤¡AºÙ¬°¶Â½èªº¤j¸£°Ï°ì¤¤ªº¯«¸g²ÓM¡]¤]ºÙ¬°¯«¸g¤¸¡^¶}©lµo¥Í¥\¯à»Ùê©Î¦º¤`¡A³o¤@¹Lµ{ºÙ¬°¯«¸gÅÜ©Ê¡C©¬ª÷´Ë¯f¬O¤@ºØ¶i¦æ©Ê¯e¯f¡A·N¨ýµÛÀHµÛ®É¶¡ªº±À²¾¡A¯gª¬·|¥[« 2018¦~·sµn°Oªº©¬ª÷´Ë¯fÁ{§É¸ÕÅç©M¦b¬ã·sÃĤ¶²Ð : 1. ·sÃĦWºÙ¡Gªü¼³¶Ü°Ø¦Þ¤U½¤¡]APL-130277¡^ ÃĪ«¾÷²z¡G¦h¤ÚÓiD2¨üÅé¿E°Ê¾¯ ¬ã¨s¾÷ºc¡GSunovion Á{§É¶¥¬q¡G3´Á 2. ·sÃĦWºÙ¡GPimavanserin ÃĪ«¾÷²z¡G¦å²M¯À5-HT 2A¨üÅé«ú§Ü¾¯ ¬ã¨s¾÷ºc¡GAcadiaÂåÃÄ Á{§É¶¥¬q¡G2´Á 3. ·sÃĦWºÙ¡GCeftriaxone ÃĪ«¾÷²z¡G§Ü¥Í¯À ¬ã¨s¾÷ºc¡GBrainX Corporation Á{§É¶¥¬q¡G2´Á 4. ·sÃĦWºÙ¡GCX-8998 ÃĪ«¾÷²z¡GCav3¶tÂ÷¤l³q¹D½Õ¸`¾¯ ¬ã¨s¾÷ºc¡GCavion Á{§É¶¥¬q¡G2´Á 5. ·sÃĦWºÙ¡GND0612 ÃĪ«¾÷²z¡G¥ª±Û¦h¤Ú/¥d¤ñ¦h¤Ú¡]LD / CD¡^ ¬ã¨s¾÷ºc¡GNeuroDerm Á{§É¶¥¬q¡G3´Á ¥t«h·s»D : ©¬ª÷´Ë·sÃÄNuplazidP¼Æ¦Ê¦W±wªÌ¦º¤`¡H¬O§_¬ÛÃö·Sª§Ä³ 2018-04-11 med.sina.com/article_detail_100_2_44128.html ®Ú¾Ú¬ü°ê¦³½u¹qµø·s»DºôCNNªº³ø¾É¡A¼Æ¦Ê¦W±wªÌ¦bªA¥Îªü¥d}¨È¡]Acadia¡^»sÃĤ½¥qªº©¬ª÷´Ë¯fÃĪ«Nuplazid«á¦º¤`¡C³ø¾ÉÁÙ´£¨ì³\¦h±wªÌ¨Ã¨S¦³±q¸ÓÃĪ«¤¤¨ü¯q¡A³o·N¨ýµÛ¸ÓÃĨèS¦³«Ü¦nªº±±¨î©¬ª÷´Ë¯fªº¶i®i¡C¥t¥~¡A³ø¾ÉÁٺ٬ü°ê¹«~©MÃĪ«ºÞ²z§½³Ìªñªº¤@¦¸½Õ¬dµ²ªGÅã¥Ü¡A700¦h¦WªA¥Î¸ÓÃĪ«ªº±wªÌ¤w¸g¦º¤`¡C Åý§ÚÌ¥ý¤F¸Ñ¤@¤U¸ÓÃÄ¡CPimavanserin Tartrate¡]°s¥Û»Ä¤Ç²ö½d¦âªL¡^¥Ñªü¥d}¨È¤½¥q¡]Acadia¡^¬ãµo¡A©ó2016¦~4¤ë29¤éÀò¬ü°êFDA§åã¤W¥«¡A°Ó«~¦W¬°Nuplazid®¡C¸ÓÃĬO¤@ºØ5-ßm¦âÓi¡]5-HT2A¡^¨üÅé¤Ï¦V¿E°Ê¾¯¡A¥Î©óªvÀø¥X²{¤Ûı©Î¦k·Q¯gµ¥ºë¯«¯e¯fªº©¬ª÷´Ë¯g±wªÌ¡C Nuplazid¬Oªü¥d}¨ÈªººXÄ¥ÃĪ«¡CFDA´¿±Â¤©¸ÓÃÄ¡§¬ð¯}©ÊÀøªk¡¨©M¡§Àu¥ý¼fµû¡¨¡A²z¥Ñ¬O¸ÓÃĥΩóªvÀø©¬ª÷´Ë¯g³o¼ËªºÄY«¯e¯f¡A¥B»P¥«³õ¤W¤w¦³ªºªvÀø¬Û¤ñ¡A¹ïÄY«©Î¦M¤Î¥Í©Rªº¯e¯fªº±wªÌªí²{¥X¡§¹ê½è©Ê§ïµ½¡¨¡C CNNªº³ø¾É¨S¦³¤ñ¸ûªA¥ÎNuplazidªº±wªÌ»P¨S¦³ªA¥ÎNuplazidªº±wªÌªº¦º¤`²v¡C¦]¦¹¡A³oºØÃĪ«¬O§_»P¸û°ªªº¦º¤`²v¬ÛÃö¡A©ÎªÌ®Ú¥»¨S¦³¥ô¦óÃöÁp©Ê¡A¥Ø«e©|¥¼©ú½T¡C »â¾ÉFDAÂå¾Çµû»ù³¡ªºÂå¥ÍPaul Andreason³Õ¤hĵ§i»¡¡A¦b¤½¥qÁ{§É¸ÕÅç´Á¶¡ªA¥Î¸ÓÃĪº±wªÌ¥X²{¤FÄY««áªG¡A¥]¬A¦º¤`¡A¨ä¤ñ²v¬OªA¥Î¦w¼¢¾¯ªÌªº¨â¿¥H¤W¡C¥L»¡¡A¸Ó¤½¥q¦³ªº¸ÕÅç¨Ã¨S¦³ÃÒ©úÀò¯q¶W¹L¤F·ÀI¡C ... ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/4/11 ¤U¤È 05:40:38²Ä 303 ½g¦^À³
|
²q·Q¤j~~ Global ip news¬Ý¨ìÃö©ó¤ß®®°T®§...¦]¹ï·Q½Ð±Ð¤@¤Uª©¤W±M·~ªº¤j¤jÌ..³oÓ¬O·sªº¥Ó½Ð¶Ü? Pharmaceutical | Fri 06 Apr 2018 Alexandria, April 6 -- Syneurx International (Taiwan) has filed a patent application for compositions containing tannic acids and uses thereof. This invention was developed by Tsai Guochuan Emil, Wang Ching-Cheng, Hsieh Tien-Lan and Mao Yi-Wen. The patent application number is 15/834428. International Patent Classification c.. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/4/11 ¤U¤È 05:36:28²Ä 302 ½g¦^À³
|
¤¤¼Ï¯«¸g¨t²Î¯e¯f»â°ìªñ´Á¬ã¨s¶i®i¡]²Ä52´Á¡^ ¨Ó·½¡GÃÄ©ú±d¼w¡@2018-04-11 med.sina.com/article_detail_103_2_44100.html 1. Sunovion¡G©¬ª÷´Ë¯f¤fªA·sÃÄ»¼¥æ¤W¥«¥Ó½Ð¡AÀò§Ö³t³q¹D¸ê®æ Sunovion¤½¥q«Å¥¬¤w¦V¬ü°êFDA´£¥æ¤Fªü¼³¶Ü°Ø¦Þ¤U½¤¡]APL-130277¡^ªº·sÃĥӽС]NDA¡^¡A¥Î©óªvÀø©¬ª÷´Ë¯f¡]PD¡^±wªÌªº¹B°Êªi°Ê¡]OFF¨Æ¥ó¡^¡CFDA¦P®É±Â¤©¨ä§Ö³t³q¹D¸ê®æ¡C 2. Allergan¡G§Üºë¯«¯f·sÃÄ3´ÁÁ{§É¹F¨ì²×ÂI ¤é«e¡AAllergan©MGedeon Richter¤½¥q¦@¦P«Å¥¬¡AÂù¤è¦X§@¶}µoªºcariprazine¦bªvÀø»P1«¬Âù¬Û±¡·P»Ùê¡]bipolar I disorder¡^¬ÛÃöªº§íÆ{¯gªºÁ{§É3´Á¸ÕÅ礤¨ì¹F¤F¥Dn²×ÂI¡C 3. Denali¡G·s§ÜÅé¥i¥HÁY¤p¾ý¯»¼Ë³J¥Õ´³¶ô ¬ã¨sªÌµo²{¡A¹v¦VAPOE°ò¦]¥i²M°£AD¤p¹«¼Ò«¬¤¤ªº¤j¶q´³¶ô¡C¬ÛÃö½×¤åµoªí¦b¡mJournal of Clinical Investigation¡n¤W¡C APOE¬O¯à´£¨ÑAD±wªÌ¹w«áªº°ò¦]¡C¦b¤j¸£¤¤¡AAPOE¨ó§U±NÁx©T¾JÂà¹B¨ì¯«¸g¤¸¥H¤ä«ù¨ä¥¿±`¥\¯à¡CAPOE°ò¦]¦³¤TºØµ¥¦ì°ò¦]¡AºÙ¬°£`2¡A£`3©M£`4¡C¤§«eªº¬ã¨s¤w¸gµo²{¡A£`4µ¥¦ì°ò¦]»PAD°ª·ÀI©M¦´Áµo¯f¬ÛÃö¡C¾Ú¦ôp¡A¦b¬ü°ê³Ì°ª¥i¹F65%ªºAD±wªÌÄâ±a¤@ÓAPOE £`4µ¥¦ì°ò¦]¡A¦Ó10-15%ªºAD±wªÌ¡]¦b¬ü°ê¤j¬ù¦³56¸U¤H¡^ªº°ò¦]«¬¬OAPOE £`4¯Â¦X¤l¡CAPOE £`4¯Â¦X¤lÄâ±aªÌ¦b¯e¯f¦hÓ¶¥¬q³£®i²{¥X§ó§Öªº»{ª¾°I°h³t«×,¦¹¥~¡A¥LÌÁÙ®i²{¥X§ó°ª§ó§Öªº¾ý¯»¼Ë³J¥Õ¿n²Ö¡C ¤§«e§ÜA£]§ÜÅé¶}µoµ²ªG¤£ºÉ¦p¤H·N¡A¦Ó¥B¥¦Ì¥i¯à¾ÉP¸£³¡ª¢¯g¡C¦ý§ÜAPOE§ÜÅéµ²ªG¥i¯à·|¤£¦P¡G¾ÚHoltzman³Õ¤h»¡¡A¦]¬°¦b¾ý¯»¼Ë´³¶ô¤¤ªºAPOE³J¥Õ½è§t¶q«D±`¤Ö¡AÃĪ«¤£·|µ²¦X±o¹L©óºò±K¡A©Ò¥H§ÜAPOE§ÜÅ骺°Æ§@¥Î¥i¯à¸û¤Ö¡C¡§³o·N¨ýµÛ§ÚÌ¥i¯à·|µo²{¸û§Cªº§K¬Ì¿E¬¡¤ô¥¡A¤£·|¬Ý¨ì¤£¨üÅwªïªº°Æ§@¥Î¡A¡¨Holtzman³Õ¤hµû½×¹D¡C¬ã¨s¤p²Õªº¤U¤@¨B¬O´ú¸Õ¬Û¦üªº§ÜÅé¡A¨Ã³]p¶i¤@¨Bªº¸ÕÅç¨Ó½T©w¥¦Ì¬O§_¹ï¤HÃþ¦w¥þ¡C ¤µ¤Ñ¦Û¥Ñ®É³øªº·s»D ªü¯÷®üÀq¯g¡u¦MÀI°ò¦]¡v¥iÃö³¬ 2018-04-11 news.ltn.com.tw/news/world/paper/1191496 ¹Î¶¤¸Õ¹Ï¡uײz¡vApoE4³y¦¨ªº²ÓM²§±`¡A¥L̳гy¤@Ãþ½Æ¦Xª«¡]Compound¡^¡A¥i§ïÅÜApoE4ªºµ²ºc¡A¨Ï¨ä»P¸ûµL®`ªºApoE3¬Û¦ü¡A¶i¦Ó®ø°£ªü¯÷®üÀq¯gªº¯fª¬¡A§Î¦P¡uÃö³¬¡v³oºØ°ª·ÀIÅܲ§°ò¦]¡C¥Ø«e¡A¹Î¶¤¥¿»PÂå¾Ç¤ÎÃľǬɦX§@¡A«ùÄò§ï¨}¤Wz½Æ¦Xª«¡A¬ß¥¼¨Ó¥i¦b±wªÌ¨¤W¶i¦æÁ{§É¹êÅç¡C³o¶µ¬ã¨s¦¨ªG¤w¥Zµn©ó°ê»Ú´Á¥Z¡m¦ÛµMÂå¾Ç¡n¡C Scientists fix genetic risk factor for Alzheimer¡¦s disease in human brain cells Date: April 9, 2018 Source: Gladstone Institutes www.sciencedaily.com/releases/2018/04/180409112559.htm ½×¤å : Gain of toxic Apolipoprotein E4 effects in Human iPSC-Derived Neurons Is Ameliorated by a Small-Molecule Structure Corrector. Nature Medicine, 2018 DOI: 10.1038/s41591-018-0004-z www.nature.com/articles/s41591-018-0004-z ¤Æ¦Xª«¥N¸¹ : PH002 ¥t¤@½g¦P¹Î¶¤ 2011 ªº½×¤å Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. www.ncbi.nlm.nih.gov/pubmed/?term=PH002 ¥t«h·s»D : vTvªüº¸¯ý®üÀq¯gÃĪ«azeliragon 3´Á¥¼¹F²×ÂI±N°±¤îÄ~ÄòÁ{§É ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-04-11 med.sina.com/article_detail_100_2_44099.html ³o¶µSTEADFAST¬ã¨s¥]¬A¨âÓ¿W¥ßªº¡B§¹¥þ¬Û¦PªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·ÓªºÁ{§É3´Á¸ÕÅç(A³¡¤À©MB³¡¤À)¡CAzeliragonªvÀø²Õ(A³¡¤À)ªºADAS-Cog¤ñ°ò½u¤U°¤F4.4ÓÂI¡A¦bCDR-sb¤¤¤ñ°ò½u¤U°¤F1.6ÓÂI¡A¦Ó¦w¼¢¾¯²Õ¤U°ªºÂI¼Æ¤À§O¬°3.3©M1.6¡C³o¨Ç®t²§¦b²Îp¾Ç¤W¨S¦³ÅãµÛ·N¸q¡Cazeliragon¤@¯ë³£¦³¨}¦nªº@¨ü©Ê¡A¦b18Ӥ뤺§ÙÂ_²v¬°25%¡A³o¦b¦w¼¢¾¯©MªvÀøÁu¤W¬O¬Û¦üªº¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/4/11 ¤U¤È 04:56:46²Ä 301 ½g¦^À³
|
¤j³Â¯À·sÃÄTHX-110ªvÀø®ÄªG¿n·¥§ïµ½¯«¸g¯e¯f¯gª¬ ¨Ó·½¡GÃÄ©ú±d¼w¡@2018-04-11 med.sina.com/article_detail_103_2_44091.html ±Mª`©ó¶}µo¤j³Â¯À·sÃĪº¥Íª«ÂåÃĤ½¥qTherapix Biosciences«Å¥¬¤F¨ä¦bC¾|¤j¾Ç¡]Yale University¡^¶}®iªºÃö©óTHX-110ªº2a´ÁÁ{§É¸ÕÅ窺µ²ªG¡C¸Ó¬ã¨sÅã¥Ü¡ATHR-110ÅãµÛ§ïµ½¤F¦«¹p¤óºî¦X¼x¡]Tourette syndrome¡ATS¡^¦¨¤H¨ü¸ÕªÌªº¯gª¬¡C ¦«¹p¤óºî¦X¼x¡]TS¡^¬O¤@ºØ©â°Êºî¦X¼x¡]Tic¡^¡A¬O¸û±`µo¥Í©ó¤Ö¦~¨àµ£¤¤ªº¯«¸g¤º¬ì¯e¯f¡C±wªÌ·|¤£¥Ñ¦Û¥D¦aµo¥XÁnµ©ÎªÌ·n®Ì¨Åé¡C¾Ú¦ôp¡A¸Ó¯e¯fªº¦~µo¯f²v¬°¨C¦Ê¸U¤H¤¤¦³5-10Ó±wªÌ¡C¸Ó¯e¯f·|µ¹±wªÌ±a¨Óºë¯«À£¤O©M¦æ¬°¯¿¶Ã¡C Therapix¶}µoªºTHX-110¬O©}¤j³Â×ô¡]dronabinol¡A¦X¦¨¤j³Â¯À¡^©M´ÄÃq酰¤A¾J酰Ói¡]palmitoylethanolamide¡^ªº²Õ¦X¡C ¾ÚTherapix³ø¾É¡A¦b¤@¶µ¦®¦b½T»{ÃĪ«¦w¥þ©Ê¡B@¨ü©Ê©M¥i¦æ©Êªº³æÁu¡B¶}©ñ¼ÐÅÒ2a´ÁÁ{§É¸ÕÅ礤¡A16¦W±µ¨üTHX-110ªvÀøªºTS±wªÌ¤¤¦³6¦W¥X²{¤F©úÅã§ïµ½¡A¥L̪º¯f±¡«öC¾|¾ãÅé©â°ÊÄY«µ{«×µû¤À¿ö¡]Yale Global Tic Severity Scale Total Tic Score¡^µû©w¡A¦b12¶g«áµû¤À°§Cªºµ{«×¶W¹L25¢H¡C¨Ó¦ÛC¾|¤j¾Çªº¬ã¨s¤Hû¤]³ø§i¤F°ª¹F7.9¡]±q38.4¨ì30.5¡^ªº¥§¡®tÈ¡A³o·N¨ýµÛ¥§¡©â°Ê´î¤Ö¤F21¢H ¡A©â°Ê¬O±wªÌªº¤ÏÎ`µL·NÃѰʧ@©MÁnµ¡A¬OTSªº¯e¯f¯S¼x¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/4/8 ¤U¤È 09:56:34²Ä 300 ½g¦^À³
|
ÁÂÁÂliaw6575¤j¤j¤À¨É¤Îª©±ªº§ïÅÜ ÀH®Éª`·Nliaw6575¤j¤jªº°ÊºA´N¦³¿}¦Y liaw¤j¤j³Ì·sªº½×¤å¾ã¦X ¡u Back to Basic:D-µ·®ò»Ä´£¤ÉNMDA¯à¯«¸g¶Ç¾É¡A¨ã¦³¼W¶i»{ª¾¡B¾Ç²ß»P°O¾Ð¥\®Ä ¡v liawbf.pixnet.net/blog/post/47880849-back-to-basic:d-%E7%B5%B2%E6%B0%A8%E9%85%B8%E6%8F%90%E5%8D%87nmda%E8%83%BD%E7%A5%9E%E7%B6%93%E5%82%B3%E5%B0%8E%EF%BC%8C%E5%85%B7%E6%9C%89 liaw¤j¤j¥Ñ¦h¦ì¾ÇªÌ±M®aªº¤£¦PÁ{§Éµ²ªG¡]½Ð°Ñliaw6575¤j¤j±M¤å¡^¡AÂk¯Ç¥X¡G ¡uD-µ·®ò»Ä¤w¦b¤HÅé¸ÕÅ礤¡A§¡¥i¨£¨ìÅãµÛ´£¤É»{ª¾¡B¾Ç²ß»P°O¾Ð¥\¯à¡AÃҹ괣¤ÉD-µ·®ò»Ä¿@«×¡A¶i¦Ó´£¤ÉNMDA¨ü¾¹¥\¯à¡A´£¤Éªø´Á¼W¯q§@¥Î¡A«P¶i¬ðIJ¥i¶ì©Ê¡A³Ì²×´N¦³´£¤É»{ª¾¡B¾Ç²ß»P°O¾Ðªº®Ä¥Î¡A¦ÛµM¤]¶¡±µ©Îª½±µ§ïµ½¯«¸g°h¤Æ©Ê¯e¯f¦pªü¯÷®üÀq¯g©Îºë¯«¯e¯f¦pºë¯«¤Àµõ¯gªº»{ª¾¯gª¬©Î»{ª¾¯fµ{¡C¥Ñ©ó»{ª¾¥\¯à²§±`³£¬Oºë¯«¤Àµõ¯g¡B¥¢´¼¯g¡B¼~Æ{¯g¤Î¦Ñ¤Æªº¥Dn¯f²z¯S¼x¡A·íµM¶}©l¦³¾ÇªÌ«ä¦ÒD-µ·®ò»Ä°µ¬°»{ª¾¼W±j¾¯(Áo©úÃÄ)ªº¼ç¯à»P¬D¾Ô¡A¸Û¦pGuercio & Rogerio (2018)©Ò¨¥¡AD-µ·®ò»ÄªºÃIJz»P¹ïÀ³NMDAR¾÷Âà¡A¤w¸g©ú½T¤F¡A¦ÓD-µ·®ò»Ä»Pf¥Ò»Ä¶u«K©y¤S¤Ö°Æ§@¥Î¡A¥B¨¾»G¨Ï¥Î©ó¨ä¥LÃĪ«¤w¤[¡A±N¬O³Ì¾A¦Xªº¿ï¾Ü¡C¤ß®®¬ãµo¤ñD-µ·®ò»Ä¤ñ·s¤@¥NªºSND-1(¬¡©Ê¦¨¤À¬°f¥Ò»Ä¶u)¡A¥i¥H§í¨îD-µ·®ò»Äªº¥NÁ¡A¶¡±µ¼W¥[¨ä¿@«×¡A¤Wz¾Ç³N¬ã¨sªºÄ£²´µ²ªG¡A¤Ï®g¥XSND-1À³¸Ó¨ã¦³ªvÀøCNS¯e¯fªº»{ª¾¯gª¬ªº¼s®ÄÃÄ(Broad spectrum agent)»P¥¿±`¤H©Ò¥ÎÁo©úÃÄ¡A¬Æ©Î°w¹ï°ª¦MÀI¸s¹w¨¾©Ê§ëÃĪº¥¼¨Ó¥ú¨~(Fujita, Ishima & Hashimoto,2016)¡C ¦pªGNMDA¯à¯«¸g¶Ç¾É¨t²Î¦û¤j¸£¯«¸g¶Ç¾É¨t²Î80%¥H¤W¡A¬O³o»ò«n¡A«o¨S¦³NMDAP®Ä¾¯ªºÃĪ«¡A°Z¤£¿ò¾Ñ?NMDAP®Ä¾¯ªºÃĪ«¦Ü¤µÁÙ¨S¦³¤W¥«¡A¦pªG¤@¥¹Àò±oFDA»{¥i¡A¤£¥u¾Ç³N¬É»PÂå¾Ç¬É¡A³s°Ó·~¬ÉÀ³¸Ó³£·|¤Þ°_«Ü¤jªº¾_¾Ù§a!¡v liaw6575¤j¤jªºµ²½×¡A¥y¥y¬Ò¸g¨å¡A¤ÓÃø¨ú±Ë ©Ò¥Hì¤å·Ó¶K¡AÁÙ½Ðliaw6575¤j¤j®ü²[ ÁÂÁÂliaw6575¤j¤j ÁÂÁ¤j®a¡I |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/3/27 ¤U¤È 05:27:20²Ä 299 ½g¦^À³
|
²q·Q¤j~~~ ÁÂÁ±zªº¦^ÂФΤÀ¨É·s¸ê°T...·P®¦... ¦b¥Í§Þ·sÃĤ½¥q¤¤...¤ß®®¬O«e¬q¯Z¦n¾Ç¥Í... ÁöµM¥»¤H¥[¤Jªº¤ñ¸û±ß...¦ý§Ú³o¤Hº¡°õµÛªº... ¬Ý¦n§Yªø´Á«ù¦³..¤ß®®ªº¥¼¨Ó¬Û·íȱo´Á«Ý... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/3/27 ¤U¤È 04:39:34²Ä 298 ½g¦^À³
|
ÁÂÁÂliaw6575¤j¤j³Ì·sªº±M¤å [ ·L½¦²ÓM¤£¦A¥u¬O±½©U§£ ] liawbf.pixnet.net/blog/post/47863806-%E5%BE%AE%E8%86%A0%E7%B4%B0%E8%83%9E%E4%B8%8D%E5%86%8D%E5%8F%AA%E6%98%AF%E6%8E%83%E5%9E%83%E5%9C%BE ¥B¤º¤å©Òªþªº¤Þ¥Î¨Ó·½ , ¶Z¨äµoªí¤]ÁÙ¤£¨ì¤@¤Ñ [ Microglia Use Filopodia To Help Synapses Grow And Rearrange ] by D.C. Demetre March 26, 2018 reliawire.com/microglia-filopodia/ ¤×¨ä liaw6575¤j¤jªº±Ò¥Ü , §óȱo²Ó²Ó©CÄZ ¤p§Ì¤]§ä¤F¨â½g¥H«eªº½×¤å ´£½Ð¤j®a°Ñ¦Ò Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive, Reduces Microglial and Astroglial Inflammatory Responses www.jimmunol.org/content/183/9/5917 ¯«¸g½¦½è²ÓM¡]¤p½¦½è²ÓM©M¬P§Î½¦½è²ÓM¡^ªº¬¡¤Æ¤w¸g²o¯A¦b¦hºØ¯«¸gÅܩʯe¯f¡A¥]¬Aªüº¸¯ý®üÀq¤ó¯f¡]AD¡^¡Aµo¯f¾÷¨î3©¬ª÷´Ë¤ó¯f¡A§J-¶®¯f¡AHIV¬ÛÃö©Êè§b¡]HAD¡^¡A¤¤·¡A©M¦hÓµw¤Æ¯g¡]MS¡^¡]1¡A2¡^¡C¤w¸gµo²{ªº¬O¬¡¤Æªº¤p½¦½è©M¬P§Î½¦½è²ÓM¿n»E¦b¯«¸gÅÜ©ÊCNS¡]·l¶Ë³¡¦ì©Î´³¶ô1¡A2¡A3¡A4¡A5¡A6¡A7¡^¡CÁöµM¬¡¤Æªº¤p½¦½è±qCNS²M°£¦º²ÓM©M¤Àªc¥Î©ó¯«¸g¤¸¦s¬¡¤£¦Pªº¯«¸gÀç¾i¦]¤l¡A¦ý»{¬°ÄY«¿E¬¡¤Þ°_ªº¦UºØ¦Û¨§K¬ÌÀ³µª¾ÉP¯«¸g¤¸¦º¤`©M¸£·l¶Ë¡]1¡A2¡A3¡A4¡A5¡A6¡A7¡^ ¡C¦b¿E¬¡¹Lµ{¤¤¡A¤p½¦½è²ÓM©M¬P§Î½¦½è²ÓMªí¹F»Pª¢¯g¬ÛÃöªº¦UºØ°ò¦]¡A¦p«Pª¢©Ê²ÓM¦]¤l¡A«Pª¢酶¡A©M«Pª¢Öߪþ¤À¤l¡]1¡A2¡A3¡A4¡A5¡A6¡A7¡A8¡A9¡^¡C¦]¦¹¡A¿E¬¡½¦½è²ÓM©Ò»Ýªº«H¸¹¶Ç¾É³~®|ªºªí¼x¬O¤@Ó¬¡ÅDªº¬ã¨s»â°ì¡A¦]¬°¯à°÷«ú§Ü³oºØ«H¸¹¶Ç¾É¨BÆJªº¤Æ¦Xª«¥i¯à¦b¯«¸g°h¦æ©Ê¯e¯f¤¤¨ã¦³ªvÀø®ÄªG¡C ¦b³o¸Ì¡A§ÚÌ´£¨Ñ¤F²Ä¤@ÓÃÒ¾Ú¡A§YNaB´î®z¤p½¦½è²ÓM¡A¬P§Î½¦½è²ÓM©M¥¨¾½²ÓM¤¤¥i»¤¾ÉªºNO¦X酶¡]iNOS¡^©M«Pª¢²ÓM¦]¤lªºªí¹F¡C... §Ú̪º¬ã¨sµ²ªG´£¥X¤F¤@ºØ¥i¯à©Ê¡A§Y¤HÃþ§¿¯À´`Àô»Ùê³B¤èÃĪ«NaB©M¼sªx¨Ï¥Îªº¹«~¨¾»G¾¯¥i¯à·|¦b¯«¸gª¢¯g©M¯«¸g°h¦æ©Ê¯e¯f¤¤§ä¨ì¶i¤@¨BªºÀ³¥Î¡C(Google½Ķ) Cinnamon and Its Metabolite Sodium Benzoate Attenuate the Activation of p21rac and Protect Memory and Learning in an Animal Model of Alzheimer¡¦s Disease journals.plos.org/plosone/article?id=10.1371/journal.pone.0130398 ¤fªA¦×®Û¡]Cinnamonum verum¡^¯»©MNaB§í¨î¤Fp21 racªº¬¡¤Æ¨Ã³q¹L°§C¤G²B¤A¿õ¡]DHE¡^©Mµv°ò¹T®ò»Ä¬V¦â¡A°§C¦P«¬¥b¯Ö®ò»Ä¤ô¥©M¼W¥[ÁÙ쫬½\¯Ö¥Ì肽¤ô¥¨ÓÃÒ©úTg¤p¹«ªº®ü°¨¤¤ªº®ñ¤ÆÀ³¿Eªº´î®z¡C³o¦ñÀHµÛ§í¨î¯«¸g²ÓMä¤`¡A§í¨î½¦½è²ÓM¿E¬¡¡A´î¤Ö®ü°¨A£]t²ü¡A«OÅ@Âà°ò¦]¤p¹«ªº°O¾Ð©M¾Ç²ß¡C(Google½Ķ) ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ¤p©¯¹B¤j ©Î³\ADªºBTDÀ³¸Ó«ÜÃø ¥i¹J¤£¥i¨D Y¯u®³¨ì ·|§ó¥YÅ㥦ªº¬Ã¶Q liaw6575¤j¤jªº±M¤å [ ¦Ñ¦~ , ®ò°Õ--f¥Ò»Ä¶u¹ïªvªü¯÷®üÀq¯gª¾¥t¥~¯f²z»PÃIJz°²»¡ ] liawbf.pixnet.net/blog/post/47709222 ¤p§Ì¹ï¤§¬O®®Åª®®¦³©Ò·P§r! |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/3/26 ¤U¤È 02:04:57²Ä 297 ½g¦^À³
|
¤ß®®ª©¤W±M·~Âå¾Çª¾ÃѪº¤j¤jÌ~~~ ¦³¤@Ó·Qªk·Q½Ð±Ð¤@¤U~~~ Ãö©óf¥Ò»Ä¾Y©Mf¥Ò»Ä¶uªº¦@´¹µ²ºcªº³¡¤À~~~ ²q·Q¤j©ó 2018/3/19 ¤U¤È 01:21:43¦³¤À¨É¤@¨Ç½×¤å½Ķ¸ê®Æ...¨ä¤¤³Ì«á¤@¬q... ----------------------------------------------------------------------------------------------------- ¦bAD°Êª«¼Ò«¬¤¤¡Af¥Ò»Ä¶u´î»´¤F®ñ¤ÆÀ³¿E¡A«OÅ@¤F°O¾Ð©M¾Ç²ß¡]116¡^¡C¤£¹L¡Aȱoª`·Nªº¬O¡Af¥Ò»Ä¶uªºªvÀø®ÄªG¤£¶È¥i¯à¨Ó¦Û¨ä§Ü®ñ¤Æ§@¥Î¡A¤]¥i¯à¨Ó¦Û¨ä§K¬Ì½Õ¸`§@¥Î¡]122¡^¡C µL½×¦p¦ó¡A¦pªG³o¨ÇÁ{§Éµo²{³Q½Æ»s¡Af¥Ò»Ä¶u¥i¯à³QÃÒ©ú¬OªvÀøAD¦´Á±wªÌªº¬ð¯}¡C ------------------------------------------------------------------------------------------------------ ³oÓ«áÄò¦bAD·sÃĪº³¡¤À...¦³¥i¯à¥Ó½Ð²Ä¤T±iBTD¶Ü? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/3/23 ¤U¤È 04:17:55²Ä 296 ½g¦^À³
|
©ú/«á¤Ñ©ó¤º´ò°ê¨¾Âå¾Ç¤¤¤ß§Y±NÁ|¦æªº²Ä33©¡¥Íª«Âå¾ÇÁp¦X¾Ç³N¦~·|¡]www.jacbs.org.tw/upload/attachment/20180322/40cd04c0b331454ea119164e0d5e17f3/40cd04c0b331454ea119164e0d5e17f3.pdf¡^ ¨ä¤¤¤@¶µ¬F¤j»P°ê½Ã°|ªº¬ã¨s³ø§i¡A¦b¤p¹«¹êÅ礤¡A¬I¥´f¥Ò»Ä¶u«á¡A¥i°fÂà«ÂмÉÅS¦bK¥L©R¤Uªº¤p¹«©Ò§e²{ªº¦æ¬°²§±`¡B°O¾Ð¯Ê·l¡BÃþ¼~Æ{¦æ¬°¤Î¯Ê¥F¥k±ÛÓi°ò»Ä®ñ¤Æ酶©ÒPªº¹L«×¤ÏÀ³¦æ¬°µ¥¡Aµ²½×¬Of¥Ò»Ä¶u¥i¯à¨ã¦³§ïµ½««×K¥L©R¨Ï¥ÎªÌt¦V¦æ¬°ªº¼ç¤O¡C Page 122/374 TX011 PC ¡uSodium benzoate ameliorates subchronic ketamine-induced behavioral disturbances.¡v ºKn : Ketamine is a synthetic dissociative anesthetic. In recent years, it has become a common abused substance. Heavy ketamine use often results in behavioral disturbances including depression, social deficits and cognitive impairments. Growing evidence shows that enhancement of NMDA receptor function can ameliorate the effects of ketamine-induced behavioral and neurochemical responses. Sodium benzoate (SB), an inhibitor of D-amino acid oxidase, can indirectly increase the NMDA receptor function and is also beneficial to the patients with depression or schizophrenia. The present study examined whether SB can reverse the behavioral dysfunction in mice that repeatedly exposed to ketamine. Male ICR mice received either ketamine (20 mg/kg, i.p.) or saline twice a day successively during postnatal days (PN) 32-46. Subsequently, SB (30 or 100 mg/kg, i.p.)was given during PN55-69. The social interaction test, novel object recognition task, three-chamber social test, tail suspension test and forced swimming test were monitored. Furthermore, a hallucinogenic 5-HT2A agonist 1-[2,5-dimethoxy-4-indophenyl]-2-aminopropane (DOI) was administered to induce head twitch responses. Our results showed that SB reversed the subchronic ketamine-induced social deficits, memory deficits, depression-like behavior and hyper-responsivity to DOI-induced head twitch responses. These findings suggest that SB might have potential to reduce negative behavioral consequences of heavy ketamine use. |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/3/23 ¤W¤È 11:17:57²Ä 295 ½g¦^À³
|
¤p¨È¤j~~~ ¨S¿ìªk...¥xÆW´²¤á¤j³¡¤À³£¹ï¥Í§Þ·sÃIJ£·~³£¨S«H¤ß... ¤]¥¿¦]¬°¦p¦¹...¤ß®®2±iCNSªºBTD»{ÃÒ¤~·|³QÄY«§C¦ô»ùÈ... ¦Ü©ó»´äªÑ¥«©ñ¼eªº³W©w...¤j·§¬Ý¤F¤@¤U...¨ä¹ê¤ß®®ÁÙº¡²Å¦Xªº... ¦pªG¥H³yºÖ¥þ¥@¬É¯f¤Hªº¨¤«×¨Ó«ä¦Ò...¥»¦¸ªÑªF·|¥i¥H¦V½²Âå®v´£Ä³¬Ý¬Ý.... -------------------------------------------------------------------------------------- »´äªÑ¥«¥h¦~©³¤½¥¬·s¨î¡A©ñ¼eµLÀò§Q¡BµLÀ禬¤½¥q¡A ¥un¥«È¹F15»õ´ä¤¸¡]¬ù¥x¹ô57»õ¤¸¡^´N¥i¥H¡u¯S§OªÑ¡v¤è¦¡¦b»´äªÑ¥«±¾µP¡A ¤£¹L¥²¶·¥H¬ãµo¬°¥D¡A¥B¨ã¦³¯S©w³Ð·s´¼°]Åv¡A¨Ã¦Ü¤Ö¦³¤@ÃÄ«~¶i¤JÁ{§É¤G´Á¡C --------------------------------------------------------------------------------------- ¥H¤W~~Ó¤H·Qªk¨Ñ¤¤ªø´Á§ë¸ê¤H°Ñ¦Ò~~~ |
|
|
·|û¡G¤p¨È10135608 µoªí®É¶¡:2018/3/23 ¤W¤È 10:48:14²Ä 294 ½g¦^À³
|
½²±Ð±Â»â¾É¬ãµoªº¤ß®®À³¸Ó¤£¯Ê¸êª÷¡A¤W¦¸200¤¸ªº¼W¸ê¤j®a³£«D¬Ý¦n¡A¬Ý¾Ì¨Ó¬Ý¬Ý¡A¥h¦~©³»´ä¥æ©ö©Ò¬°ÁÙ¨SÀ禬¡BÀò§Qªº³Ð·s¬ãµo¥Í§Þ¤½¥q¶}¤F¤@®°¤jªù¡A¥i¥H¦b¥DªO±¾µP¤W¥«¡A¥H¦PªÑ¤£¦PÅv¤è¦¡«O»Ùì©l§ë¸êªÌ¡C¥_¨Ê¥[¬ì´µ§Y³W¹º©ú¦~¦b´ä±¾µP¡A§ë³ø²v½Ä20¿¡A¤ß®®§ë¸êªÑªFÌ¡A¤j®a¬Ý¤F¬O§_¤]¤ßÄoÄo¦a¡I |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/3/23 ¤W¤È 10:20:43²Ä 293 ½g¦^À³
|
¤p¨È¤j... ¤º¦æªºªü...¥«³õ¤¤¹ê¤á/¤j¤á¸êª÷²¾©¹¥Í§ÞÃþªÑ... ±q3¤ëªì¶}©l´N¤w«Ü©úÅã... ¤]±a°Ê¥Í§Þ«ü¼Æ¬Û¹ï¦ì¸m¦¤w¹L¤j½L°ªÂI11270ªº¦ì¸m... ¥Ø«e¥Í§ÞÃþªÑº¦¦h¤p¦^ÀÉ.... «áÄò..¥«³õ¸êª÷Âà¤J¥Í§ÞÃþªÑÁͶÕ...±N¦]¤¤¬ü¶T©ö¤j¾Ô¥[³t´é¤J... Àu½è·sÃĪÑ...¥un¦^ÀÉ...´N¬O§ë¸ê§ä¶RÂIªº¦n¾÷·|... |
|
|
·|û¡G¤p¨È10135608 µoªí®É¶¡:2018/3/23 ¤W¤È 10:10:04²Ä 292 ½g¦^À³
|
»{©w¬O¦n¤½¥q¡A´Nn¶X½L±²V¶Ã®É¥[½XÁÈ«K©y¡A¥®É§ä¤£¨ì¸û§CªºªÑ»ù¥i¥H¤J¤â¡C |
|
|
·|û¡G¤p¨È10135608 µoªí®É¶¡:2018/3/23 ¤W¤È 09:18:56²Ä 291 ½g¦^À³
|
¬ü°êÁ`²Î¤t´¶©ó¬üªF®É¶¡22¤é¤¤¤È«Å¥¬¹ï¤j³°301½Õ¬d¨îµô¤è®×¡AÀÀ¹ï¤j³°²½¥XÃg»@©ÊÃöµ|¡A¤¤¬ü¶T©ö¾Ô±¡¶Õ¤É·Å¡A®£ªi¤Î§Ú°ê¥ø·~¡C¸gªø¨Hºa¬z¬Q¡]22¡^¤é¨ü³X®É¤ÀªR¡A¦b¤j³°¥Í²£²×ºÝ²£«~¾P©¹¬ü°ê¡A¥H¤Î¦b°ê¤º¥Í²£¡A´£¨Ñ¹s²Õ¥ó¡B¥b¦¨«~µ¥¤¤¶¡°]¥h¤j³°»s¦¨²£«~ªº¥x°Ó¡A·|¨ü¸û¤j¼vÅT¡C¤¤¥¡»È¦æÁ`µô·¨ª÷Às¤]«ü¥X¡A§ÚICT½ÄÀ»³Ì¤j¡A¨ä¥L²£·~¤]·|¦³¤@©wµ{«×ªº¼vÅT¡C ¡½¸ê³q°T¡B®ø¶O¹q¤l¨ü¼vÅT ¸gÀÙ³¡«ü¥X¡A¥h¦~¥xÆW¥X¤f¬ù4¦¨¬O¨ì¤j³°¤Î»´ä¡A¨ä¤¤86.97¢H¬O¤¤¶¡°]¡A¤¤¶¡°]¥X¤fÃB¬°763.6»õ¬ü¤¸¡A§Ú°ê¥X¤fÁ`ÃB¬°3,172.5»õ¬ü¤¸¡A¤]´N¬O»¡¡A¥X¤f¦Ü¤j³°ªº¤¤¶¡°]¥e§Ú°ê¥X¤fÁ`ÃB¬ù24.1¢H¡C ¨Ì°]¬F³¡¸ê®Æ¡A¥h¦~§Ú¥X¤f¤j³°³f«~¥H¹q¾÷³]³Æ¤Î¨ä¹s¥ó¬°¥D¡A¥e¤ñ¹F55.4¢H¡A¨ä¦¸¤À§O¬°¥ú¾Ç¾¹§÷µ¥ºë±K»ö¾¹¥e8.8¢H¡B¾÷±ñ¥Î¨ã¤Î¹s¥ó¥e8.4¢H¡C ¡½¹ê»Ú¥Ñ¤j³°¿é¬ü¤~¬O«ÂI ªk°ê¥~¶T©ö¦æ¨È¤Ó°Ïº®u¸gÀپǮa¦ã¦è¨È¡] Alicia Garcia Herrero¡^¬Q¤Ñ¤]ªí¥Ü¡A¤¤¬ü¶T©ö¾Ô¤õ¥¿³Qº´°Ê¡A¬ü°ê²½¥X¶T©ö¾ÀÂS¡A±q²£·~±¨Ó¬Ý¡A½ÄÀ»³Ì¤j´NÄݸê³q°T·~¡A¦Ó¨T¨®¡Bì§÷®Æ¡B¹s°â³q¸ô»Pª÷¿Ä·~µ¥¥|¤j²£·~¡A¦]ªñ¦~¨Ó®ü¥~¦¬¤J¥eÀ禬¤ñ·U¨Ó·U°ª¡A¦b¤U¤@ªi¥þ²y¶T©ö¾Ô¤¤·|¬O¸û®e©ö¨ü¨ì¼vÅTªº²£·~¡C ¥Í§Þ·~§O©È¡A²{¦b¤ÏˬOn§ä¥Í§ÞªÑ·íÁ×·¶í¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/3/21 ¤W¤È 11:22:56²Ä 290 ½g¦^À³
|
¤S¨Ó¤@Ó Prothena seals potential $2.2B deal for neurodegenerative diseases with Celgene www.bioworld.com/content/prothena-seals-potential-22b-deal-neurodegenerative-diseases-celgene-0 22 »õ¬üª÷? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/3/21 ¤W¤È 09:30:58²Ä 289 ½g¦^À³
|
¬O§_CNS»â°ìªº·sÃij£«ÜÈ¿ú??? ³o¬O¥Nªí·sÃīܯʶÜ??? << ªü¯÷®üÀq >> ªZ¥Ð¤Q»õñ¬ùªº Denali «Å¥¬±À¶i¤HÅéÁ{§É Ó¤Hı±o¤ß®®À³¸Ó»°§Ö¼W¸ê , »°§Ö¥[³t¦h¶µÁ{§É ÁÙ¬O¦bµ¥±ÂÅv??? ³o¼Ë´N¤£¥Î¼W¸ê¤F ??? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/3/19 ¤U¤È 01:21:43²Ä 288 ½g¦^À³
|
ÁÂÁ Cliff ¤j®¦¼w Tannic acids effectively inhibited the activity of DAAO. Tannic acids would benefit treatment of diseases and disorders associated with DAAO and/or glutamatergic neurotransmission, such as obesity, diabetes, hyperlipidemia and CNS disorders. ¥t¦³¤@½g½×¤å±Ð¾Ç,¾ã¦X¦h½g½×¤åªºÆ[ÂI Potential and Challenges for the Clinical Use of d-Serine As a Cognitive Enhancer www.frontiersin.org/articles/10.3389/fpsyt.2018.00014/full (¥H¤U¬°Google½Ķ) D-µ·®ò»Ä³q¹L¨ä¹ïNMDA-¨¦®ò»Ä¨üÅ骺§@¥Î¦Ó³Q¤½»{¬°¬ðIJ¥i¶ì©Ê©M»{ª¾¹Lµ{ªº½Õ¸`¾¯¡C«nªº¬O¡A»{ª¾»Ùê¬Oºë¯«¤Àµõ¯g¡Aªüº¸¯ý®üÀq¯f¡A§íÆ{¯g©M°I¦Ñµ¥¯e¯fªº®Ö¤ß¯S¼x¡A¨Ã»PNMDA¨¦®ò»Ä¨üÅ鯿¶Ã¦³Ãö¡C f¥Ò»Ä¶u©MGlyT1§í»s¾¯¦Ù®ò»Äªº²Õ¦X´£°ª¤Fºë¯«¤Àµõ¯g±wªÌªº»{ª¾©M¥þ±¥\¯à¡A¦Ó¦Ù®ò»Ä³æ¿W¨Ï¥Î¨S¦³®ÄªG¡]75¡^¡CµM¦Ó¡A¥Ñ©ó¯Ê¥F³æ¿W±µ¨üf¥Ò»Ä¶uªº¤@²Õ±wªÌ¡A§Ṳ́£ª¾¹D³o¨âºØ¤Æ¦Xª«¤§¶¡¬O§_¦s¦b¨ó¦P®ÄÀ³¡A©Î¶È¶È¬Of¥Ò»Ä¶uªº§@¥Î¡C ...¦³ÃÒ¾Úªí©ú¡A»P´â´á¥¬Û¤ñ¡AD-µ·®ò»Ä»P¨ä¥L§Üºë¯«¯fÃĬۤñµL®Ä¡]76¡^¡A¥i¯à¬O¦]¬°´â´á¥ªº§@¥Î¾÷¨î¥i¯à¥]¬A¼W¥[D-µ·®ò»ÄªºÄÀ©ñ¡]77¡^¡C ¦bAD°Êª«¼Ò«¬¤¤¡Af¥Ò»Ä¶u´î»´¤F®ñ¤ÆÀ³¿E¡A«OÅ@¤F°O¾Ð©M¾Ç²ß¡]116¡^¡C¤£¹L¡Aȱoª`·Nªº¬O¡Af¥Ò»Ä¶uªºªvÀø®ÄªG¤£¶È¥i¯à¨Ó¦Û¨ä§Ü®ñ¤Æ§@¥Î¡A¤]¥i¯à¨Ó¦Û¨ä§K¬Ì½Õ¸`§@¥Î¡]122¡^¡CµL½×¦p¦ó¡A¦pªG³o¨ÇÁ{§Éµo²{³Q½Æ»s¡Af¥Ò»Ä¶u¥i¯à³QÃÒ©ú¬OªvÀøAD¦´Á±wªÌªº¬ð¯}¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/3/19 ¤U¤È 12:56:46²Ä 287 ½g¦^À³
|
2018/02/08 ¬ü°ê±M§Q Title¡G (US20180036267) COMPOSITIONS CONTAINING BENZOATE COMPOUND AND TANNIC ACID FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS Abstract¡G ¡uCompositions (e.g., pharmaceutical compositions or nutraceutical compositions) comprising a benzoate compound and an excipient, wherein the excipient is tannic acid, and uses thereof for treating central nervous system disorders.¡v Summary of ivention¡G¡]¸`¿ý¡^ ¡uThe present disclosure is based, at least in part, on the unexpected discovery that tannic acid potentiated the therapeutic effects of benzoate salt on symptoms associated with CNS disorders, for example, locomotion activity and sensorimotor function as observed in a mouse model of CNS disease.¡v Benzoate salt¥[¤W§t¦³Tannic acid ªº½á§Î¾¯¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/3/13 ¤W¤È 11:34:30²Ä 286 ½g¦^À³
|
ÁÂÁÂliaw6575¤j¤j³Ì·sªº±Ð¾Ç liawbf.pixnet.net/blog/post/47709909 ¸£²ÓM¹ÏÃЬã¨s¹ïªvÀøCNS¯e¯fªº±Ò¥Ü |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/3/2 ¤W¤È 07:24:08²Ä 285 ½g¦^À³
|
·PÁ liaw6575 ¤j¤j ¬°§Ú̾ã²z½ĶµûªRSND-12ªº2a³ø§i liawbf.pixnet.net/blog/post/47781858 ¦³±z©M¦Ñ¥v¤j¤j¯u©¯ºÖ ÁÂÁ±z ÁÂÁ¤j®a¡I |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2018/2/7 ¤U¤È 10:12:22²Ä 284 ½g¦^À³
|
Sage Therapeuticsè«Å¥¬Sage-217Àò±o««×¼~Æ{¯gªºBTD¡A³o¬OÄ~Sage-547¨ú±o²£«á¼~Æ{¯gBTD¤§«á¡A¦A¦¸Àò±oªÖ©w¡A¨S¦³À禬ªºCNS¤½¥q¯à¨ú±o¨â¶µBTD¡A¬Û·í¬Û·í¤£®e©ö¡A¯S§O¬O¤jÃļt³°Äò±qºë¯«¬ì»â°ìºM°hªºÀô¹Ò¤U¡ASage ¤´°í¦u±^¦ì¬°ºë¯«¯e¯f±wªÌ§V¤O¡A§Ú̯ण¬°Sage³ø¥H¼ö¯P´xÁn¶Ü¡H·s»D½Z³sµ²¦p¤U investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-receives-fda-breakthrough-therapy-designation |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/2/7 ¤W¤È 07:33:35²Ä 283 ½g¦^À³
|
ÁÂÁ¦ѥv¤j¤jªº·s»D¤À¨É ¤]ÁÂÁÂCliff¤j®¦¼wªº¸É¥R«ü¾É ¤pªº¦b·Qf¥Ò»Ä¾Yªº¥ÎÃľ¯¶q¡] O ~ OOO mg/kg) À³·|²Å©ó¸Ó¯¶µ¡¤~¬O «Ü³øºp¡I¤pªº®··®»¼v¬ïÆwªþ·|¼vÅTµøÅ¥ ©|½Ð¤j®a®ü²[ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/2/6 ¤U¤È 11:40:48²Ä 282 ½g¦^À³
|
¾YÆQ¥Î©óªvÀøļÆ{¯g¡]Bipolar disorder©ÎManic depression¡^¥Ñ¨Ó¤w¤[¡A¤@»¡¬O±q1880¦~¶}©l¡]¬ù·í²M¥úºü6¦~¡^¡C¥¦ªºÃĪ«¦w¥þ¿@«×½d³ò«Ü¯¶¡]¦å¤¤¾Y¿@«×0.6-1.2mmol/L¡^¡A¤@¥¹¶W¹L1.5mmol/L´N¥i¯à¤¤¬r¡A¤@¯ë¨CªA¥Î6-12Ó¤ën©â¦åºÊ´ú¤@¦¸¡C¡]exdep.edah.org.tw/cp/index.php/2017-06-26-08-19-55/2017-06-28-09-06-14/259-lithium-li ¡^ |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2018/2/6 ¤U¤È 11:05:44²Ä 281 ½g¦^À³
|
¤@¯ë»¡¨Ó¡AFDA§Æ±æ¥Ó½ÐBTDªº®É¶¡¤£n±ß©óEOP2¡AèèZogenix«Å¥¬¥LÌ®aªº§C¾¯¶q´îªÎÃÄÀò±oDravet SyndromeªºBTD¡A®Ú¾Úªº«o¬O¤T´ÁÁ{§Éµ²ªG¡¨ the results from Study 1, Zogenix¡¦s first global Phase 3 trial of ZX008¡¨¡A¤]´N¬O»¡°µ¤F¤T´Á¤~¥h¥Ó½ÐBTD¬O¥i¥Hªº¡A·s»D½Z³sµ²¦p¤U zogenixinc.gcs-web.com/news-releases/news-release-details/zogenix-announces-receipt-fda-breakthrough-therapy-designation¡A ³oÓÁ{§É¼Æ¾Ú³y¦¨¥h¦~9/29³æ¤é¼Éº¦172%¡A¥«È½Ä¤W12»õ¬üª÷¡A¥ú¨~¤@«×À£¹LGW¡C ZX008¬O¦ÑÃÄ·s¥Î¡Aª¾¦W´îªÎÃÄ®³¨ÓªvÀøÀ¦«Ä¨àÅöíw¡A¥h¦~1/30ªº·s»D½Z´£¨ìÀò±omethod of use±M§Q¡¨ U.S. Patent No. 9,549,909 from the U.S. Patent & Trademark Office. The patent, entitled ¡§Method for the Treatment of Dravet Syndrome¡¨, covers claims related to a method for the adjunctive treatment of seizures associated with Dravet syndrome with ZX008. This patent is expected to provide protection of the associated claims through 2033.¡A·íµM¡A¤@®a¤½¥q¹ï±M§Q«OÅ@¤£·|¶È¤î©ó¦¹¡A©Ò¥H¥LÌ»¡ ¡§We are continuing to pursue multiple additional patent families related to ZX008 globally in order to further protect our lead product candidate. ¡A·s»D½Z³sµ²¦p¤U zogenixinc.gcs-web.com/news-releases/news-release-details/zogenix-announces-issuance-us-patent-zx008-dravet-syndrome¡A ¥Ø«eZogenix¤Wº¦5%¡AGW¤U¶^3.2%¡A©Î³\©M¦¹BTD¦³Ãö |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/2/6 ¤U¤È 09:21:25²Ä 280 ½g¦^À³
|
ÁÂÁÂCliff¤j®¦¼w ¥t¥~½Ð¬Ý¤@½g©|¥¼Àò±M§Qªº¡u¥L¤s¤§¥Û ¥i¥H§ð¿ù¡v±M§Q¤å¥ó Low- dose lithium for the treatment of neurodegenerative disorders www.google.ch/patents/WO2012007387A1?cl=en ¡u lithium ¡v¦ü´¿¬ÛÃѪº ¡u ¾Y ¡v ì¨Ó¾Y¤]¥iªvÀøCNSªº¯e¯f ¨º¡u lithium benzoate ¡v·|¦³Âù«®ÄªG¶Ü¡H ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/2/5 ¤U¤È 11:49:28²Ä 279 ½g¦^À³
|
¸ò²q·Q¤j1/31´£¨ìªº¨º¤@½g½×¤å³ø§i¬O¦P¤@¥ó¨Æ±¡¡C 2018/02/04 MedicalResearch.com³XÂÅ¥ý¤¸¥D¥ô ¡uAdd-On Preservative May Improve Outcomes in Refractory Schizophrenia¡v ¡umedicalresearch.com/mental-health-research/schizophrenia/add-on-preservative-may-improve-outcomes-in-refractory-schizophrenia/39813/ ¡v doi.org/10.1016/j.biopsych.2017.12.006 Biological Psychiatry Available online 26 December 2017 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/2/5 ¤W¤È 09:40:05²Ä 278 ½g¦^À³
|
¯¬¶P ¤ß®®Àò¬ü°ê±M§Q Co-crystals of substituted glycine and uses thereof patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=Co-crystals.TI.&OS=TTL/Co-crystals&RS=TTL/Co-crystals «¢!¦ý¬O¤pªº¨S¬ÝÀ´ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/2/4 ¤U¤È 10:10:21²Ä 277 ½g¦^À³
|
ì¨Óf¥Ò»Ä¾Y©Mf¥Ò»Ä¶uªº¦@´¹µ²ºc¦P®É°e¥ó ¡u CO-CRYSTALS OF LITHIUM BENZOATE AND USES THEREOF¡v ¡u CO-CRYSTALS OF SODIUM BENZOATE AND USES THEREOF¡v ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/2/4 ¤U¤È 06:12:39²Ä 276 ½g¦^À³
|
¸É¥R: ì¨Ó¤w¸g¦³Lithium Benzoate ¬¡©Ê¦¨¤ÀªºÃĪ«Uraseptine Rogier (Lithium Benzoate) www.sdrugs.com/?c=drug&s=uraseptine%20rogier ¨º¬O¤£¬O¤S¥i§K°µ¤@´ÁÁ{§É??? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/2/4 ¤U¤È 03:09:41²Ä 275 ½g¦^À³
|
Cliff ¤j®¦¼w ³oÓ§ª«¤]¤ÓµL»ù ¦n¤jªº¤@Ó¦ÊÄ_½c »õÄ_½c ¬Æ¦Ü¬O¤@Ó¥üÄ_½c ½c¸Ì°®©[ À³¦³ºÉ¦³ ¦³°÷Æg ¤pªº¦A¨Ó¦³±o¦£¤F ÁÂÁ±z! ÁÂÁ¤j®a! ¥t¥~§i¶D¤j®a¤@Ó LiBen ªº¦n®ø®§ lithium benzoate unexpectedly showed better pharmacokinetic features and therapeutic efficacies as compared with sodium benzoate and lithium chloride in combination. the unexpected results that lithium benzoate exhibited protective effects in various in vitro and in vivo CNS disease models lithium benzoate was used to explore the potential cytoprotective actions against A£]25-35 in primary cortical culture. In addition, the effects of sodium benzoate and lithium chloride on the same condition were also examined, revealing the extraordinary potential efficacy of lithium benzoate on Alzheimer¡¦s disease. ... pubchem.ncbi.nlm.nih.gov/compound/lithium_benzoate#section=Top ... Toxicity : mouse LD50 oral 1198mg/kg (1198mg/kg) Russian Pharmacology and Toxicology Vol. 33, Pg. 266, 1970. mouse LD50 subcutaneous 964mg/kg (964mg/kg) Russian Pharmacology and Toxicology Vol. 33, Pg. 266, 1970. chem.nlm.nih.gov/chemidplus/sid/0000553548 ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/2/4 ¤U¤È 12:49:53²Ä 274 ½g¦^À³
|
²q·Q¤j¤j¡G DOI¡G¡u10.1016/j.biopsych.2017.12.006¡v ©ñ¶i³oùØ¥h¬d¡G¡usci-hub.tw/¡v§Y¥i±o¥þ¤å¡C Page 5¡G¡uThe trial was registered with the number of NCT 01390376.¡v |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/2/3 ¤U¤È 10:26:06²Ä 273 ½g¦^À³
|
LiBen? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/31 ¤W¤È 07:42:20²Ä 272 ½g¦^À³
|
³o¬OSND-12 ªº 2a Á{§É³ø§i¶Ü¡H Sodium Benzoate, a D-amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial www.sciencedirect.com/science/article/pii/S0006322317322977 ¤£¹L¥u¦³ºKn¡AY¦³¤j¤j¥i¥H´£¨Ñ¥þ¤å³sµ²¡A½Ð¤£§[¤À¨É¡AÁÂÁ¡I liaw6575¤j¤j¥H«eªº±M¤å¦³§ó¦hªº¸ê°T liawbf.pixnet.net/blog/post/47594838-snd-12%EF%BC%8C%E6%9B%B4%E5%A0%85%E5%AF%A6%E7%9A%84%E6%8C%91%E6%88%B0daoa ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/29 ¤U¤È 08:48:39²Ä 271 ½g¦^À³
|
¦Ñ¥v¤j¤j»¡¡u ºë¯«¤ÀµõNMDAR°²»¡¾ú¥v ¡v mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2018-01-29&e=snoopychiang&t=.htm&j=2439&f=main&v=1 ¤£¹L¦b³o§N¤Ñ¸Ì¡A¤pªº¥i¬O¬Ý±o¤j²É¦½¤p²É¦½ªº ´Á«Ý¤j®a³£¬Ý±o¤ñ¤pªº»´ÃP ÁÂÁ¦ѥv¤j¤j ÁÂÁ¤j®a¡I |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2018/1/26 ¤W¤È 12:16:31²Ä 270 ½g¦^À³
|
ÁÂÁ²q·Q¤jô´£¨Ñªº¤å³¹ ¤é¥»¤d¸¤j¾Ç¾ô¥»Á¾¤G±Ð±Âµ¥¤H¦b2015¦~µoªí¤@½g¤å³¹¡¨ Effects of sodium benzoate on prepulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine¡¨¡AùØÀY´£¨ì¦]¬°¬Ý¨ì§ÚÌSND13ªº¼Æ¾Ú«Üº}«G¡A¦ý«o¨S¦³°Êª«¼Ò¦¡ªº¸ê®Æ¡A©Ò¥H¥L´N°µ¤FÓ«e¯ß½Ä§í¨îªº¦Ñ¹«¹êÅç¡A¡¨ More recently, Lane et al. performed a randomised, double-blind, placebo-controlled study using SB in stabilised patients with schizophrenia. Given at a dose of 1 g/day for 6 weeks, SB produced a 21% improvement in Positive and Negative Syndrome Scale (PANSS) total scores and large effect sizes in the PANSS total and subscales, Scales for the Assessment of Negative Symptoms (SANSS)-20 items, Global Assessment of Function, Quality of Life Scale, and Clinical Global Impression, as well as improved neurocognition . In addition, SB was well tolerated without significant ad-verse effects. However, there are no reports demonstrating the antipsychotic effects of SB in animal models of schizophrenia, although SB could be a potential therapeutic drug for this disorder¡¨¡A½²±Ð±Â2016¦~¨º½g«p«p¤å³¹«h¼gµÛ ¡¨Our human findings in schizophrenia and mild AD are supported by an animal study showing benzoate¡¦s effects on prepulse inhibition and locomotion disrupted by PCP.¡¨´N¬O«ü¾ô¥»Á¾¤G±Ð±Â°µªºÅçÃÒ¡C ²{¦b¤S¦³ªZ¥Ð¨ÓÀ°§Ú̪ºSNDÅçÃÒ¤@¦¸¡A·Pı«Ü¤£¿ù§a¡I SND12©M13¦¬®×¦~ÄÖ¤WÀ£¨ì55·³¡A§Ú·Q³o¬O¬°¤FÁקK¦¬¨ì¤j¸£¨ü·l¹L¤[ªº¯f¤H¦Ó¼vÅTÁ{§É¼Æ¾Ú¡A·Q¤£¨ìTAK-831¦~ÄÖ¤WÀ£¨ì50·³¡A¦³·N«ä¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/25 ¤U¤È 05:25:37²Ä 269 ½g¦^À³
|
¥H¤U»¡ªkY¦³»~ , ¦³½Ð¤j®a«ü¥¿ , ÁÂÁÂ! §ó¥¿ : ªZ¥Ð»sÃĬãµoªºDAAO§í¨î¾¯ ( TAK - 831 ) ¤w¶i¤JÁ{§É¤G´Áªº¾AÀ³¯g , °£¤F¤§«e»¡ªº¥±¤ó¦@ÀÙ¥¢½Õ ( Friedreich Ataxia ) , ÁÙ¼W¥[ «äı¥¢½Õ¯g clinicaltrials.gov/ct2/results?cond=&term=TAK-831&cntry=&state=&city=&dist= ¥Ñ³o«h³ø¾É Recent Findings from Takeda Cambridge Ltd. Has Provided New Information about Clinical Trials and Studies ... m.4-traders.com/news/Recent-Findings-from-Takeda-Cambridge-Ltd-Has-Provided-New-Information-about-Clinical-Trials-and-St--25595117/ §ä¨ìªº½×¤åºKn Assessment of the Target Engagement and D-Serine Biomarker Profiles of the D-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756. www.ncbi.nlm.nih.gov/pubmed/28780732 ùØÀY»¡¤F One approach to activate the co-agonist site is to increase synaptic d-serine levels through inhibition of d-amino acid oxidase (DAO), the major catabolic clearance pathway for this and other d-amino acids. A number of DAO inhibitors have been developed but most have not entered clinical trials. One exception to this is sodium benzoate which has demonstrated efficacy in small trials of schizophrenia and Alzheimer¡¦s disease. Herein we provide data on the effect of sodium benzoate and an optimised Takeda compound, PGM030756 on ex vivo DAO enzyme occupancy and cerebellar d-serine levels in mice. Both compounds achieve high levels of enzyme occupancy; although lower doses of PGM030756 (1, 3 and 10 mg/kg) were required to achieve this compared to sodium benzoate (300, 1000 mg/kg). Cerebellar d-serine levels were increased by both agents with a delay of approximately 6 h after dosing before the peak effect was achieved. According to the news reporters, the research concluded: Our data and methods may be useful in understanding the effects of sodium benzoate that have been seen in clinical trials of schizophrenia and Alzheimer¡¦s disease and to support the potential clinical assessment of other DAO inhibitors, such as PGM030756, which demonstrate good enzyme occupancy and d-serine increases following administration of low oral doses. ¤p§Ì¤£²M·¡¤å¤¤ªº PGM030756 ¬O§_´N¬O TAK- 831 ? ¦ý¤£ºÞ¦p¦ó Â\¦b²´«eªº´N¬O , ³oÓ DAAO §í¨î¾¯ªº¾÷Âà¤S¦A¤@¦¸Àò±o¨ä¥L¹Î¶¤ªº¦LÃÒ TAK- 831 ÁöµMºò°l¦b«á , ¦ý«äı¥¢½Õ¾AÀ³¯g ¤~èè¶i¤JÁ{§É 2 ´Á ¥¦°£¤F§í¨îDAAO ¥~ , ÁÙ¦³NaBenªº¨ä¥L¥\¯à¶Ü?! ©|µL¤åÄm¥i¦Ò ¥BÅý§Ú̦A¨Ó½Æ²ß¤@¤U NaBenªº¥\¯à ½Ð°Ñ liaw6575 ¤j¤jªº±M¤å liawbf.pixnet.net/blog/post/47570421-snd-14%EF%BC%8C%E7%9C%9F%E6%AD%A3%E6%9C%89%E6%84%8F%E6%80%9D(2a%E8%A9%A6%E9%A9%97%E7%A0%94%E7%A9%B6%E6%91%98%E8%A6%81%EF%BC%8C%E7%82%BA%E6%85%B6%E7%A5%9D%E5%9C%8B liawbf.pixnet.net/blog/post/47709222-%E8%8B%AF%E7%94%B2%E9%85%B8%E9%88%89%E5%B0%8D%E6%B2%BB%E9%98%BF%E8%8C%B2%E6%B5%B7%E9%BB%98%E7%97%87%E4%B9%8B%E5%8F%A6%E5%A4%96%E4%B8%80%E7%A8%AE%E7%97%85%E7%90%86%E5%81%87%E8%AA%AA ... §Ú̧ƱæSND-1 ¨t¦C¦¨¥\¨Ã¾¨¦§¹¦¨Á{§É Åý±wªÌ ¤½¥q ªÑªF¤TĹ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/24 ¤U¤È 07:33:34²Ä 268 ½g¦^À³
|
¦Ñ¥v¤j¤jn§Ú̦hŪ®Ñ NMDAR¥\¯à§C¤U»Pªü¯÷®üÀq mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2018-01-24&e=snoopychiang&t=.htm&j=2438&f=main&v=1 Ū®Ñ¤~¬O¤ý¹D ª¾ÃÑ´N¬O¤O¶q ¬O«H¤ßªº®Ú·½ ¦³½Ð¦Ñ¥v¤j¤j¦h±a»â§Ú̦n¦nŪ¦n¤å³¹ ÁÂÁ¦ѥv¤j¤j ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/17 ¤U¤È 04:47:20²Ä 267 ½g¦^À³
|
¦Ñ¥v¤j¤jÀ°§ÚÌÁ¿zAD¾ý¯»¼Ë³J¥Õ¬ã¨sªº«e¥@¤µ¥Í " AD amyloid deposition°²»¡...... " http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2018-01-17&e=snoopychiang&t=.htm&j=2437&f=main&v=1 ÁÂÁ¦ѥv¤j¤jºë±mªº¬G¨Æ °²¦p®É¶¡¯à°÷«¨Ó , ¤j¼tÁÙ·|°l³v£]¾ý¯»¼Ë³J¥Õ©Îtau³J¥Õ¶Ü? ÁÙ¬O·|¦bNMDAR½Õ±± , ApoE°ò¦]Åܲ§µÛ¤â©O? µM¦ÓApoE°ò¦]Åܲ§ , ³o¤]·|¬Oª¾¦W¾÷ºc®ÄÀ³¶Ü? ÁÙ¬O¥tºØP¯f¦]¤l¤§¤@? "¤£¬O£]¾ý¯»¼Ë³J¥Õ©Îtau³J¥Õ¡A¡mNature¡nµo¥¬ªvÀøADªº·s¹v³J¥Õ" http://www.ebiotrade.com/newsf/2017-9/2017921161612443.htm |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/1/11 ¤W¤È 09:40:16²Ä 266 ½g¦^À³
|
§ó¥¿¡G 2018/1/8 ¤W¤È 12:37:05²Ä 261 ½g¦^À³¡G ì¤å¡G¡u¡K¥¦Ì¦b¬¡Åé¥~¯à°÷§í¨î¤HÃþ¶À¯À®ñ¤Æ酶¡]Flavooxidase¡^¡A¨ä®Ä¤O¤ñ¥j¨å§í»s¾¯°ª3¿¡K¡v §ó¥¿¡G¡u¡K¥¦Ì¦b¬¡Åé¥~¯à°÷§í¨î¤HÃþ¶À¯À®ñ¤Æ酶¡]Flavooxidase¡^¡A¨ä®Ä¤O¤ñ¥j¨å§í¨î¾¯°ª1000¿¡K¡v ¾ÇÃÀ¤£ºë¡A»~§â¡u¡Kpotency up to 3 orders of magnitudes¡K¡vĶ¬°¡u...3¿...¡v¡F µ²ªG¦Ñ®v»¡¨º¬O«ü10ªº3¦¸¤è¡A¤]´N¬O1000¿¤~¹ï¡C¡]°Ï°Ï¤@¤V¡Aµu®t¤E¤Ø¡I¡^ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/9 ¤U¤È 10:21:09²Ä 265 ½g¦^À³
|
ÁÂÁ¦ѥv¤j¤jªº±Ð¾É ¤Ó´Îªº¸ÑªR¡I AD³oÓÁ¼¼Ëªº¯f¯g¥»¨´NÃøÀ´¡A¦b±z®U®U¹D¨Ó¤¤ ¡A¹D²zºë·L¡A·N¹Ò²`»· ¤p§Ì°£¤F·q¨Ø±zªº´¼ÃÑ¥~¡A¤´n·PÁ±z¼ö¤ßªº«ü¾É ²¦³º³oÄ_¶Qªº¤@½Ò¬O±o¨Ó¤£©öªº ¦A¦¸ÁÂÁ±z ¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2018/1/9 ¤U¤È 08:43:25²Ä 264 ½g¦^À³
|
²q·Q¤jô¡A¤£¦n·N«ä¡A§Ú¤W¤@½g¶K¤å¥i¯à·|Åý¤H»~¸Ñ¡A¾¨ºÞSND14¥i¯à°§Camyloidªº²£¥Í¡A¦ý³o¨Ã¤£¬OSND14ªº¥Dn¶D¨D¡A«ÂI¬On¦bamyloid¥D®_¯f²z¤§«e´N»°ºòªvÀø¡C±Ð±Â½×¤å´£¨ì¡uthe British Association for Psychopharmacology ¦b2011¦~¤j·|¤W¦³¤F¦@ÃÑ¡A§YAchEI»Pmemantine¹ï©óADªº«eÅX¯f¯gaMCI¬O¨S¦³Àø®Äªº¡A³o·N¨ýµÛ¡A¦bÃþ¾ý¯»¨I¿n»P¯«¸gÅÖºûªÈµ²©|¥¼¥D®_¯fµ{¤§«e¡A¦´ÁADÀ³¸Ó¥t¦³¨ä¥Lµo¯fì¦]¡Aother mechanisms might underlie the pathogenesis of early-phase AD when the pathology of amyloid or the neurofibrillary tangle has not dominated the progression of the illness¡v SND¶D¨Dªº¬O¦b¶Ë®`ÁÙ¤£ÄY«ÁÙ¥i®¾±Ï®É¡A¬¡¤ÆNMDAR¦Ó¹ï¯«¸g¶i¦æ׸ɫOÅ@¡A¥H«ì´_»{ª¾»P°O¾Ð¥\¯à¡AµM°ê»Ú¤j¼t¶D¨Dªº¬O¥h°£amyloid¡B©Î§í¨î£]secretase¡A«oµLªk·m±Ï¨ü·l©Î¦Ñ¤Æªº¯«¸g¡Aþ¤@ºØ¤ñ¸û¦X²z©O¡H ¤j·§¦b1990¦~John HardyÆ[¹îð¤ó¯g«á´£¥XamyloidªºP¯f°²³]¡A¥D¾É«áÄòªñ30¦~ªºÃĪ«±´¯Á¤è¦V¡A¦ý¨ä¹ê¦b1988¦~¥ª¥k¡A±K¦è®Ú¤j¾ÇTimothy Greenamyle´N´£¥X¤£¦Pªº·Qªk¡A·Qªk¤§¤@¥]¬A¡u¶}µo¿³¾Ä©ÊÓi°ò»ÄªºP®Ä¾¯¥H«P¶i»{ª¾¥\¯à¡A¦P®Éµ²¦X«á¬ðIJ¨üÅé«ú§Ü¾¯¥H§í¨î¿³¾Ä¯«¸g¬r¯À¡v¡Ait may be possible to exploit EAA agonists as cognition enhancing drugs, by combining their use with agents that block specifically the postreceptor mechanisms responsible for toxicity. «¥ÌSND¤£´N¬Ocognition enhancing¶Ü¡H²{¦b¤w¸gª¾¹D¿³¾Ä©Ê¯«¸g¬r¯À¬O¤¤±ß´ÁAD¤~nÃö¤ßªº¨Æ(©Ò¥H¦³menantine)¡A¦´ÁAD¥Ñ©ó¤j¸£¯«¸g¥h¬r¯Àªº½Õ¸`¥\¯à©|¥¼·l¶Ë¡A©Ò¥H®³SNDªvÀø¦´ÁAD¤£¥Î¦Ò¼{¿³¾Ä¯«¸g¬r¡A³o¼Ë¬O¤£¬O«Ü¦X²z¡H ¦³®ÉÔ¤jÃļt¨«ªº¸ô¤£¨£±o¬O¥¿½Tªº¡A2016¦~Bristol¤j¾ÇPeter Roberts±Ð±Â»¡¡¨ The problem, to my mind, is completely fundamental. There is still no convincing evidence that shows a clear relationship between amyloid deposition and deficits in cognition in humans. All we really know is that evidence of amyloid deposition begins up to maybe 20 years before the onset of Alzheimer¡¦s disease. This might be a good indicator, but does not prove causality¡¨¡A¥L¬Æ¦Ü»{¬°³o¨Ç¤jÃļt¦bamyloid¡Btauªº¨ú¦V¥u¬O»°¬y¦æªº¦Ï¸s®ÄÀ³¡¨they all jump on the bandwagon, unfortunately¡¨ ¦bAD³o»â°ì¡A½Ð¤£n»{¬°¤j¼t¤£¦æ¡A§ÚÌ´N¤@©w¤£¦æ¡A¦pªG¤j¼t¤@¶}©l´N¨«¿ù¸ô¤F¡A¦Ó¥¿½Tªº¸ôª½¨ì²{¦b¤~¥Ñ§Ú̽ñ¤W¥h©O¡H¦^·Q¤@¤UJohn Hardy¡BTimothy Greenamyle¤£¦Pªº½×z¡K¡K |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/9 ¤U¤È 05:35:28²Ä 263 ½g¦^À³
|
ÁÂÁ¦ѥv¤j¤jªº¸ÑªR ·sÃÒ¾Ú¡Gªüº¸¯÷®üÀq¯gP¯f³J¥Õ·|¶Ç¼½ ¨Ó·½¡G ¥Íª«±´¯Á ¡@2018-01-09 §@ªÌ¡GFlora¨Ó·½¡G¥Íª«±´¯Á http://med.sina.com/article_detail_103_1_39533.html ¤w¦³¬ã¨sªí©ú¡A³o¤@¯«¸g°h¦æ©Ê¯e¯f»P¨âºØ¦b¤j¸£¤¤²§±`²Ö¿nªº³J¥Õ¦³Ãö¡GTau³J¥Õ©M£]-¾ý¯»¼Ë³J¥Õ¡]A£]¡^¡C³Ì¥D¬yªº±ÀÂ_¬O¡G£]-¾ý¯»¼Ë³J¥Õ³Ì¥ý²Ö¿n¡A¤Þµo¯«¸g¤¸¬ðIJ¥\¯à»Ùê¡BTau³J¥Õ¹L«×ÁC»Ä¤Æ©MÄ~µoª¢©Ê¤ÏÀ³¡A¾ÉP¯«¸g¤¸Åܩʦº¤`¡A±q¦Ó§]¾½°O¾Ð¡B»{ª¾µ¥¥\¯à¡C SND-14 ±q¤W´åªvÀø , ªý¤î¤U´ål¥Í? |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2018/1/9 ¤U¤È 01:50:15²Ä 262 ½g¦^À³
|
ªÑªF·|¤WÁÙ´£¨ìSND14¥i¯à°§Cbeta-amyloidªº²£¥Í¡C §Ú¦b±Ð±Â¤å³¹ªºª`ÄÀ§ä¨ì³o½g¨Ó¦ÛÛ´°°ê¤ý¾Ç°|¡¨Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production¡¨ ª½±µ¬Ýµ²½×¡A¡¨We have studied whether stimulation of NMDA receptors, which are key molecular complexes involved in synaptic plasticity and learning and memory processes, influences APP metabolism, and our findings suggest that synaptic NMDA receptor activity promotes APP processing down the nonamyloidogenic £\-secretase generated pathway, while at the same time dampening down A£] production and release.¡¨ §Ú̬ã¨s¤F¨ë¿ENMDA¨üÅé¬O§_¥i¥H¼vÅTAPP(amyloid precursor protein)ªº¥NÁ¡A§Ú̵o²{³o¥i¥H«P¶iAPPªº¤À¸Ñ¹Lµ{ªuµÛ¡u«D¾ý¯»³J¥Õ¥Í¦¨¡vªº£\-secretase¸ô®|¡A¦P®É§í¨î¤FA£]ªº²£¥Í»PÄÀ©ñ¡C ²³æ»¡©ú¡G¤j¸£¯«¸g²ÓM½¤¤W´OµÛÃþ¾ý¯»«e¸m³J¥ÕAPP¡A·|³Q£\¡B£]¡B£^¤TºØsecretase¤Á°£¡A¥¿±`±¡ªp¬O¥Ñ£\¡B£^¤Á°£«á´N«Ü®e©ö¤À¸Ñ±¼¤F¡A²§±`±¡ªp¬O¥Ñ£]¡B£^¤Á°£¡AAPP¸H¤ù¤ñ¸ûªø¦ÓÅܦ¨A£]¡A¤£©ö¤À¸Ñ¥B®e©ö»E¦¨plaques |
|
|
·|û¡G³¯ÀR10141886 µoªí®É¶¡:2018/1/9 ¤W¤È 10:53:24²Ä 261 ½g¦^À³
|
¹ê¦b¨SßÓ¡A¤£ºÞ¶Â药¥Õ药¡A·|ªv¯fªºßÓ´N¬O¦nßÓ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/9 ¤W¤È 08:37:52²Ä 260 ½g¦^À³
|
ÁÂÁ¦ѥv¤j¤jºî¦X®É¨Æ»¡¬G¨Æ Åý§ÚÌ®®Å¥»D ¤]ÁÂÁÂliaw6575¤j¤jµ¹§Ṳ́W¤F¬ü¦nªº¤@½Ò http://liawbf.pixnet.net/blog/post/47709222-%E8%8B%AF%E7%94%B2%E9%85%B8%E9%88%89%E5%B0%8D%E6%B2%BB%E9%98%BF%E8%8C%B2%E6%B5%B7%E9%BB%98%E7%97%87%E4%B9%8B%E5%8F%A6%E5%A4%96%E4%B8%80%E7%A8%AE%E7%97%85%E7%90%86%E5%81%87%E8%AA%AA ¤µ¤Ñªº¤u°Ó®É³ø³ø¾É¦³Ãö½÷·ç°±¤î¶}µoªü¯÷®üÀq¯g»P©¬ª÷´Ë¤ó¯gÃĪ«ªº®ø®§¡A¨Ã´£¤Î¤ÀªR®v»{¬°¡AY¦¨¥\¶}µoªvÀøÃĪ«¡A¦ôp¥i±a¨Ó¼Æ¤Q»õ¬ü¤¸ªº¼ç¦b¦¬¤J¡C ¬Q¤Ñliaw6575¤j¤jªº³o½g±M¤å¡A Á¿zf¥Ò»Ä¶u¹ïADªvÀøªº¥t¥~¯f²z¤ÎÃIJz°²»¡---°ª¦å®ò¯g µ²»y»¡±o§ó¦n¡Aµo´§liaw6575¤j¤j¤@³eªºµo±¸»P³sµ²¯à¤O liaw6575¤j¤jµû¹D ¹L¥hf¥Ò»Ä¶uªvÀø°ª¦å®ò¯g ¡A¦p¤µ¥Î¨ÓªvÀøAD(©ÎSCZ¡A HD)ªººC©Ê¡A¨È°ª¦å®ò©Ò¾ÉPªº¯«¸g¬r©Ê¯gª¬ ¦pªG®ò©Î§¿¯À¥NÁ²§±`¬OAD¥Dn¯f¦] ¡Af¥Ò»Ä¶u±N¹ïAD¨ã¦³¯e¯f×¹¢ªº®ÄªG ¦ý¦pªG®ò©Î§¿¯À¥NÁ²§±`¶È¬O¦ñÀHADµo¯fªº¯gª¬µ²ªG¡A f¥Ò»Ä¶u±N¹ïAD¨ã¦³¯gª¬§ïµ½ ¡AÁקK¯f±¡¥[¼@ªº«OÅ@®ÄªG liaw6575¤j¤j¦P®É¤]´£¿ô§ÚÌ Áö¾Ç¬É¡A¤j¼t¦P¼Ëµo®iDAAO§í¨î¾¯ ¡A¦ý¨º¤@ÓDAAO§í¨î¾¯¯à¹³f¥Ò»Ä¶u¤@¼Ë ¡A¨ã¦³ ¥i¥H§í¨îDAAO ¥i¥H§í¨î½¦½è²ÓMµoª¢ ¥i¥H¼W¶i BDNF ©Î NT-3 ¯«¸g´þ¾i¦]¤l ¥i¥H§Ü¸zG¹DÃaµß ¡A¼W¶iµß¸z¸£¶b½u¥¿¦V®ÄÀ³ ¤S¥i¥HÀ°§U²M°£¸£¤¤®ò¬r? liaw6575¤j¤j±j½Õ ¡A¥L¬Û«H³oºØ½Æ¦XMOA¾÷Â઺Àø®Ä¡A µ´¹ï¤ñ³æ¤@MOA¾÷Â઺Àø®Ä§ó±j ¦³Ãöªº½×z ½Ð¤j®a«e©¹®®Åªliaw6575¤j¤j±M½× ÁÂÁ¤j®a! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2018/1/8 ¤U¤È 10:37:00²Ä 259 ½g¦^À³
|
¥h¦~¤E¤ëAxovantªºIntepirdine(RVT-101¡B5HT-6¨üÅé«ú§Ü¾¯¡AGSK¤G´Á¥¢±Ñ«á¥H500¸U¬üª÷½æµ¹Axovant±µµÛ°µAD¤T´Á)¥¢±Ñ¾ÉPªÑ»ù«®À73%¡Aèè¤S«Å§GRVT-101¥t¥~ªº¨âÓÁ{§É¤]¥¢±Ñ¡A½L«e«®À48%¡C¤@Ó¬OPhase 2b¸ô©öÅ饢´¼dementia with Lewy bodies ¡A¤@Ó¬OPhase2¥¢´¼¯g¨BºA¥¿Å¨ü·l gait and balance impairments in dementia¡ACEO¨M©w°±¤îRVT-101ªºÁ{§Épµe¡A¡§Based on the totality of Intepirdine data to date, there is no evidence to support its further development. ¡§¡A¨ä¹ê¡A³oÓ¾÷ÂàLundbeck¦b2016¦~9¤ë´N¦bAD±Ñ¤U°}¤F¡K¡K Axovant¥t¤@ÓÁ{§ÉÃĪ«RVT-102«h¡u²¤¨£¾÷·|¡v¡A¾÷Âà¬O5HT-2a receptor inverse agonist¡A¾÷Âà©MAcadiaªºZuplazid¤@¼Ë¡A©Ò¥HÁ{§Éªº¯gª¬¤]Ãþ¦ü¡A¥s¸ô©öÅé»P©¬ª÷´Ë¤ó¯g¥¢´¼ªºµø¤Ûı¡Cªì¨B¼Æ¾Ú¬Ý¨Ó¡A¦³§ïµ½ªºtrend¡A¨Æ«á¤ÀªR¡u¤ñ¸ûÄY«ªº¯f¤H¡v«h¦³²Îp¤Wªº®t²§¡A³o¤@ÂI©MNuplazid¤]«Ü¹³¡A¤£¹LÁ{§É¤H¼Æ¤£¦h¡A¥¼¨Ó¦³«Ý§ó¤j³W¼ÒªºÁ{§É¨ÓÅçÃÒ¡C ³s¤T±Ñ¤§«á¡A²{¦b¥«ÈÁÙ¦³3»õ¬üª÷...... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/8 ¤W¤È 11:15:24²Ä 258 ½g¦^À³
|
¨â¦ì^°ê¾ÇªÌ¹ïf¥Ò»ÄÆQ©M¤s±ù»ÄÆQ¦b¦w¥þ©Ê©MÀ³¥Î¤W§@¨t²Îªºµû»ù Benzoate and Sorbate Salts: A Systematic Review of the Potential Hazards of These Invaluable Preservatives and the Expanding Spectrum of Clinical Uses for Sodium Benzoate f¥Ò»ÄÆQ©M¤s±ù»ÄÆQ¡G³o¨ÇÄ_¶Q¨¾»G¾¯¼ç¦b¦M®`ªº¨t²Îµû»ù©Mf¥Ò»Ä¶uÁ{§É¥Î³~ªºÂX¤j http://onlinelibrary.wiley.com/doi/10.1111/1541-4337.12284/full ¥E¬Ý¼ÐÃD , "¼ç¦b¦M®`"¦n¦ü¦³¦w¥þºÃ¼{ , ¦ý«o¤S¥Î"Ä_¶Q"¨Ó§Î®e , ¨ì©³¬O«ç»ò¦^¨Æ? ¨â¦ì¾ÇªÌªí¥Ü " ¬F©²ºÊºÞ¾÷ºc¨Ï¥Î¡§¦b³Ì©ö·P¬V°Êª«ºØÃþ¤¤¥¼Æ[¹î¨ì¤£¨}¤ÏÀ³ªº³Ì°ª¾¯¶q - µLÆ[¹î¨ìªº¤£¨}¤ÏÀ³¤ô¥¡]NOAEL¡^¡¨§@¬°»s©w¤HÃþ¹¥Î²K¥[¾¯¦w¥þ¼Ð·Çªº°ò¦¡CNOAEL¬O¥H²@§J¨C¤d§JÅ髨C¤Ñ´ú¶qªº¡C³Ìªì¥Ñ³¹A²Õ´/¥@¬É½Ã¥Í²Õ´¹«~²K¥[¾¯Áp¦X±M®a©eû·|©ó1961¦~¤Þ¤Jªº¨C¤é¥i±µ¨üÄá¤J¶q³Q°²©w¬°¦b¤@¥Í¤¤¨C¤Ñ¥i¤fªAÄá¨úªº¹«~²K¥[¾¯ªº¶q¡A¨S¦³©úÅ㪺°·±d·ÀI¡C¬ü°ê¹«~©MÃĪ«ºÞ²z§½¡]FDA¡^©M¼Ú¬w¹«~¦w¥þ§½¡]EFSA¡^µ¥²Õ´©w´Á§ó·s¹«~²K¥[¾¯§å㪺¼Ð·Ç¡A¨Ï³o¨Ç¼Ð·Ç¤é¯qÄY®æ¡]Authority EFS 2012¡^¡C¦ý¬O¡A¹ï©ó¤w¸g§åã¤F«Üªø®É¶¡ªº²K¥[¾¯¡A«Ü¤Ö¶i¦æ³o¨Ç³Ì·s«ü«nªº´ú¸Õ¡C¦³Ãöf¥Ò»ÄÆQ¦b²ÓM°ö¾i©M¼Ò¦¡¥Íª«Å餤¼ç¦b¤£§Q¼vÅTªº³ø¾É¡]ªí1¡^¨S¦³´£¥Ü®Ú¾Ú²{¥N¼Ð·Ç«·s´ú¸Õ¸Ó¤Æ¦Xª«¡C³o¤Ï¬M¤F³oºØ¨¾»G¾¯¦b¤HÃþ¶¼¹©MUCD(§¿¯À´`Àô¥\¯à»Ùê)ªvÀø¤¤¤jÅé¦w¥þ¡A¤j³W¼Ò¡Aªø´Á¨Ï¥Îªº¾ú¥v; ¤]¨S¦³¥ô¦ó©ú½TªºÃÒ¾Úªí©ú³n¦¡¶¼®Æ¤¤ªºf¥Ò»ÄÆQ·|¼W¥[2«¬¿}§¿¯fªº·ÀI¡C " ¦ý¹ï©ó¬Y¨Ç¯S©wÓÅé(¨Ò¦p¯S©wÂå¾Ç¯f¯g©Î¿ò¶Ç¯Ê³´,·¥°ª¨Ï¥Î¾¯¶q...) ¤´À³ª`·N¨ä·ÀI ¦Ü©ó"Ä_¶Q" , °£¤F·í¹«~²K¥[¾¯¥~ , ¶V¨Ó¶V¦hªºÁ{§ÉÀ³¥Î , ©Î¦Û¤£«Ý¨¥ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G³¯ÀR10141886 µoªí®É¶¡:2018/1/8 ¤W¤È 02:20:48²Ä 257 ½g¦^À³
|
±q·s¾÷Âà¨ì¦¨ßÓ¬O¤@¤j¬q¶ZÂ÷¡C«Ü¤j¤@¬q¶ZÂ÷¡C ºâ¤@ºâ¡F ¤£¥i¹w´úªº¦X¦¨¤À¤l¦w¥þ©Ê °Êª«©M¤H¸£ªº®t²§¡A¦P¤@¤À¤lDAAO¤]¦³®t²§ ·s¾÷Âà¡B¤HÅéÂàĶ¬ã¨snÅçÃÒ¥X¨Ó¡B¦]爲§ïÅܦ欰ªº§xÃø¤Î¨ä¤£¥i¹w´ú©Ê ³oÁÙ¤£°÷¬D¾Ô¶Ü¡H SND1 ¦n¦b¨ºùØ¡H¤£¦n¦b¨º¸Ì¡H Á`n¬°¦Û¤vt³d¡B´±§@´±·í§a¡H »{¬°¡u¦n¡vªº´N¯d¡B»{¬°¡u¤£¦n¡vªº´N¹³°·X¦NXX¹©½æ¥ú¨«¤H§a¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/1/8 ¤W¤È 12:37:05²Ä 256 ½g¦^À³
|
§ë¸ê¤H¥i¯à±`¦³³o¼ËªººÃ°Ý¡AÃø¹D¨S¦³¤j¼t§ä¨ì©Î¦X¦¨¸òNabenÃþ¦ü¥\¯àªºDAAO§í¨î¾¯¶Ü¡HÃø¹D¤j¼t¹ï¤¤¼Ï¯«¸g¥ÎÃĨS¦³¿³½ì¡H©ÎªÌ»¡¡A°ê¥~¦U¬ã¨s³æ¦ì¹ïDAAO§í¨î¾¯¯uªº¨º»ò¨S¦³¿³½ì¶Ü¡H Ū¨ì¤@½g2017ªº¤å³¹¡A¦bµ²½×¤¤´£¨ì¤F³oÓ°ÝÃD¡C 2017/11/27 ¡uCompetitive Inhibitors Unveil Structure/Function Relationships in Human D-Amino Acid Oxidase¡v(Ävª§©Êªº§í¨î¾¯´¦ÅS¤F¤HÃþDAAOªºµ²ºc»P¥\¯à¶¡ªºÃö«Y) ¡]www.ncbi.nlm.nih.gov/pmc/articles/PMC5715370/ ¡^ ¡uConclusions¡]¸`¿ý¡^ The huge efforts by public and corporate research laboratories to identify novel pharmaceutical drugs to fight schizophrenia symptoms identified hundreds of different hDAAO ligands which in vitro are able to inhibit the human flavooxidase with a potency up to 3 orders of magnitudes higher than classical inhibitors (e.g., benzoate, see Table Table3).. These compounds were also effective in inhibiting hDAAO activity ex vivo and/or in vivo as demonstrated by measuring residual hDAAO activity in cell lines and tissues from murine models. Unfortunately, none of the identified hDAAO compounds has yet been approved for schizophrenia treatment (or other diseases). The main drawbacks of these compounds are the poor bioavailability, high rate of clearance, and poor ability to cross the BBB. Consequently, the observed increase in D-Ser in the CNS observed after administration of such compounds should mainly be due to the systemic increase in the concentration of this D-amino acid caused by inhibiting kidney hDAAO (Hin et al., 2015). An additional drawback is the fact that the human and murine DAAOs show different biochemical properties and expression patterns. Consequently, the efficacy, pharmacokinetics, and pharmacodynamic properties of potential hDAAO inhibitors tested in rat, the ¡§standard¡¨ animal model in pharmaceutical research, could be misleading (Frattini et al., 2011; Sasabe et al., 2014). As a matter of fact, the distribution of hDAAO activity between mouse and human CNS is different as, in the former, the activity of the enzyme is confined to the lower brain. This suggests that cells able to express DAAO may have migrated to the cerebral cortex in concert with the evolution of human forebrain (Sasabe et al., 2014).¡v µ²½×¡G¡]¸`¿ý¡^ ¡u¤½¦@©M¥ø·~¬ã¨s¹êÅç«Ç¬°¤F½T»{§Üºë¯«¤Àµõ¯g¯gª¬ªº·sÃĪ«©Ò§@ªº¹d¤j§V¤O¡A½T»{¤F¼Æ¦ÊºØ¤£¦PªºhDAAOµ²¦XÅé¡A¥¦Ì¦b¬¡Åé¥~¯à°÷§í¨î¤HÃþ¶À¯À®ñ¤Æ酶¡]Flavooxidase¡^¡A¨ä®Ä¤O¤ñ¥j¨å§í»s¾¯°ª3¿¡]¨Ò¦p¡Af¥Ò»ÄÆQ¡A¨£ªí3¡^¡C¡]µù¡GhDAAO¡×¤HÃþªºDAAO¡^ ³z¹L´ú¶q¨Ó¦Û¹«¼Ò«¬ªº²ÓM®è©M²Õ´¤¤ªº´Ý¯dhDAAO¬¡©Ê¡A±oª¾³o¨Ç¤Æ¦Xª«¥ç¯à¦³®Ä§í¬¡Åé¥~©M/©Î¬¡Å餺hDAAO¬¡©Ê¡C ¿ò¾Ñªº¬O¡A¨S¦³¤@ºØ¤wŲ©wªºhDAAO¤Æ¦Xª«³Q®Öã¥Î©óºë¯«¤Àµõ¯gªvÀø¡]©Î¨ä¥L¯e¯f¡^¡C ³o¨Ç¤Æ¦Xª«ªº¥Dn¯ÊÂI¬O¥Íª«§Q¥Î«×§C¡A²M°£²v°ª¡A¬ï¶V¦å¸£«Ì»Ù(BBB)ªº¯à¤O¤£¨Î¡C ¦]¦¹¡Aµ¹¤©³o¨Ç¤Æ¦Xª««áÆ[¹î¨ìªº¤¤¼Ï¯«¸g¨t²Î¤¤Æ[¹î¨ìªºD-Ser¼W¥[¥DnÀ³Âk¦]©ó¥Ñ§í¨îµÇhDAAO¤Þ°_ªº³oºØD-®ò°ò»Ä¿@«×ªº¥þ¨©Ê¼W¥[¡]Hin et al.,2015¡^¡C ¥t¤@Ó¯ÊÂI¬O¤H©M¹«DAAOÅã¥Ü¥X¤£¦Pªº¥Íª«¤Æ¾Ç©Ê½è©Mªí¹F¼Ò¦¡¡C¦]¦¹¡A¤j¹«¸ÕÅ礤¼ç¦bªºhDAAO§í»s¾¯ªºÃĮġAÃĪ«°Ê¤O¾Ç©MÃĮľǯS©Ê¡]ÃĪ«¬ã¨s¤¤ªº¡§¼Ð·Ç¡¨°Êª«¼Ò«¬¡^¥i¯à¬O»~¾É©Êªº¡]Frattiniµ¥.,2011; Sasabeµ¥.,2014¡^¡C ¨Æ¹ê¤W¡A¤p¹«©M¤HCNS¤§¶¡ªºhDAAO¬¡©Êªº¤À§G¬O¤£¦Pªº¡A¦]¬°¦b«eªÌ¤¤¡A酶ªº¬¡©Ê§½©ó¸û§Cªº¤j¸£¡C³oÅã¥Ü¯àªí¹FDAAOªº²ÓM¥i¯à¤w¸g¾E²¾¨ì»P¤HÃþ«e¸£ªº¶i¤Æ¤@Pªº¤j¸£¥Ö½è¤¤¡]Sasabeµ¥.,2014¡^¡C¡v ©Ò¥H¤£¬O¨S¿³½ì¡A¦Ó¬O¥LÌ©|¥¼§ä¨ì©Î¦X¦¨¥i»PNaben¤À®x§Ü§ªº¦¨¤À¡C |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2018/1/7 ¤W¤È 01:26:12²Ä 255 ½g¦^À³
|
¤WÓ¤ë¤~¦bIPO round¤@Á|®³¤U2.87»õ¬üª÷(¥[p©Ó¾P°Ó»{Áʪº3700¸U¬üª÷)ªºDenali Therapeutics¡A¬Q±ß¤S¦³¤j·s»D¡A¤é¥»ªZ¥Ð»sÃÄ©M¥Lñ¤U¤@¯È¤jªº¦X§@¨óij¡AªZ¥Ð°£¤F¤ä¥I4000¸U¬üª÷ªºupfront¡A¦P®ÉÁÙ·|¥H·¸»ù62%¡A§Y26.1¤¸ÁʶRDenaliªºªÑ²¼4214559ªÑ¡A¬ù·í1.1»õ¬üª÷¡C«áÄòªºmilestone¤j¬ù»ùÈ10»õ¬üª÷¡A¦ýÁÙ¤Ó¹L»»»·´N¥ý¤£¥h¬Ý¡C Denaliªºpipeline¬O¨âÓPhase1ªº©¬ª÷´Ë¤ó¯g¤p¤À¤lÃÄ¡A4Ó¦bpreclinical¡A1Ó°w¹ïªü¯÷®üÀq»PALS¥¿n°eIND¡A³o¼Ëªºpipeline¦b¥h¦~12¤ë8¤é©w»ù18¤¸IPO¡A¥«È16.5»õ¬üª÷¡C¦¹¥~¡A¸Ó¤½¥qA round¶Ò¸ê´N¨ú±oVC°ª¹F2.17»õ¬üª÷¡A³Ð¤U¥Í§Þ¤½¥q¦³¥v¥H¨ÓA roundªº¶Ò¸ê°O¿ý¡C¬O¤°»òì¦]Åý¸ê¥»¥«³õ¼ö±¡¶R³æ¹³³o¼Ë¶È³B©ópreclinical¡BPhase 1ªº¥Í§Þ¤½¥q¡H³sªZ¥Ð»sÃĤ]¨Ó¯{¿ú¡H§Úªº²z¸Ñ¦p¤U¡G¤@¡BÂê©wµL¸Ñªºªü¯÷®üÀq»P©¬ª÷´Ë¤ó¯gµ¥¯«¸g°h¤Æ¯e¯f¡A¦pªG§ë¸ê¤H°O±o·í¦~¥«³õ¹ïAxovantµoºÆ¯ëªº¨g¼ö¡A´N¤£Ãø²z¸Ñ¡A¤G¡B¤½¥q´Xӳпì¤H¨Ó¦ÛGenentech¹Î¶¤¡A¤T¡B©xºôpipelineªº¶D¨D°÷¬¯¡¨Each program is addressing a target or pathway that is genetically validated to cause or increase the risk for neurodegenerative diseases¡¨¡A©Ò¥HªZ¥Ð¯«¸g¬ì¾ÇÀøªk³¡ªº¦Ñ¤j»¡¡§This partnership further exemplifies Takeda¡¦s continued commitment to developing genetically validated therapies for neu-rodegenerative diseases through an enhanced portfolio comprised of new modalities, We are excited to partner with the Denali team, whose innovative technology is uniquely poised to deliver the next generation of antibody therapeutics for patients.¡¨ Denali¦bIPO«e¬ù«ù¦³1.9»õ²{ª÷¡AIPO¤S¨ú±o2.87»õ¬üª÷¡AªZ¥Ð»sÃĤSÀ°¥Lªºª÷®w²K¥[1.5»õ¬üª÷¡AÁ`p¦³6.27»õ¬üª÷¥iªá¡A¥H¥L2016¦~¡B2017¦~¦U¿N9000¸U¬üª÷ªº³t«×¡ADenali¥i¥H¿NÓ6~7¦~¨S°ÝÃD¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/5 ¤U¤È 05:29:15²Ä 254 ½g¦^À³
|
2017°ß¤@¦bCNS»â°ìÀò±oBTDªº¬O½Ö? ±z²q±o¥X¨Ó¶Ü? ¦Ñ¥v¤j¤j¬°§ÚÌ»¡©ú¥Õ http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2018-01-05&e=snoopychiang&t=.htm&j=2436&f=main&v=1 ³Ì«á¦Ñ¥v¤j¤j¥H¤@±i¤p§Ì¥¼´¿¨£¹L¦n¥i·R¤S¦³¥Í®ðªºSNOOPY¶K¹Ï°µµ²»y ÁÂÁ¦ѥv¤j¤jªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2018/1/4 ¤U¤È 12:15:14²Ä 253 ½g¦^À³
|
Cliff¤j~ ·s¦~§Ö¼Ö ©Ó»X§AªºÃö¤ß»P©ï·R. »¡¯uªººÃ´b«Ü¦h ¥u¬O¤£ª¾¹D±q¦ó»¡°_. °O±o·í¦~¯E¹©¸Ñª¼·í¤Ñ¤U¤È §AÁٲĤ@®É¶¡PO¤å½Ð¤j®a§NÀR ¸g¹L§Ö¤G¦~ ¥Í§Þ¤£³Ó®D¼N ¯E¹©±q755¥´¤F2§éÁÙ¦b§C¨¦±r«Þ ¦ý¬O¨ä¥L¥Í§ÞªÑ»ù¤]³£¸y±Ù«á¦A¥´§é ¥H·í®Éªº¥ú´º¯uªº«ÜÃø¥Ø«eªººG¿F ¤£¬O¶Ü? §Ú¬Ý·í¦~¤ä«ù¯E¹©ªº¤H¨ì³B¬y« ¨ä¤¤¥H¤¤¸Î ¥_·¥¬P¸ò¤ß®®¬°³Ì¦h ¤ß®®¥Ø«e¯Z©³¦³¦Ñ¥v¤j ²q¤j SÀ°ÁÙ¦³§A ¦ý¬O¤ß®®«o¤]¬OªÑ»ù¸òµÛ¯E¹©¥´2§é ¯uªº¬OºG¤£§Ô¸@ ·íªì¦]¬°¦³BTD¸òSÀ°ªºÃö«Y §Ú¤]¤¶²Ð¤£¤Ö¤H¶R ¤j®a¤]»{¦P«Ü¦h ¦ý¬O§Ú¯uªº®`¨ì¤H¤F! ¬Ý¨ìªáªá¤j»¡230¤@¸ôÅu¤U¨Ó §Ú¬Ý¤F¤ß¸Ì¯uªº¦³ºØÃø¥H¶D»¡ªºÆ{´e... ¥Ø«e¤jªÑªF¦ü¥G¤]¬OÄ~Äò´£´Ú ¤°»òBTD ¤°»ò¦hÓÁ{§É¤@°_¶i¦æ »P°ê¥~CNS¤½¥q¥«È¬Û¤ñ©úÅã§C¦ôµ¥µ¥... ¦ü¥G¤]¤£¯à§ïÅܪѻù¤@ª½¯}©³ªºÁÍ¶Õ ¦Ó§Úµ¥¤]¥u¯à¦b®Ç§N²´®ÇÆ[ ¦ü¥G¤]µLp¥i¬I. ¨ä¹ê°ÝÃD»P·P´n³£«Ü¦h ¥u¬O¤@®É¤£ª¾¹D±q¦ó´£°_ ¤µ¤Ñ´N¥ý²µu¶Ã¼g¤@³q ½ÐCliff¤j§O¨£©Ç ¦pªG§A¦³¤°»ò¥i¥H¤À¨É ¦A·Ð§A¤W¨Óµo¤å¤À¨É ¨ä¥Lµ¥º¸«á§Úµy·L¾ã²z«äºü«á¦A¤W¨Ó½Ð¯q§A. ¦Ñ¥v¤j~ ¤£¦n·N«ä¦ûª©±¶Ã§è¤@³q ÁÂÁ§Aªºªø´Á¥I¥X ¯¬·sªº¤@¦~¯à§ó¤W¼h¼Ó. ¥xÆW¥Í§Þ¥[ªo! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/1/3 ¤U¤È 03:28:19²Ä 252 ½g¦^À³
|
³\¤j¡G ·s¦~§Ö¼Ö¡A§Æ±æ±z¦b·sªº¤@¦~¥i¥HÅwÅw³ß³ß¡A§Ö§Ö¼Ö¼Ö¡C ¤p§Ì¥b¦~¦h¨Ó¡A¬J¯î¼o¤SÃi´k¡A¯ÝµLÂI¾¥¡A¥HP¦R¤£¥X¶H¤ú¡A ¥¿¦b¨É¨ü·í¤@¦ì¤p¤pŪªÌ¡A¤£¥²¬°¥²´IºVÁä½Lªº¤é¤l¡A«o¤]¹ï©ó·s°T®§ªºªÅ¥F»PªÑ»ùªº¶^¸¨·P¨ìµJ«æ»PµL©`¡C ¦ý¬O«H¤ß¥¼´î¡A¥Ø«e¤´¨³B¶Â·t¡Aµ¥«Ý¾¤©ú¡C ½Ð°Ý²{¦b§xÂZ±zªº¬O¡H |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2018/1/3 ¤U¤È 12:40:21²Ä 251 ½g¦^À³
|
Cliff¤j~ ·s¦~§Ö¼Ö ³ß¼Ö¥¦w! ·s¦~·s§Æ±æ ¥i¥H½ÐCliff¤j¼g¥Õ¸Ü¤@ÂIªº¤ß±o´£¨Ñ¤j®a¾Ç²ß ²¦³º³o¨ÇªF¦è¤ÓÁ}²`ÃøÀ´ ¥u¦³¤§«e§A¨ºÓ¼v¤ù§Ú¬ÝÀ´ ü~µ{«×®t¤Ó»·¤F! ¤@¤H¤@«H½Ð¤½¥q¦Ò¼{¥h»´ä±¾µP ¦n¶Ü??? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/3 ¤W¤È 11:49:56²Ä 250 ½g¦^À³
|
¤w¥Ó½Ð¤F,µM¶K¤åY¦³¤£·í ,½Ðª©¥D¤j¤j³w¤©§R°£ , ÁÂÁÂ! CO-CRYSTALS OF SODIUM BENZOATE AND USES THEREOF Applicants: SYNEURX INTERNATIONAL (TAIWAN) CORP. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/2 ¤U¤È 03:23:54²Ä 249 ½g¦^À³
|
·s¬K¶}½L , ¦Ñ¥v¤j¤j´Nµ¹§ÚÌÁ¿±æ±ö¤î´÷ªº¯u¹ê¬G¨Æ ¤£¹L³oÓ§@¥Î¤O¤]¤Ó¤j , Åý¤p§Ì¤£¸T¬y°_¤f¤ô¨Ó ³o¨S«Ü»· , ´Nµo¥Í¦b§Ú̹j¾À©M¥h¦~ ¬Ý¬Ý¤¤´äÂåÃĪѪº2017 http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2018-01-02&e=snoopychiang&t=.htm&j=2435&f=main&v=1 ¦Ñ¥v¤j¤j¦b¤å³¹ªº³Ì«á»¡ ¥L«Ü¦n©_ "¤µ¦~½Ö·|¬O²Ä¤@ÀɨSÀ禬ªº·sÃĪÑu´ä³ø¨ì? ¥«³õ·|µ¹¤©¬Æ»ò¼Ëªº¦ôÈ , ³o¹ê¦b¤Ó¦³½ì¤F" §Æ±æ¥xÆWªº¤ßÃÄªÑ ºò¸ò¦b«á ¥xÆW¥Í§ÞªÑ¥[ªo 2018 ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/1/1 ¤W¤È 08:20:36²Ä 248 ½g¦^À³
|
2018 ¤j®a·s¦~§Ö¼Ö ÁÂÁÂCliff¤j®¦¼w 2018¶}¬Kµ¹¤F¤j®aª¾ÃѪºÅW®b ·PÁ±z! ¤pªº·|Ä~Äò§V¤O°lÂÜRS-D7ªºÁ{§É ¤pªº¥¿·Q¼gÓmailµ¹¥x¤j¥ÍÂå¹q¤l»P¸ê°T¾Ç¬ã¨s©ÒªºO³Õ¤h ½Ð±Ð¥L¦³ÃöRS-D7ªºÁ{§Éµ²ªG ¦ý¤p§Ì¤]¦³¤ß²z·Ç³Æ,©Î±o¤£¨ì·Qnªº¸Ñµª,²¦³º½×¤å¥i¯àÁÙ¥¼¤½¶} Y¦³¶i®i , ¦A¦V¤j®a³ø§i ÁÂÁ¤j®a! ·q¯¬¤j®a ¨¤ß°·±d ¦p·N¦~¦~ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/1/1 ¤W¤È 12:49:00²Ä 247 ½g¦^À³
|
²q·Q¤j 2018¤¸¥¹¤pÂI¤ß¡A¿ÕµØ-¥x¤jRS-D7ªº¸ê®Æ¡C ¡u§@¬°D-Ói°ò»Ä®ñ¤Æ酶§í¨î¾¯¤§¤wª¾®ñ¤Æ¾¯¤§¥Î³~¡v ¡uir.nctu.edu.tw/bitstream/11536/132257/1/201610246.pdf ¡v ¤w¨ú±o¤¤µØ¥Á°ê±M§Q¡]2016/03/16¡^¡C Page 15/40¡Gµ²ºc¦¡ RS-D7 ´N¬O¦³¦Wªº§Ü®ø¤Æ¹D¼ìºÅªvÀøÃĪ«¤§¤@-@¾A®¦¿õ¡]Nexium¡Fesomeprazole¡^ªºl¥Íª«5-O-¥h¥Ò°ò-¶ø¬ü©ÔÐü¡]5-O-desmethyl-omeprazole¡^ §âesomeprazole (drugsdetails.com/wp-content/uploads/2015/06/Esomeprazol.jpg ¡^µ²ºc¤¤³Ì¥ªÃ䪺¨ºÓCH3§ï¦¨H´N¬O¤F¡C¡]www.trc-canada.com/prod-img/D292120.png ¡^ Page 25/40 ªí1¡GIC50 (£gM)ªº¤ñ¸û¡C¡]¼ÆÈ·U§C¡AÃĮķU±j¡^ RS-D7¡G1.185 ¶ø´á¥¡]Olanzapine¡F§YZyprexa¡Fª÷µÐÂÄ¡^¡G3.278 PM-BRL 36610A¡G3.450 PM-BRL 36583A¡G3.669 «×¬¥¦è¥Å¡]§Yduloxetine¡F¤d¼~¸Ñ¡^¡G5.469 f¥Ò»Ä¶u¡G71.74¡]page 24/40¡^ Page 37/40 ªí2¡G¦P¼Ë¬O¦UÓÃĪ«ªºIC50(£gM)ªº¤ñ¸û¡C ¥H¹Ï¨Óªí¥Ü¡A¥i¬Ý¨ì³Ì¥ª¤èªºRS-D7¡]¹ê¤ß¶êÂI¡^¤Î³Ì¥kÃ䪺¤@±ø¬Of¥Ò»Ä¶u¡]ªÅ¤ß¤è¶ô¡^ ¥tªþRS-D7»D¡G 2016/11/18¡G¡uwww.shineinbio.com/dec-18-2016 ¡v °ê®a·s³Ð¼ú¡G¡uinnoaward.ibmi.org.tw/AwardDetail.php?REFDOCTYPID=0mgfrvtcrys9qdy4&NumID=0oixuy260jqlagj5&REFDOCID=0oj6xnkvim0acpwd ¡v ¤¤®É¹q¤l³ø2016/11/15¡G¡uwww.chinatimes.com/realtimenews/20161115003315-260405 ¡v ·q½ÐªÈ¿ù¡F ¨Ã¯¬2018¨Æ¨Æ¦p·N¡A¨¤ß°·±d¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/12/30 ¤W¤È 08:21:33²Ä 246 ½g¦^À³
|
ÁÂÁ¦ѥv¤j¤jªº¤À¨É ¥t¥~¥@¶T¤TÀ]¥¿¦b®i¥X¡u2017¥¼¨Ó¬ì§Þ®i¡v¡X12/28¡ã12/30¤T¤Ñ ¡A¨C¤Ñ10¡G00¡ã18¡G00 ¨ä¤¤¥xÆW¤j¾Ç¦b¡u¥Í§Þ·sÃÄ¡v°Ï¡A ®i¥XDAAOi·sÃÄ ¡A¤]¬O¦ÑÃÄ·s¥Î ¡u§Þ³N¦WºÙ¡G ¥H¤H¤u´¼¼z§Þ³N¶}µo¥iªvÀø«äı¥¢½Õ¯g¬ÛÃö¯gª¬¤§·s«¬NMDA¨üÅé½Õ¸`¾¯¡v http://www.futuretech.org.tw/tech1.php?n=d9d4f495e875a2e075a1a4a6e1b9770f&s=0 ¦³¥h°ÑÆ[ªº¤j¤j¡A ¥i§_¤À¨É·P·Q ¡AÁÂÁ³á¡I ÁÂÁ¤j®a¡I |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/12/29 ¤U¤È 03:22:39²Ä 245 ½g¦^À³
|
®¼¦³·N«äªº¡A§t¦³THCªºSativexÁÙµLªk¦b¬ü°ê¤W¥«¡A¤£§tTHC¥u§tCBDªºEpidiolex©Î±N¦b¬ü°ê¤W¥«¡A¦¨¬°²Ä¤@ÓFDA®Ö㪺¤j³ÂÃĪ«¡H¬Q¤ÑGWªº·s»D½Z GW Pharmaceuticals today announced that the FDA has accepted for filing with Priority Review its recently submitted NDA for Epidiolex® (cannabidiol or CBD), an investigational treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, two rare and difficult to treat conditions of childhood-onset epilepsy. The PDUFA goal date for completion of the FDA review of the Epidiolex NDA is June 27, 2018........ GWªººë¯«¤Àµõ°µ§¹¤G´Á¤§«á°±Â\¨â¦~¦h¤F¡Aµ¥«Ý¥Lªº¤U¤@¨B |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/12/20 ¤U¤È 07:29:29²Ä 244 ½g¦^À³
|
ALKS-5461¬O¬Æ»ò¼Ëªº¬ãµo¤¤·sÃÄ? ¦Ñ¥v¤j¤j¬°§ÚÌ»¡¤À©ú Alkermes¤½¥qÁÙº¡¦³½ìªº §â¸ÕÅçµ²ªG«·s°µ¤@Ó§¹¬üªº²Õ¦X¨Ó¸ÑªR ¥u¬OFDA·|«ç»ò·Q§r Åý¤H«Ü¦n©_ ÁÂÁ¦ѥv¤j¤jªº¨¯³Ò ÁÂÁ¤j®a! |
|
|
·|û¡G³¯ÀR10141886 µoªí®É¶¡:2017/12/20 ¤W¤È 08:37:17²Ä 243 ½g¦^À³
|
¥v¤j»¡ªº¬O¤Ñ¤jªº®ø®§¡C¥xÆW¥Í§Þ¤½¥q¦h¤F²Ä¤G±ø±Ï©R¯Á¡C²Ä¤@±ø¯Ç´µ¹F§J¤ÓÃøÃkª¦¡C»´ä¬O²Ä¤G±ø¥Í¸ô¡B¦Ó¥B³W©w¤F¤G´Á¥H«áªº¸ê®æ¡A½Ö¯à¤J³õ¤w¸g«D±`©úÅã¤F¡C |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2017/12/19 ¤U¤È 05:50:09²Ä 242 ½g¦^À³
|
¬°¦ó·íªìªÑªF¸Ì±¨S¦³¤@®a¬O°ê¥~ªºª¾¦W³Ð§ë,¬Æ¦Ü¦³¤jªÑªFn¥X²M,¬°¦ó¨S¦³¦w±Æ³o¨Ç³Ð§ë°µ¤@Óblock trade? ¦pªG¤½¥q¯u¦p¤j®a¬Ý±o³o»ò¦n(¨âÓBTD),¬°¦ó³o¨Ç³£¨Sµo¥Í? «ç»ò·|Åܦ¨´X¥G©Ò¦³ªº¤jªÑªFÅܦ¨¤@½L´²¨F,¤ñ´²¤áÁÙ¤£¦p? ³o¨Ç·íµM³£¤£¬O¤½¥q¥D¨ÆªÌªº¿ù,³£¬O¨ä¥L¤Hªº¿ù! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/12/19 ¤U¤È 05:17:34²Ä 241 ½g¦^À³
|
¦Ñ¥v¤j¤j¤µ¤Ñ«È¦ê°OªÌ¥ý¥Í¬°§ÚÌ°µ"·s»D³ø¾É" ´ä¥æ©Òªº·sÁ|±¹ ¨Ã¥Ü¥H½d¨Ò Åý§Ú̬ݬݧO¤H ·Q·Q¦Û¤v http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-12-19&e=snoopychiang&t=.htm&j=2433&f=main&v=1 ÁÂÁ¦ѥv¤j¤jªº¤À¨É ¤]ÁÂÁ¤j®aªº±·³õ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/12/19 ¤W¤È 08:23:27²Ä 240 ½g¦^À³
|
liaw6575¤j¤j À°§Ú̫إ߫H¤ß¤§®È¤S«·s±Ò°Ê http://liawbf.pixnet.net/blog/post/47699220-%E5%BC%B5%E6%85%A7%E8%B2%9E%E9%86%AB%E5%B8%AB%E3%80%81%E8%97%8D%E6%95%99%E6%8E%88%E8%88%87%E8%94%A1%E6%95%99%E6%8E%88%EF%BC%8C%E5%9C%A8%E5%8F%B0%E7%81%A3%E7%B2%BE%E7%A5%9E%E9%86%AB ÁÂÁÂliaw6575¤j¤j ÁÂÁ¤j®a |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/12/12 ¤U¤È 06:49:17²Ä 239 ½g¦^À³
|
¦n¬Ýªº¬G¨Æ¨Ó¤F! ¦Ñ¥v¤j¤jÂIµûMDD·sÃÄ , ·íµM¥]¬A§Ú̪º SNG-12 ¦b³o¸Ì ½Ð¬Ý " ±qSage-217¬ÝMDD " http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-12-12&e=snoopychiang&t=.htm&j=2432&f=main&v=1 ¬Ý¨ì¤H®aªº¥«値 ... ÁÂÁ¦ѥv¤j¤jªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/12/7 ¤U¤È 10:33:23²Ä 238 ½g¦^À³
|
12¤ë3~7¤é¬O²Ä56©¡American College of Neuropsychopharmacology¦~·|¡AACNP³oÓ²Õ´©Î³\¤j®aÁÙ¨SÅ¥¹L¡A¦ý¥¼¨Ó»ÝnºCºC»{ÃÑ¥¦¡A¦]¬°½²±Ð±Â¥¿¬O¸Ó·|ªºfellow¡A¥Lªº¦Ñ®vJoseph T. Coyle¾á¥ôSecretary¡AÁÙ¦³¤@¦ì©M½²±Ð±Â¦P¼Ë¨Ó¦Û«¢¦òÂå¾Ç°|¡B MGHªº¤j¤Hª«Steven Hyman¾á¥ô¸Ó·|ªºPresident¡]Steven Hyman¦b1996~2001¾á¥ôNIMH¥D¥ô¡B2001~2011«¢¦ò±Ð°Èªø¡^¡C »¡»·¤F¡A§Ú¥u¬Oè¦n¬Ý¨ìIntra-Cellular³o®a¤½¥q(¦^·Q¤@¤U2000¦~¿Õ¨©º¸Âå¾Ç¼ú±o¥DPaul Greengard)´£¨ì¥L̦bACNP¦~·|ªºPoster¤W¡Aµoªí¤@ÓÃD¥Ø§l¤Þ§Úªº¥Ø¥ú¡A Lumateperone Uniquely Enhances Glutamatergic Neurotransmission Through Activation of Both NMDA and AMPA Channels via a Dopamine D1 Receptor-Dependent Mechanism: Implications for Treatment of Mood Disorders¡A¨¦Ói»Ä¯«¸g¶Ç¾É¡BNMDA¡BAMPA Channels¡A³o¤£´N¬O§Ú¸g±`¦bŪªºµü¨à¡H in addition to the potent serotonin transporter inhibition previously described with lumateperone, suggest the potential for lumateperone to exhibit potent and rapid antidepressant effects in patients suffering from a range of mood disorders including co-morbid depression in schizophrenia, bipolar depression, major depressive disorder and treatment-resistant depression. èè¬Ý¨ìSage-217¦bMDDªº¥¿±°T®§¡A±µµÛ¤S¬Ý¨ì³o±ø·s»D¤]¬O¦³Ãöantidepressant¡ACoyle±Ð±Â»¡GABA¡BGlutamic acid¬O¤j¸£¸Ì±ªº³±¶§¡A¦Ó¦¹³±¶§©Ò¥Nªíªº§í¨î©M¿³¾Ä§@¥Î³£¥i¯à¹ïªvÀøMDD¦³®Ä¡A¹ê¦b¤Ó¦³½ì¤F¡C |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/12/7 ¤U¤È 08:53:26²Ä 237 ½g¦^À³
|
¤~è¦b²£«á¼~Æ{¤T´ÁÁ{§É¹F¼ÐªºSage¡A褽¥¬¤fªAªºSage-217««×¼~Æ{¯g¤G´ÁÁ{§Épositive top-line results¡A½L«eªÑ»ù¤jº¦52%¡A¥«È¬ð¯}50»õ¬üª÷¡C89¤HÀH¾÷¤À¬£¡A¨C¤Ñ±ßÀ\®ÉªA¥Î¤@Áû¡A²Ä15¤Ñµû¦ô¡A¥ÎÃIJÕHAM-D¥§¡¤À¼Æ±q25.2¤À°¦Ü7.6¤À¡A´î¤Ö17.6¤À(p<0.0001)¡Aremission rate 64% (p=0.0005)¡A¦ý¬O¹ï·Ó²Õ¤À²Õ³ºµM¤]±q25.7¤j´T°¦Ü15¤À¡A´î¤Ö10.7¤À¡Aremission rate ¤]¦³23%¡A¦w¼¢¾¯¤ÏÀ³¬Ý°_¨Ó«Ü°ª¡A±ß¤@ÂI¬Ý¬ÝConference Call«ç»ò»¡ |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/12/7 ¤U¤È 01:18:38²Ä 236 ½g¦^À³
|
¦¦b2016¦~3¤ë¡A¤]´N¬OOBI¸Ñª¼¥¼¹F¼Ð¦¸¤ë¡A¤j®aªÈµ²¦bOBI§n±o±¬õ¦Õ¨ª®É¡A½²±Ð±Â«K¤w»»¨£·í¤U¦UºØ¥ú©Ç³°Â÷ªºÄpµ²©Ò¦b¡A³o¤@¦~¦h¨Ó§Ú¤ÏÂЫä¦Ò¡Õ¥Í§Þ³Ð·s²£·~ªº°Êª«©Ê¡Öªº¯uª¾¨`¨£¡A¤º¤ß¦´N¦h©Ò·Ç³Æ¡A¬O¬G¨Ã¤£¥H²{ª¬¬°²§¡A¹ê¤D¡u°Êª«©Ê¡v¤§·¥P¤]¡C¬Û«H²×±N¦pRobert Shiller±Ð±Â©Ò¨¥¡A©Ò¥H§Ú²{¦b¥u¬O¬°¥t¤@Ó¤è¦VªºÂ\°Ê´£«e·Ç³Æ¡A¤£Ä@·¡¥}·s«F¦Ó¤w¨o¡C¥þ¤å³sµ²©ó¦¹www.chinatimes.com/newspapers/20160309000059-260202¡A³½s¤Tµ´¡A©Î¦³©Ò¯q¡C ¥v¤ª¡A¯ÝÃh¶©¤¤¹ï¡A°ZµL¸g½n¤§µ¦¡H«Ý¤Ñ®É¡A¤@¦V©{¬¥¡A¤@¥X¯³¤t¡A°¹³ý¼ß¥Hªï¤§¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/12/6 ¤U¤È 08:04:33²Ä 235 ½g¦^À³
|
¦Ñ¥v¤j¤jÁ¿z ^°êGW¤½¥qªº¬G¨Æ¡A¨Ãªþ±a´£¤ÎÄvª§ªÌZogenixÁÙ¦³Ovid¤½¥qªº¤G¤T¨Æ ¬ÝµÛ¤H®aªº¥«È¡A®ü¤º¥~«ç»ò®t³o»ò¦h¡H ½²±Ð±Â¯à§_·QÓ¿ìªk§r¡H¡I ÁÂÁ¦ѥv¤j¤jªº¤À¨É ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/12/2 ¤U¤È 10:09:51²Ä 234 ½g¦^À³
|
¿Ë·Rªº¤j®a ½Ðì½Ì¤p§Ì¦Ñ¤F¡A¬Q¤Ñ¸ò¤µ¤Ñ³ºµM³£§Ñ¤F¶K³sµ² ²{¦b¸É¤W http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-12-01&e=snoopychiang&t=.htm&j=2429&f=main&v=1 http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-12-02&e=snoopychiang&t=.htm&j=2430&f=main&v=1 ÁÂÁ¦ѥv¤j¤j ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/12/2 ¤U¤È 08:02:18²Ä 233 ½g¦^À³
|
¦Ñ¥v¤j¤jÁ¿Avanirªº±M§Q¶D³^¬G¨Æ À°§Ú̸ѪR§P¨M®Ñªºn¶µ ¤@Ó¦ÑÃIJզX·s¥Îªº±M§Q«OÅ@¾Ä¾Ô¥v ¦Ñ¥v¤j¤j»¡¶V¨Ó¶VÃhºÃ¥L¦Û¤v¬O¾Ç¤°»òªº ¥v¾Ç®a¡Bªk¾Ç®a¡BÃIJz¾Ç®a¡B§@®a...¥H¤W¬Ò¬O ÁÙ¦³´N¬O¤ß®®¾Ç®a ÁÂÁ¦ѥv¤j¤jªº¤À¨É ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/27 ¤W¤È 07:50:46²Ä 232 ½g¦^À³
|
¤p§ÌÁÙ¦bºÎ¡A§Ñ¤F¶K¤W³sµ² http://liawbf.pixnet.net/blog/post/47657154 ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/27 ¤W¤È 07:42:10²Ä 231 ½g¦^À³
|
liaw6575¤j¤jµ¹§Ú̺ë±mªº¤@½Ò ¦h±½×zSND¨t¦Cªº±M§Q«OÅ@ ´Ü¨Øliaw6575¤j¤jªº³Õ¾Ç»P¹¡¾Ç ÁÙ¦³ÁÂÁÂ¥LÅý§Ú̦³§ó²`¤Jªº»{ÃÑ»P»{ª¾ ÁÂÁÂliaw6575¤j¤j¡A·P®¦¡I ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/26 ¤W¤È 09:43:37²Ä 230 ½g¦^À³
|
¼W¥[ª¾ÃÑ ¦p¦ó¾\Ū¬ü°ê±M§Q¡H http://www.patent-tutorial.net/website/node/1102 µo©ú¬ö¿ýªº«n©Ê http://www.patent-tutorial.net/website/content/book/1064 ¨ä¥L±M§Q¸ê°Tºô§} http://www.patent-tutorial.net/website/node/1110 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/25 ¤U¤È 08:53:00²Ä 229 ½g¦^À³
|
·q½Ð°Ñ¦Ò¦³Ãöschizophreniaªºmethod±M§Q Patent number: 9649304 Type: Grant Filed: January 19, 2010 Date of Patent: May 16, 2017 Patent number: 9675604 Type: Grant Filed: November 24, 2014 Date of Patent: June 13, 2017 ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/24 ¤U¤È 08:25:25²Ä 228 ½g¦^À³
|
¦Ñ¥v¤j¤jÁ¿¬G¨Æ " ±qOvidµo²{¦³½ìªºZogenix " http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-11-24&e=snoopychiang&t=.htm&j=2428&f=main&v=1 ZogenixªºZX008¬O¦ÑÃÄ·s¥Î , ®³¨ìmethod«OÅ@±M§Q´N¤«¼Q ¨º§ÚÌ©O? 2034 ¦P®É , ¤]ÁÂÁ¦ѥv¤j¤j´£¿ô§ÚÌ " ²ßºD§CÀY¬ÝµÛ¤¸¤jÂù©M , ²×±N§Ñ¤F¨º¤ù´ïÂŬO¦h»ò¬üÄR " ©ïÀY¬ÝµÛ´¸¤Ñ´ïÂŪº¬üÄR , ²×±N§Ñ¤F¤¸¤jÂù©MªºÀnÀnÀn , ÁÙ¦³µ¹§Ú̪ºÃZÃZÃZ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GªÅ¤]ªÅªÅ10145331 µoªí®É¶¡:2017/11/22 ¤U¤È 03:48:00²Ä 227 ½g¦^À³
|
¦Ñ¥v¤j¡A·PÁ±z¸ÔºÉªº¸ê°T¡A«Ü¦³À°§U¡C ¦n¬°¤H®v¡B¥B¥u¦b«Ü¯¶ªº»â°ìµy¦³¯A²¤¡A¹ê¦b¤£°tÁ¾»¹³Õ¾Ç¡C ¦pªG¤@¤Á¨Ì½²±Ð±Â©Ò¨¥¡A¬O¨S°ÝÃD¡C¥u¬O¦³ÂI¾á¤ß±Ð±Â·|¤£·|¾ÇªÌ®ð®§¤Ó«¡A¤£ª¾¤H¥@¤§ÀI´c¡C ±M§Q©Î»s³y³£¦³¨rÆN¨nµÛ¬Ý¡A¥Ḻ`¥i¥X©_¤£·N¦a§ä¨ì¯}¸Ñ¤èªk¡A¤£¯à»´¼Ä¡C ±M§QÅv¤Î»s³y¤è±¡AÓ¤H¤@ÂI·§©À¤]¨S¦³¡Cµ´¹ï¨S¦³¸ê®æ¸ò±Ð±Â¡B¬ãµo°ÆÁ`°Q½×³oÃþªº°ÝÃD¡C ˬOª©¤W°ª¤â¦p¶³¡AÀµ½Ð¨ã¦³³o¤GÃþ±M·~ª¾ÃѪº¤j¤j¥X¨Ó¬D¾Ô¡C ÁôÁô¬ù¬ùı±o±M§Q¤Î»s³y¬O¦ÑÃÄ·s¥Î¬ãµo¡A¯à¤£¯à¦³Â׫p§Q¼íªº«ÂI¡C ¦b³o¤GÃþ°ÝÃDµ¹§ó¤jªºÀ£¤O¡AÅý¤½¥q¦³°Ê¾÷¥h°µ§ó²`¤Jªº¬ã¨s¡A¹ï§ë¸ê¤HÀ³¸Ó¬O¦n¨Æ¡C |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/22 ¤W¤È 01:16:52²Ä 226 ½g¦^À³
|
DearªÅ¤]ªÅªÅ ¤£¬O«Ü¤F¸Ñ±zªº·N«ä¡A¦ý§Ú¸ÕµÛ¦^µª¡C2009¦~¤w¸gµn°Omethod of use¡A±M§QºKn¬OMethods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuro-psychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.¡A¤£¥u«OÅ@³æ¥Î¡A¤]«OÅ@Áp¥Î¡A¦b¦¹±M§Q¨ì´Á¤§«e¡A¶D½Ð¤s±ù»Ä¡Bf¥Ò»Ä¤Î¨äl¥Íª«³æ¥Î©ÎÁp¥Î©ó¬ÛÃö¯«¸gºë¯«¯e¯fªºANDA¡A¤½¥q·|´£§i§a¡I ¥t¥~¡A¾Ú§Ú²z¸Ñ¡Af¥Ò»Ä¶u³oÓ¤À¤l¯à§ä¨ìªº´¹«¬«Ü¤Ö¡A¦Ó¥B·»¸Ñ«×¦³°ÝÃD¡A®³¨Ó©MClozapine¥´¦¨¤@¿õ¡AÁÙ·|²£¥Í³\¦h¥æ¤¬§@¥Î°ÝÃD¦ÓÄY«¼vÅT¦w©w©Ê¡AµLªk¦¨ÃÄ¡A¥u¦³¤½¥q§ä¨ìªº´¹«¬¥i¥H¸Ñ¨M³o°ÝÃD¡A³o¤]¬O¤½¥qªº±M§Q¡A¨ì´Á¤é¤ñmethod of useÁÙ¤[¡Cexcipient¡Bformulationµ¥·íµM¤]¦³«OÅ@¡A²Ó¸`§Ú¤£²M·¡¡C¬O¬G±z»¡¾Ç¦WÃļtn¶¹L»s³y±M§Q¤£Ãø¡A¾Ú§Ú©Òª¾¬O¬°¼Æ¤£¦hªº¸ô®|¤w¸g³]¤U¸ô»Ù¡A¤£¹L§Ú¤£À´¤Æ¾Ç¡A¤]¤£¯à¥Nªí¤½¥q¡A¦U¶µ±M§Q«OÅ@ªººÃ°ÝÀ³¸ÓnÅ¥¤½¥q»¡ªk¤~±o©P¥þ¡C «Ü´Á«Ý©ú¦~ªÑªF·|¤W¯àÅ¥¨ì±z©M±Ð±Â¡B¬ãµo°ÆÁ`ªººëªö¹ï¸Ü¡A³o¼Ë§Ú¤]´N¯à·í±¦V±z³o¦ìÁ¾»¹³Õ¾Çªº«e½ú½Ð¯q^^ |
|
|
·|û¡GªÅ¤]ªÅªÅ10145331 µoªí®É¶¡:2017/11/21 ¤U¤È 08:33:43²Ä 225 ½g¦^À³
|
¦Ñ¥v¤j¡A·PÁ±zªº»¡©ú¡A±æ½Ð¦h¦h¶}¥Ü¡C ±M§Q«OÅ@¦ü¥G¦bAPI¡B¨Ï¥Î¤èªk¡B¾¯«¬¡Bexcipient¡Bco-crystal¡Bpolymorphismµ¥µ¥¡C Ó¤H¹ï±M§QÅv²Ê²Lªº»{ÃѬO¡G¾Ç¦WÃÄ¥unÃÒ©úBE¬Ûµ¥§Y¥i¡A»s³y±M§Q¬O¤£Ãø¶¹L¡C ¤£ª¾Åý¨ä¥L¼t°Óª¾Ãø¦Ó°hªºÂ¬ªù¬°¦ó¡A¥ø»D¨ä¸Ô¡C |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/21 ¤U¤È 06:58:32²Ä 224 ½g¦^À³
|
DearªÅ¤]ªÅªÅ ¦³Ãö±M§QÅv«OÅ@¡A±Ð±Â¦b¤W¿³Âdªk»¡¸ÑÄÀ¹L¥|¼h«OÅ@¡A¦b¥h¦~ªÑªF·|¤W¤]»¡¹L¡A ¤µ¦~ªÑªF·|²Ä¤@Ó´£°Ý¤]¬O¦³Ãö±M§QÅv¡A³o¨Ç¤º®e§Ú´N¤£ÂØz ±Ð±Â¸ÑÄÀ¨ì³Ì«á»¡¡G¡u§Ú̪º±M§Q¨Ã¤£¬O¥u¦³¤T¨ì¤C¦~¡A³o¬OÄY«ªº»~·|¡C¡v |
|
|
·|û¡GªÅ¤]ªÅªÅ10145331 µoªí®É¶¡:2017/11/21 ¤U¤È 04:01:55²Ä 223 ½g¦^À³
|
³\¤j¤j¡A·PÁ±zªº¬ü¨¥¡A·\¤£´±·í¡C ¤£ºÞ¬O¯«¸g¡Bºë¯«ÃĪ«¬ãµo©Î¬O¦ÑÃÄ(¦Ñ¤Æ¦Xª«)·s¥Î¡A³£«Ü½ÆÂø¡A ¥[¤WÓ¤H¦b³o¤GÓ»â°ì¨S¤°»ò¸gÅç¡A¹ê¦b¤£´±¦h»¡¡C ³QÂI¦W¡A¥u¦n´N¦³ªº¾¥¤ô¶ÃF¡A¿ù»~³B·q½Ð«ü¥¿¡C ½²±Ð±Â¬O¥xÆW¬ãµo¤½¥qt³d¤H¤¤¡A¹ïÁ{§É¸ÕÅç¤U¥\¤Ò³Ì²`ªº¡C ¸ÕÅç«~½è«Ü¦n¡A¦³BTD¡C¦ý¬O¡A¹ï¦p¦ó¡¨½æ¡¨ÃÄ¡A¤£¤Ó¦æ¡C ¬Ý¨ì¡¨½²¸³»¡¥L¤w¸gª¾¹D¸Ó«ç»ò¦^µª¤F¡G¡u¦pªG§An³Ü¤ô¡A·|¥h¶R«K§Q°Ó©±ªº¤ô¡A ÁÙ¬O¥h³Ü¤ô·¾ªº¤ô¡HÁöµM¦P¼Ë³£¬O¤ô¡v¡¨¡AÓ¤H®t¤@ÂI¼Q¤f¤ô¡A¹º¿ù«ÂI¤F¡C «K§Q°Ó©±ªº¤ô¸ò¤ô·¾ªº¤ô¡A¦pªG¥u¬O«~½è(CMC)°ÝÃD¡A¤ô·¾¤ôGMP¼t¤]¥i¥HÅܦ¨«K§Q°Ó©±ªº¤ô¡C ¯u¥¿ªº°ÝÃDÀ³¸Ó¬O¡GÅý«K§Q°Ó©±(«OÀI¤½¥q)¥u¯à½æ¡¨·s®®¡¨ªº¤ô(ÃÄ)¡A¤£¯à½æ§O¤Hªº¡C³o²o¯A¨ì±M§QÅv¤Î©w»ù¡C ±M§QÅv¥Ø«e¬Ý¨Ó¦ü¥G¨S¦³¤Æ¦Xª«±M§Q¡A¥u¯à¦b¦X¦¨±M§Q¡Bdata exclusiveµ¥¤è±§V¤O¡C ±M§QÅv¸Ô²Ó±¡§Î¡AÓ¤H©Òª¾¦³¡A©Ò¥H¥Î³Ì«O¦uªº¤è¦¡¦ôp¡Gdata exclusive¡A¤@¯ëÃÄ3¦~¡B¨uÃÄ7¦~¡C ¦]¦¹¡AÃÄ»ù¤£¯à¤Ó§C¡A±À¼sn¨³³t¡A¤~¯àÀò§Q¡C ¤½¥q¦h»¡©ú¨ú±oÃÄÃÒ«á¡A¦p¦ó¦bµu®É¶¡¡A®³¨ì¦nªº«OÀIµ¹¥I»ù¤Î±À¼s¡A©Î³\·|Åý¤H§ó¦³«H¤ß¡C ¹ï¤£°_¡A¦]ªì¨ì³oÓÄ_¦a¡A©Î³\¤½¥q¤w¸g»¡±o«Ü©ú¥Õ¤F¡CÓ¤H¤£ª¾¤£Ä±¡A½Ð¨£½Ì¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/21 ¤U¤È 02:37:01²Ä 222 ½g¦^À³
|
쥻§C½Õ«O¦u , ¦³¤@¥u»¡¤@¤£»¡¤G ªº liaw6575¤j¤j ¤µ¤Ñªº±M½× , ¤U¤F¤@Ó¥O¤pªºÅå³Yªº¼ÐÃD... ½Ð°Ñ http://liawbf.pixnet.net/blog/post/47649963 ¤ß¦³¦P·Pªº¤j¤j , ½Ð¤£§[µ¹´xÁn ¶WÆgªºliaw6575¤j¤j ·PÁ±z ¦¨¥\»Ýn®É¶¡ , ´NÅý§Ṳ́@°_µ¥«Ý ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2017/11/21 ¤W¤È 11:08:08²Ä 221 ½g¦^À³
|
¦Ñ¥v¤j~ ±zªº·N«ä¬O®Ñ¤¤¦Û¦³¶Àª÷«Î¶Ü? »¡Åª®Ñ¦Û®T´N¤ÓÁ¾µê¤F! ªÅ¤]¤j~ ¤@¦p§Ú·íªì²Ä¤@¦¸¬Ý¨ì§Aµo¨¥ ´Nı±o§A¬O°ª¤H ¥Ø¬Ý°_¨ÓÀ³¸Ó¤£¥u¬O°ª¤H ÁÙ¦³ÂI¹³¥@¥~°ª¤H ÁÂÁ§A¨C¤Ñ¦b¦Uª©ªº¥I¥X. »¡¯uªº~ §Ú²`²`ı§A¸ò²q¤jªºstyle«Ü¹³ ¥i¯à¬O§Ú·Q¤Ó¦h°Õ... ÁÙ¦³¤@¨Æ·Q½Ð±ÐªÅ¤j ¥xÆW¥Í§Þªº¥«È»·§C©ó°ê»Ú±¾µP¤½¥q ¬O¤°»òì¦]©~¦h? ¹³¤ß®®¦hÓÁ{§É¦b¶i¦æ ¤S¦³©t¨àÃÄ»PBTD ¦ý¬O¥«È«o¤£¨ì2»õ¬üª÷ ³o¬O«ç»ò¦^¨Æ ½ÐªÅ¤j¥i¥H¥Î¦Û¨¸gÅç²á²á¬Ýªk¶Ü? ÁÂÁÂ! ¥xÆW¥Í§Þ¥[ªo! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/20 ¤U¤È 07:07:49²Ä 220 ½g¦^À³
|
ÁÂÁ ¦Ñ¥v¤j¤jÁ¿¾ú¥v ¤µ¤ÑÁ¿ªº¬O2014¦~³Q¤é¥»¤j¶ï»sÃÄ¥H 35 »õ¬ü¤¸¨ÖÁʪº Avanir http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-11-20&e=snoopychiang&t=.htm&j=2427&f=main&v=1 ³o¤]¬O¤@®aȱo¤ß®®¾Ç²ßªº¹ï¶H ¥¦ªº©xºô ¡G http://www.avanir.com/ ÁÂÁ¦ѥv¤j¤j³o»ò¦³²`·Nªº±M¤å ÁÂÁ¤j®a ¦P®É¤]ÁÂÁªŤ]ªÅªÅ¤jªº¸ÑªR |
|
|
·|û¡GªÅ¤]ªÅªÅ10145331 µoªí®É¶¡:2017/11/20 ¤U¤È 05:22:31²Ä 219 ½g¦^À³
|
²q·Q¤j¡A¹ï¤£°_¡A¬Ý¤Ó§Ö¤F¡A¥u¬Ý¨ì¦Ñ¹«¨S¬Ý¨ì¤H¡C·PÁ±z¦A¤@¦¸´£¿ô¡C ±M·~¤H¤h¤£´±·í¡A¯S§O¬O¯«¸g¡Bºë¯«»â°ì¡A³oÓ»â°ìªºÁ{§É¸ÕÅç³]p¤ñÀù¯g½ÆÂø¤Ó¦h¤F¡C ¨ü¸ÕªÌªº¿ï¨ú¡BÀø®Ä«ü¼Ð¡B¶qªíµû¦ôªÌ¡K¡A³B³B·°·°¨¤¨¤¡C ¦]¬°µû¦ôÀø®Äªº¤èªk´X¥G³£¬O¶qªí¡A´N¹³½²±Ð±Â±Ð¾Éªº¡A¥DÆ[©Ê«Ü±j¯P¡A¦w¼¢¾¯®ÄªG«Ü¤j¡C ¦³®É¬°¤Fµû¦ô¸ÕÅçÃĪ«¬O¯uªº¨S®Ä¡A©Î¬O¦w¼¢¾¯®ÄªG¤Ó¤j¡AÁÙ·|°µ3 arm trial (¸ÕÅçÃÄ¡B¦³®ÄÃÄ¡B¦w¼¢¾¯) UB-311¬OÁ{§É¤@´Á¡A¨S¦³¦w¼¢¾¯²Õ¡AÀø®Ä¸ê®Æªº·N¸q¤£¤j¡C SND-14ªº2a¬OÁ{§É¤G´Áª¼©Ê³]pªºRCT¡A¨äµ²ªG¦³·N¸q¦h¤F¡C ¯«¸g¡Bºë¯«¯e¯f³oÓ»â°ìªºÁ{§É¸ÕÅç«Ü½ÆÂø¡A¸ÑŪ§óÃø¡CJ¨¥¶Ã»y¡AÃøµn¤j¶®¤§°ó¡A¨£¯º¤F¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/20 ¤U¤È 02:44:26²Ä 218 ½g¦^À³
|
ªÅ¤]ªÅªÅ¤j Åwªï¥úÁ{ ¤p§Ì¶Kªº UB-311 ³ø§i¤]¦³Á{§Éªº¼Æ¾Ú http://www.trci.alzdem.com/cms/attachment/2109454749/2082885009/gr3_lrg.jpg ±z¤]¬O±M·~¤H¤h ½ÐÀ°§Ú̵û¦ô¤ñ¸û¦p¦ó ÁÂÁ±z§r! ÁÂÁ¤j®a! |
|
|
·|û¡GªÅ¤]ªÅªÅ10145331 µoªí®É¶¡:2017/11/20 ¤U¤È 01:53:16²Ä 217 ½g¦^À³
|
Ó¤H²L¨£¡A¦p¤U¡G ¤@Ó¬O°Êª«¹êÅç¡A¤@Ó¬OÁ{§É¸ÕÅç¡AµLªk¤ñ¸û¡C ¤@¯ë¦Ó¨¥¡A¦³Á{§É¸ÕÅ窺¸ê®Æ¡A°Êª«¹êÅç¸ê®Æªº»ùÈ´N¤£°ª¡A¥HÁ{§É¸ÕÅ窺µ²ªG¬°·Ç¡C °Êª«¹êÅ禳®Ä¡AÁ{§É¸ÕÅçµL®Ä¡A´N¬OµL®Ä¡C °Êª«¹êÅçµL®Ä¡AÁ{§É¸ÕÅ禳®Ä¡A´N¬O¦³®Ä¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/20 ¤W¤È 09:19:46²Ä 216 ½g¦^À³
|
Áp¥ÍÃĪvÀøAD¬Ì]( UB-311 )ªº³ø§i http://www.trci.alzdem.com/article/S2352-8737(17)30022-7/fulltext ©M§ÚÌSND-14ªº2a¤ñ¸û¦p¦ó? http://liawbf.pixnet.net/blog/post/47570421-snd-14%EF%BC%8C%E7%9C%9F%E6%AD%A3%E6%9C%89%E6%84%8F%E6%80%9D(2a%E8%A9%A6%E9%A9%97%E7%A0%94%E7%A9%B6%E6%91%98%E8%A6%81%EF%BC%8C%E7%82%BA%E6%85%B6%E7%A5%9D%E5%9C%8B ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/19 ¤U¤È 09:21:12²Ä 215 ½g¦^À³
|
ÁÂÁ ¦Ñ¥v¤j¤j liaw6575¤j¤j ¤µ¤é³£µoªí¦n´Îªº±M¤å http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-11-19&e=snoopychiang&t=.htm&j=2426&f=main&v=1 http://liawbf.pixnet.net/blog/post/47642511 ½Ð¤j®a¦³ªÅ«e©¹®®Åª ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/18 ¤U¤È 11:26:53²Ä 214 ½g¦^À³
|
ÂÅ¥ý¤¸±Ð±Âªº³Ì·s½×¤å Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging Chieh-Hsin Lin, Hui-Ting Yang, Chih-Chiang Chiu & Hsien-Yuan Lane https://www.nature.com/articles/s41598-017-13951-7#Abs1 This is the first study indicating that the peripheral DAO levels may increase with age-related cognitive decline. The finding supports the hypofunction of NMDA receptor hypothesis in AD. ³o¬ODAAOi ªvÀøADªº¡]³¡¤À²z½×¡^°ò¦¶Ü¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/17 ¤U¤È 12:23:35²Ä 213 ½g¦^À³
|
¦Ñ¥v¤j¤jÁ`¯àµoªí·N¸q²`»·ªº¤å³¹ , Ày§Ó¤Sµo¤H²`¬Ù µM³o¤£¥¿¬O§ÚÌf¥Ò»Ä¶uªºµo®iº]¼Ë¶Ü?! ¤À¤l²³æ¤£¬O°ÝÃD , «ÂI¦bµ¦²¤---±M§Q«OÅ@ ³o¼Ë¤@Ó¤p¤À¤lÃĪ« , ¤W¥«¨S´X¦~´N¯à³Ð 4B ¨ÎÁZ , ¨S¹F¦¨¤§«e , ¤j²³´±·Q¹³¶Ü? ¤µ¤Ñ´CÅé¤S³ø¾É , MLB¬üÁpMVP ¤ÓªÅ¤H¶¤ªº Jose Altuve ¨°ª¥u¦³167¤½¤À , «o¯à¦b¤jÁp·ùÂô¥X¦W¸¹ , ¨ÃÀòMVPªº®íºa , ³o¤£¤S¬O¥t¤@¶µ¨Æ¦b¤H¬°ªº¨å½d¶Ü?! ³Q¤H¬Ý»´¨SÃö«Y , °ß¦³¦Û¤v¤£¦k¦ÛµáÁ¡ , Ä~Äò«ù«í§V¤O ¤ß®®¥[ªo!!! ÁÂÁ¦ѥv¤j¤j ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/17 ¤W¤È 11:26:48²Ä 212 ½g¦^À³
|
²q·Q¤jô´£¨ìBiogem¦hµo©Êµw¤Æ¯g(MS)¡A«e´X¤Ñ§Ú¦b¬ÝAlkermes³o®a¤½¥qpipeline©³¤U¥Î©óMSªºALKS-8700¡A´N¦³ÁÓÂà¬Ý¨ìBiogen¦bMSªº²Ä¤@¤jÃÄTecfidera¡A2013¦~3¤ë¤W¥«¡A¥h¦~´N½æ¨ì4B¡A¶W¯Å¼F®`¡C¤µ¤ÑɥΧO¤Hªº¤å¦r¨Óªí¹F§Úªº¤ß±¡¡G¡u¥¦¥»¬O¤@ºØ§íµß¨¾¾`ªº¤u·~ì®Æ¡A«oµØÄRÂਦ¨¬°¤H¥ÎÃÄ«~¡F¥¦³Ìªì»ù®æ§C·G¡A«o³q¹L²Ó¥[Æp¬ã¦Ó¨»ù¼@¼W¡F¥¦µ²ºc¹L©ó²³æ¡A«o¯à¦¨ÃĦӥO¤HÅå¹Ä¡F¥¦¨IÀq¦h¦~¡A¤W¥««á«½S¬µ¼u®u±²¥þ²y¡C¥¦´N¬O¦Ê°·¤½¥q¶}µoªº¥Î©óªvÀø¦hµo©Êµw¤Æ¯gªº´I°¨»Ä¤G¥Òà¡ãTecfidera¡I´I°¨»Ä¤G¥Òà¡I´I°¨»Ä¤G¥Òà¡I´I°¨»Ä¤G¥Òà¡I¹ï©óÃĪ«¤Æ¾Ç¥X¨¡A¤u§@«á±q¨Æ³Ð·sÃĪ«¬ãµoªº¤p½s¨Ó»¡¡Aµ´¹ï¬OÓÀy§Óªº¨å½d¡C¨C·í¬Ý¨ì³oӤƾǵ²ºcªº®ÉÔ¡A³£·|³´¤J¨I«ä¡I§Ṳ́@ª½¦b¶O«lW¤ß¡B¸û«l¸£¥Ä²q´ú§ÚÌ©Ò³]pªºµ²ºc¦p¦ó¦p¦ó¡u¦X²z¡v¡B¡u¦³®Ä¡vªº®ÉÔ¡A®í¤£ª¾¨º³Ì²³æªºÃĪ«¤À¤l´N¦b¨º¸Ì¡u§b§bªº¡v¬ÝµÛ§ÚÌ¡A¥¦¥i¯à¬O§Ú̲ײ£ª«¦X¦¨¹Lµ{¤¤ªº¤¤¶¡Åé¡A§ó¦³¥i¯à¬O§Ú̱q¨Ñ³f°Ó¨º¸ÌÁʶR¨Óªº°_©lì®Æ¡A¥¦Â÷§Ú̬O¨º¼Ëªº»»»·¦Ó¤S¨º¼ËªºÄ²¤â¥i¤Î¡K¡K¡C¤£¹L¡A·P´nI«á¡A¤£±o¤£¨ØªAì¬ã¤½¥q¹ï©ó«~ºØ¦b«ÈÆ[¤Wªº¬ãµo³z¹ý©M¥DÆ[¤Wªº¨º¥÷°õµÛ¡A³oµ´¹ï¬O²³¦h»sÃĤ½¥q¤Î¬ãµo¤Hû©Ò»Ýn¾Ç²ßªº¡I¤]³\¡A¥u¦³¤£©ñ¹L¥ô¦ó¤@Ó¥i¯à©Ê¡A¤~¥i¯àµo²{¨ºÅý¤H·N·Q¤£¨ìªº¡u1/¤À¥À¡v(¤À¥À~¦Û¤v·QÓ¼Æȧa)¡I¡v ì¤åºô§}¡Gkknews.cc/news/294q36z.html |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/16 ¤U¤È 02:42:14²Ä 211 ½g¦^À³
|
Dear ³\¤j Ū®Ñ¦Û®T¡A§Ú«j±j¥i¥H ±zªº°ÝÃD¸g¤Ñ½n¦a¡A«D§Ú¯à¤O©Ò¤Î¡I |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2017/11/16 ¤W¤È 11:43:43²Ä 210 ½g¦^À³
|
¦Ñ¥v¤j~ ¥i§_¤ÀªR¤@¤U ±zı±o¤ß®®¥¼¨Ó³Ì¦nªºµo®i¤è¦V? ¬Ý¨ì³oºØ¨«¶Õ ¯uªº¹³ªÑ¥«¶^¤F3000ÂI ¦ý¬O¥H§A¬Ý°ê»Ú¬ÛÃö¤½¥qªº¥«È ¤S»·¤j©ó¤ß®® ¦ý¤ß®®¤S¦³2ÓBTD ¹ê¦b¤Ó¦hªº¤£¦X²z... ÁÂÁ¦ѥv¤jªºªø´Á¥I¥X! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/15 ¤U¤È 06:49:09²Ä 209 ½g¦^À³
|
ÁÂÁ ¦Ñ¥v¤j¤j¤Þ¤H¤J³ÓªºÃĪ«µo®i¥v ¸ÓÃįण¯à¦A³Ð¾P°â°ª¼é? ½Ð¬Ý·s®öÂåÀøºôªº ³ø¾É FDA§åã¥þ²yºÓ¼Æ¦r¤ÆÃĪ«Abilify Mycite http://med.sina.com/article_detail_103_2_36590.html ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2017-11-15 ¥t¥~·s®öÂåÀøºô¤]³ø¾É ISCO¯«¸g·F²ÓMÀøªkªvÀø©¬ª÷´Ë¨ú±o¿n·¥µ²ªG http://med.sina.com/article_detail_103_2_36600.html ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2017-11-15 §ó¸ÔºÉªº²Ó¸` ½Ð°Ñ¦Ò¸Ó¤½¥qºô¯¸ : http://internationalstemcell.com/company/ ¸ÓÀøªkªº³Ì¤j·ÀI ©Î³\¬Oµ¹ÃĤ覡 Stem cells injected into brain to treat Parkinson¡¦s disease in world¡¦s first trial in Australia http://news.xinhuanet.com/english/2016-09/14/c_135686602.htm Neurologist Andrew Evans and neurosurgeon Girish Nair, the two doctors who carried out the procedure, said it took several months to plan the operation from scratch and receive approval to go ahead. The two brain experts created a three-dimensional model of the patient¡¦s brain, which they used to complete "dummy runs" of the operation. Nair said the slightest mistake in the surgery could have resulted in the death of the patient and injecting the cells too slowly could have resulted in the cells becoming stuck and developing into a tumor. "The site is very close to the brain stem - the most critical part of the brain - and if you poke around in the wrong places then it could end in paralysis or death," Nair said. "And if you have a bleed there, even a small one, it¡¦s a major stroke." Evans said it was an enormous relief for the team when scans 24 hours after the surgery revealed the cells had reached all the target sites. ... ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/15 ¤U¤È 02:56:06²Ä 208 ½g¦^À³
|
¤µ¤Ñ¨â¤j³ø§¡´£¨ìFDA®Öã²Ä¤@ӼƦìÃĪ«¡A¤j¶ï»sÃĥΦbºë¯«¤Àµõ»PļÆ{¯gªº¶Ç©_ÃĪ«Abilify¡A¾Ú§Ú²z¸Ñ¡AÂå¥Í¥§¡¶}10ÁûÃÄ¡Aºë¯«¤Àµõ¯f¤H¤j·§¥u·|¦Y4Áû¡A¶¶±q©Ê«D±`®t¡A©Ò¥H¤j¶ïªº°µªk¬Û·í¦X²z¡A¦ý¤£ª¾¯à§_¦A³ÐAbilify±Û·¡C ¬Q¤Ñ¤j¶ï¤½§G°]³ø¡A«e¤T©uÀ禬9190»õ¤é¶ê¡A¸û¥h¦~¦P´Á8901»õ¦¨ªø3.2%¡A¨ä¤¤·sÃÄÀ禬2454»õ¡A¸û¥h¦~¦P´Á1917»õ¦¨ªø28%¡A¦¨ªø°Ê¯à»á±j¡AÂǦ¹¾÷·|¬Ý¬Ý¤j¶ï°£¤F¯{35»õ¬üª÷¶R¿Õ¤ñµÎ«y¨Ó³Ü¡]¤]¥i¥H»¡¬O¶R´µ´µ¨Ó¦Y¡^¤§¥~¡A¦bCNS¦³¤°»ò§G§½¡C ¤§«e´£¹L¡AAbilify¨Ã«D¦bÃĮĦ³¹L¤H¤§³B¡A¦Ó¬O¬Û¹ï¤ñ¸û¤Öªº°Æ§@¥Î¡A¹ï©ó¤ß±¡¤w¸g¬Û·ít±Æ{¨òªº¯f¤H¤ñ¸û¤£·|³·¤W¥[Á÷¡F¹Å誾¨ý§a¡A¤j¶ï©M¤¦³ÁLundbeck¦@¦P¶}µoªºRexulti(brexpiprazole)´N¬O©ÓÄ~Abilify¦h¤ÚÓiéw¾¯(dopamine system stabilizers)ªº·§©À¦Ó¨Ó¡C®Ú¾Ú2015¦~¥|¤ëµoªí¦bmerican Journal of Psychiatry>ªº¤T´ÁÁ{§É½×¤å´£¨ì¡¨Brexpiprazole shows partial agonism with lower intrinsic activity at the D2 receptor and stronger antagonism at the 5-HT2A receptor than the only currently available D2 partial agonist, aripiprazole , suggesting a relatively lower potential to induce D2 partial agonist-mediated adverse effects, e.g., akathisia, insomnia, restlessness, and nausea. The potential to induce D2 antagonist-like adverse effects, e.g., extrapyramidal symptoms, hyperprolactinemia, and possibly tardive dyskinesia, is also considered to be lower than with full D2 antagonists. Further, brexpiprazole¡¦s balanced 5-HT2A/D2 and 5-HT1A/D2 receptor binding profile may contribute to low incidences of both activating and neuromotor adverse effects clinically . Finally, brexpiprazole has a moderate affinity, relative to D2/5-HT1Areceptor affinity, for histamine H1 receptors , which may result in low sedation levels¡¨¡A¤å¤¤±j½ÕRexulti°§C°Æ§@¥Îªº¾÷Âà¡A¤@¶}©l´N¥ý»¡©ú¸òAbilifyªº®t²§¡C¦³¤ÀªR®v´£¨ì¡ARexultiªº¾P°âªí²{³Ì²×n¬Ý¤j¶ï©MLundbeck¦p¦ó¯à©MAbilify°µ¥X°Ï§O¡A§_«h¤j®a¦Y«K©yªºAbilify¾Ç¦WÃÄ´N¦n¤F¡CRexulti©ó2016¦~²Ä¤@Ó§¹¾ã¾P°â¦~«×¦¨ÁZ¬O2.6»õ¬üª÷¡A¤µ¦~¹w¦ô¯à¦¨ªø¨ì4»õ¬üª÷¥H¤W Rexulti¥ý¨ú±o®Ö㪺¬O°w¹ï«æµo´Áªººë¯«¤Àµõ¯f¤H¡APANSS total score©M¹ï·Ó²Õ¬Û¤ñ¡A2mg²ÕªºES=0.41¡A4mg²ÕªºES=0.36¡A¦bCGI severityµû¦ô¤W¡A2mg²ÕªºES=0.29¡A4mg²ÕªºES=0.33¡A¼Æ¾Ú¨S¦³«Ü«G²´¡A½×¤å«ü¥X¹ï·Ó²Õ¦w¼¢¾¯®ÄÀ³¤Ó°ª¤§¬G¡]PANSS total´î¤Ö12¤À¶W¹L¥H©¹¤åÄm¸ê®Æ¡^¡CNaben¦n¹³¨S¦³¥Î©ó«æµo¯f¤HªºÁ{§É¸ê®Æ¡A¦ýSarcosine´¿¸g³æ¥Î¡A¤]´¿¸g©MRisperidone¨Ö¥Î¡A¤£¹L¸ê®Æ¤£¨¬¡AÁ{§É³]p¤£¦P¡AµLªk®³¨Ó©MRexulti¤ñ¸û¡CÂÅ¥ý¤¸Âå®v¦³°µ¹LSarcosine PK Risperidone¡AN=32:30¡Aµ²½×»¡¨â²Õ²Îp¤WµLÅãµÛ®t²§¡ASarcosine¥Î©ó«æµo¯f¤HªºÀø®Ä¡u¤£¨È©ó¡vRisperidone¡A¥B¦w¥þ©Ê¸û¨Î¡C°ò¥»¤WRisperidone¦bÁ{§É¸gÅç¤WªºÃĮIJ¤Àu©óAbilify¡A¦ý¦b°Æ§@¥Î¤W¤£¦pAbilify¡C«ö·ÓÄå¤ìªá¹DÅÞ¿è¡A¤jµVµV¤ñ¬y¤t·¬¼F®`¡AÄå¤ì¤ñ¤jµVµV¼F®`¡A©Ò¥HÄå¤ì¤ñ¬y¤t·¬¼F®`¡FNaBen¤ñSacorsineªºES¦h¤T¿¡ASacorsine¤£¨È©óRisperidone¡ARisperidoneÃĮIJ¤Àu©óAbilify¡K¡K¡A«¢«¢¡A§Ú¤£¸Ó¶Ã¥[¸ÑÄÀ¡A¥H¤W¯Âºéª±¯º¸Ü¡A½Ð§â³o¬q§Ñ¤F¡A¥¼¸g¥¿¦¡Á{§É¯ÂÄÝJ»¡ ¤@¤£¤p¤ß§è»·¤F¡A¦^¨ì¤j¶ïRexulti¡C2016¦~¤E¤ë®Öã¥Î©óºë¯«¤Àµõºû«ùªvÀø¡A³o´N¤ñ¸û¹³SND13¶D¨Dªº¯f¤H¡A¤£¹LRexultiªºÁ{§É¤è¦¡©M§Ṳ́j¤£¬Û¦P¡A¤Ï¦Ó«D±`Ãþ¦üAcadiaªºDementia-related PsychosisÁ{§É¡A a 12 to 36-week, single-blind Rexulti stabilization phase, patients who had been symptomatically stable on Rexulti for 12 con-secutive weeks in the stabilization phase were randomized in a double-blind treatment phase to either Rexulti (n=97) or placebo (n=105). Impending relapse during the dou-ble-blind phase was determined if patients met any of the following pre-specified criteria: worsening symptoms defined by changes in PANSS or CGI-I scores; hospitalization for worsening psychotic symptoms; suicidal behavior or; violent/aggressive behavior¡A¤ñ¸û²Ä¤G¶¥¬q¥ÎÃIJջP¹ï·Ó²Õ¡u¹Gªñ´_µo¡vªº®É¶¡®t²§¡]Y±Ä¯u¥¿´_µo´N¤Ó¶Ë¸£¤F¡^¡CÁ{§É³]p©MSND13¤£¦P¡AµLªk¤ñ¸û Abilify¦]¬°±M§Q¨ì´Á¡A¾P°â¼Æ¦r«ùÄò¤U·Æ¡A¤£¹L¤µ¦~¹w¦ôÁÙ¥i¥H½æ¨ì5»õ¬üª÷¡]¥h¦~½æ8.3»õ¡^¡A·íµM¡A¦Ò¼{¨ì¯f¤H¶¶±q©Ê¡A¦U«D¨å«¬ÃĪ«¦h¦³¶}µoªø®Ä¾¯«¬¡AAbilify¤]¤£¨Ò¥~¡Aªø®Ä¾¯«¬¥s°µAbilify Maintena¡A¤@Ó¤ë¤@°w¡A¹w¦ô¤µ¦~¥i¥H½æ¨ì6.3»õ¬üª÷¡A¸û¥h¦~5»õ¬üª÷¦¨ªø26%¡C¾ãÅ黡¨Ó¡AAbilify»PAbilifyÁclªº²£«~¡A¤µ¦~ÁÙ¯à°^Äm¤j¶ï16»õ¬üª÷ªºÀ禬¡A¯uªº¼F®`¡CRexulti¥¿¦b¥Ó½Ð¼Ú¬w»P¤é¥»ºë¯«¤ÀµõÃÄÃÒ¡A©Ò¥HÀ禬ÁÙ¦³«ùÄò¦¨ªøªÅ¶¡¡C¥Ø«e¥¿¦b¼Ú¬w¶i |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/14 ¤U¤È 05:50:50²Ä 207 ½g¦^À³
|
ÁÂÁ ¦Ñ¥v¤j¤j¸g¨åªº¤º®e ¦³¾ú¥v©Ê ¬G¨Æ©Ê µû½×©Ê ݨã±Ð¨|¥\¯à ¤j®a³£µ¹±z»¡Æg ÁÂÁ±z! ¦P®É liaw6575 ¤j¤j¤]µoªí·s±M¤å http://liawbf.pixnet.net/blog/post/47636652 ¦P¼Ë¨ã¦³¿@¿@ªº¾Ç³N·®æ ¦ý¬Oliaw6575 ¤j¤j«o¯à±N½×¤åªº¥Íµw , ¥ÎµÛ¥©öªñ¤Hªºµ§½Õ , Åý§ÚÌ©ö©ó§l¦¬¤F¸Ñ liaw6575 ¤j¤jªº¥Î¥\¥Î¤ß , §Ú̳£¦n·PÁ ÁÂÁ±z! ÁÂÁ¤j®a! |
|
|
·|û¡G¤p³ì10135960 µoªí®É¶¡:2017/11/14 ¤U¤È 04:15:49²Ä 206 ½g¦^À³
|
Á¦ѥv¤j¶O¤ß§ä¤F³o»ò¦h¸ê®Æ¤À¨É,¥u¯à»¡ºë±m¤F ¤£¦P¥«³õ¦ôÈ®t²§¦p¦¹¤§¤j,¤£ª¾¬O¨ºÓ¥«³õ¥X¤F°ÝÃD |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/14 ¤U¤È 01:11:15²Ä 205 ½g¦^À³
|
¬Q¤ÑAC Immune³o®a¨Ó¦Û·ç¤h¡A±Mª`©óªü¯÷®üÀqªº¤p¤½¥q¤½§G°]³ø¡AQ3Á«·l0.13¤¸¡A¨S¤°»ò¯S§O¤§³B¡C¬G¨Æ¬O³o¼Ëªº¡A·íBapineuzumab±²°_¥«³õªü¯÷®üÀq³æ§ÜÃĪ«¨g¼ö®É¡AAC Immune¦b2006¦~±NCrenezumab±ÂÅvµ¹Genentech¡A2014¦~7¤ëRoche«Å¥¬»´«×¨ì¤¤«×ADªº¨âÓP2¥¼¹F¼Ð¡A¦ý2015¦~7¤ëRoche¦ü¥Gµo²{¨Ç¦³½ìªºData¦Ó¨M©w®¼¶iP3¡A¤]¦³¤H»¡Roche¬O¨ü¨ìBiogenªºAducanumab¨ë¿E¤~®¼¶iP3¡AÁ{§É§ï¦¬¤ñ¸û»´·Lªº¯f¤H¡¨prodromal to mild¡¨¡A¤]´N¬OMCI©M»´«×AD¡C2017¦~Q2¥[¶}²Ä¤GÓP3¡A¦³¿ú¤H¯u¦n¡A¨S§â¿ú·í¿ú¡C ²³æ¬Ý¹L¤WzI´º¤¶²Ð¡AAC Immune¦b2016¦~¤E¤ëu¬ü±¾µP·|«ç¼Ë¡H¬ü°ê¤H®¼¤£®¼¡Hµª®×¬OIPO©w»ù11¤¸¶Ò±o6600¸U¬üª÷¡AIPO¤é¤Wº¦42%¡A²Ä¥|¤Ñº¦¨ì19.3¤¸¡A¥«È¹F12»õ¬ü¤¸¡C³o¬O¤@®aP2¥¢±Ñªº¤½¥q¡AÁÙ¥BÁÙ¬O¦¦§C·G±ÂÅv¥X¥hªº¤½¥q¡A¦ý¬ü°ê¥«³õÁÙ¬Oµ¹¤©¼ö±¡¤ä«ù¡C³o¨âÓ¤T´Á¡¨prodromal to mild¡¨ªº¦¬®×±ø¥ó¤§¤@¬OMMSE score of greater than or equal to 22 points ¡A¨C¥|¶g¥´¤@°w¡An¥´100¶g¡A2020¦~«á¤~·|¦³ªì¨Bµ²ªG¡F«¥ÌP2¯f¤Hªº±ø¥ó¬OMMSE score of 17~26¡A¤]´N¬O¯f¤H±¡ªp¤ñCrenezumabÄY«¤@¨Ç¡A¦ý«¥Ì¦Y¨ì16¶g´N¦³º}«Gªº¼Æ¦r¤F¡CAC Immune¤µ¦~´¿¿ì²z²{¼W2000¸U¬üª÷¡A¨ì¬Q¤Ñ¥«È¬O6.5»õ¬üª÷¡AY´`¦¹ÅÞ¿è¡A¤£ª¾¦Ñ¥~·|«ç»òµû»ùSND14¡C ¦P¥x¥[ºtAxovant¡Aªá500¸U¬üª÷¦VGSK¶R¤UP2¥¢±ÑªºSB-742457¡A§ó¦W¬°RVT-101«á®¼¶i¤T´Á¡A¸Ó¸ØÆg¤½¥q«i®ð¥i¹ÅÁÙ¬O¡K¡K¡H©Ò¥H¤E¤ëP3®À±Ñ¤@ÂI³£¤£·N¥~¡A¸Ó·N¥~ªº¬O°g«H·s¥ô©ú¬PCEOªº§ë¸ê¤H§a¡A¥i¬OAxovant¥«ÈÁÙ¦³5.5»õ¬üª÷¡A·N«ä¬O»¡¥t¦³¨ä¥L¥¢´¼P2ªºpipelineÁÙÈ5.5»õ¬üª÷¡C±qAC Immune»PAxovant¥iª¾¡A¾¨ºÞP2®À±Ñ¡A¥¢´¼¬ÛÃöÁ{§ÉÁÙ¬O«ÜÈ¿ú¡C 覨¬°¥¥°ü°é¤j¬õ¤HªºSage¡A¬Q¤Ñ¥´ÅK¶X¼ö«Å§Gn¿ì²z²{¼W¤T»õ¬ü¤¸¡A¤âÀY²{ª÷©ú©úÁÙ¦h¹F2.43»õ¬üª÷¡I¦b¥xÆWÀ³¸Ó·|³Q½|ºG¤F¡A§ó¦óªpµuµu¨â¦~¤w¸g®³¹L¦n´XÓ»õ¡C©Ò¥H»¡°Õ¡A¦³¼ö±¡°·¥þªº¸ê¥»¥«³õ¬Û®¼¡A¥Í§Þ¤½¥qÁÚ¶}ªº¨B¥ï¤~·|¤j¡A«e¶iªº³t«×¤~·|§Ö¡C ¦pªG¨S¦³BTD¡A§Ú¼gªº³o¨Ç¤º®e¥i¥H·í¦¨©ñX¡A¦Û§Ú¿±µÈ¡F¥¿¦]¬°§Ú̦³BTD¡A©Ò¥H§Ú¤~Ä@·Nªá³o»ò¦h®É¶¡¤¶²Ð³o¨ÇCNS¤½¥qµ¹¤j®a»{ÃÑ¡C¯¸°ª¤@ÂI¡A´N¥i¥H¬Ý»·¤@ÂI¡A¯¸¶V°ª¡A¬Ý¶V»· |
|
|
·|û¡G·Q·Q10140340 µoªí®É¶¡:2017/11/14 ¤W¤È 07:22:53²Ä 204 ½g¦^À³
|
¤ñ¤@¤ñ Acadia ¥«È 30»õ ¬üª÷=1000»õ¥x¹ô Sage ¥«È 30 »õ ¬üª÷ = 1000»õ¥x¹ô ¤ß®® ¥«È 55 »õ ¥x¹ô «Ü¦h¥«³õ¤ÀªR¤H¤h»{¬°ºë¯«¯e¯f¬OÁôÂïe¯f ¤£¼öªù ¦ý¼Ú¬ü¤H¤h¹ï©óºë¯«°·±d¤ÎªvÀø «o¥±`¨ì¤£¦æ ¥«È§YÅKÃÒ ¦³»Ý¨DªºÃÄ´N¬O¦n薬 ¡I |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/14 ¤W¤È 01:39:16²Ä 203 ½g¦^À³
|
¤WÓ¤ëAcadia¨ú±o²Ä¤GÓBTD¡A¬O°w¹ï¥¢´¼¬ÛÃöªººë¯«²§±`¡¨Dementia-Related Psychosis¡¨¡AÀòBTDªº²z¥Ñ¬O°ò©ó019studyªü¯÷®üÀqºë¯«²§±`»P020study©¬ª÷´Ë¤ó¯gºë¯«²§±`ªº¼Æ¾Ú¡C·í¤U§Ú«Ü¯Ç´e¡A¦]¬°019Studyªºªì¨B¼Æ¾Ú¨Ã¤£¬O«D±`¬ð¥X¡AÀH¾÷¤À²Õ6¶g«á¡A primary endpoint «ü¼ÐNPI-NHªºpȬO0.0451¡AES¥u¦³0.32¡A²¤Àu©ó«D¨å«¬§Üºë¯«ÃĪ«ªº0.2¡A¥B12¶g«á©M¹ï·Ó²Õ¬Û¤ñ¨Ã¨S¦³®t²§¡A³o¼Ëªº¼Æ¾Ú¦bEOP2©MFDA°Q½×¤T´Á³]p«áÀò±oBTD¡Hèè¬Ý¤F½u¤Wªk»¡¤å¦r½Z¤~²z¸Ñì¦]¡Aì¨Ó®Ú¾Ú¦¸±Ú¸s¤ÀªR¡A¤¤«×¨ìÄY«ªºpsychosis¯f¤H(NPI-NH Psychosis score ≥12)¡A¦bNPI-NH«ü¼ÐªºES¿¼W¨ì0.73¡Ap=0.0114¡C°ò©ó¦¹¡A¤T´ÁÁ{§É³]p©M¤G´Á¤j¤£¦P¡A¥s°µ¡¨A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis¡¨¡A¤À¬°¨âÓ¶¥¬q¡A²Ä¤@¶¥¬q¬O12¶gªº¶}©ñÁ{§É¡A©Ò¦³¨ü¸ÕªÌ³£¦YPimavanserin¡A¦b²Ä8¶g»P²Ä12¶gµû¦ô³£¹F¨ìresponseªº¨ü¸ÕªÌ¤è¥i¶i¤J¤U¶¥¬q¡C²Ä¤G¶¥¬q26¶gÀH¾÷¤À°t¡A¤@¥bÄ~Äò¦YPimavanserin¡A¥t¤@¥b¦Y¦w¼¢¾¯¡AThe primary endpoint in the study is time to relapse¡A¦Ó¤£¬Oµû¦ô26¶g«áªºNPI-NH¤À¼Æ®t²§¡C³oºØ³]p¦³´XÓ¦n³B¡A²Ä¤@¬O¡¨ efficiency, and power enrichment¡¨¡A²Ä¤G¬O¦w¼¢¾¯®ÄÀ³¤£¤Ó¥i¯àºû«ù26¶g³o»ò¤[¡A±N·|©úÅã°§C¡C¾¨ºÞ¤½¥q»{¬°³oºØÁ{§É³]p·|´£°ª³Óºâ¡A¤£¹L¦Û11/3¦bªi¤h¹yClinical Trials on Alzheimer¡¦s Disease (CTAD) 2017 Meeting¤½¥¬§ó¸ÔºÉªº019study¼Æ¾Ú«á¡Aµu½u¶^´T20%¡A§ë¸ê¤H¤£¤Ó¶R³æ¡C¥t¥~¡A¤½¥q½Õ°ªNuplazid(Pimavanserin)¤µ¦~¾P°â¥Ø¼Ð¬°1.24~1.27»õ¬üª÷ §Ú¨S¦³²á«Ü»·¡A¦]¬°SND5¥¼¨Ó¤]¥i¯à¶i¦æADP©ÎDementia-Related Psycho-sis¡A¿ð¦¤]·|¦b¥@¬É¬×¤W¨ü¨ì°ê»Ú¤ÀªR®v«~ÀY½×¨¬¡A´£¦¤F¸Ñ§O¤H¦b°µ¬Æ»òÁ`¬O¦³À°§Uªº¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/12 ¤U¤È 05:52:42²Ä 202 ½g¦^À³
|
liaw6575 ¤j¤jªñ¦ü½×¤åªº±M¤å http://liawbf.pixnet.net/blog/post/47629143-%E6%86%82%E9%AC%B1%E7%97%87%E7%8B%80%EF%BC%8C%E7%A5%9E%E7%B6%93%E7%99%BC%E7%82%8E%EF%BC%8C%E5%AE%89%E6%81%AF%E5%90%A7 ¥»¤å½×z ¼~Æ{¯g»P¯«¸gµoª¢¬ÛÃöªº¯f²z°²»¡ ¨ÃÄÄzf¥Ò»Ä¶uªvÀø¼~Æ{¯gªº¯f²z¤Î¯f¨Ò ³Ì«á¥Ñliaw6575 ¤j¤jªº¤ß±o°µÁ`µ² ¦³½Ð®®¤Í«e©¹®®Åª ÁÂÁÂliaw6575 ¤j¤j±o¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G·Q·Q10140340 µoªí®É¶¡:2017/11/10 ¤W¤È 07:41:11²Ä 201 ½g¦^À³
|
¤ß®®¬OÓ¦³¨âÓBTDªº¤½¥q¡I ¨âÓBTD¡I ¨âÓBTD¡I ¨âÓBTD¡I www1.jihsun.com.tw/ECADMIN_Market/Bonus/NBbonus/images/GoodsImages/ResearchFile/20160129114307957.pdf |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/10 ¤W¤È 06:51:39²Ä 200 ½g¦^À³
|
Sage Therapeutics, Inc. (SAGE) NasdaqGM - NasdaqGM Real Time Price. Currency in USD 96.65+33.99 (+54.25%). ¥«È 36 »õ¬ü¤¸ https://finance.yahoo.com/quote/SAGE?ltr=1 2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here¡¦s Why. https://finance.yahoo.com/news/2-antidepressant-focused-biotech-stocks-174000853.html |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/9 ¤U¤È 10:20:43²Ä 199 ½g¦^À³
|
®¥³ßSage¨âÓ²£«á¼~Æ{P3³£¹F¼Ð¡AÁöµM¼Æ¾Ú¤ñP2»¹¦â¨Ç¡C Both trials, Study 202B in severe PPD and Study 202C in moderate PPD, met the primary endpoint of a statistically significant average reduction from baseline in a scale for depression called HAM-D versus placebo at hour 60 (p=0.0242 and p=0.0160, respectively) ¥»¨Ó¹L´X¤Ñ·Q¼gMarinus¡A«ÂI¦b±j½Õ¡u¨S¦³BTD¥«È®t«Ü¤j¡v¡A¨S·Q¨ì¤µ¤ÑSage¸Ñª¼¹F¼Ð¤]±a°ÊMarinus½L«e¤jº¦¶W¹L¤T¦¨¡A´N²³æ´£¤@¤U§a¡CMarinusªºGanaxolone©MSage-547¤@¼Ë¬O¦X¦¨§O¥¥²m¾Jà¬allopregnanoloneªº¬Û¦üª«¡A¤]¬O§@¥Î¦bGABA¨üÅ骺¥¿¦V²§¦ì½Õ±±¡C¥«È2.7»õ¬üª÷¡A°£¤F¦]¬°Pipeline¤ñSage³æÁ¡¡A¶i«×¤ñSage½wºC¥~¡A¥h¦~6¤ë©MSage¤@¼Ë±Ñ¦bÅöíw¡AÃøªv«¬§½³¡©ÊÅöíwdrug-resistant focal onset seizures¡C§Ú·Q»¡ªº«ÂI¬O¡ASage¦³BTD¥[«ù¯uªº®t«Ü¦h¡ASRSE¤T´Á®À±Ñ«á¥«ÈÁÙ¦³23»õ¬üª÷¡A¥H¬Q¤Ñ¨â®a¦¬½L¥«È¨Ó¬Ý®t¤F¤Q¿¡C |
|
|
·|û¡GSeanYang10141436 µoªí®É¶¡:2017/11/9 ¤U¤È 08:25:47²Ä 198 ½g¦^À³
|
Sage rockets up after two small PhIIIs score in postpartum depression Two months after getting hammered on the failure of its lead late-stage study for a rare type of seizures, Sage Therapeutics is claiming a victory in a pair of Phase III studies for the same drug in postpartum depression. Sage reported this morning that both of its late-stage studies for brexanolone (SAGE-547) for major postpartum depression successfully edged out a placebo ¡X but failed to register the big improvement over a sugar pill that was seen in Phase II. And the biotech $SAGE says that it will use the data to back an FDA submission for their drug ¡X which requires a 60-hour infusion ¡X next year. Sage¡¦s shares spiked 48% in pre-market trading on Thursday. |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/9 ¤U¤È 02:18:56²Ä 197 ½g¦^À³
|
¬Q¤ÑIntra-cellular¤½§G°]³ø¡Aºô¸ô¤W¥i¥H§ä¨ì¹q¸Üªk»¡ªº¤å¦r½Z¡C ³o®a¤½¥qlead productITI-007¬O2005¦~6¤ë±qBMS±ÂÅv¶i¨Óªº¡A¨Ã¥B±q¹©¹©¤j¦WªºPaul Greengard¹êÅç«ÇÀò±o¦h¤ÚÓi¨üÅé³J¥Õ½èÁC»Ä¤Æ½Õ±±§Þ³Ndopamine receptor phosphoprotein modulation¡C Paul Greengard¦ó³\¤H¤]¡H¥L©MArvid Carlsson¡BEric Kandel¦@¦PÀò±o2000¦~¿Õ¨©º¸Âå¾Ç¼ú¡AArvid Carlsson¸òAbilifyªº°Ý¥@¦³«Ü¤jÃö«Y¡A Paul Greengardªº°^Äm´N¬Oµo²{¯«¸g¶Ç¾É¦]¤l¦b¬ðIJªº§@¥Î¾÷¨î¡A¤×¨ä¬Oµo²{³J¥Õ½èÁC»Ä¤Æ¦b³o¾ãÓ¨BÆJ¤¤§êºt«D±`«nªº¨¤¦â¡CIntra-cellular³z¹LºÊ±±ºë¯«ÃĪ«¤Þ°_ªº³J¥Õ½èÁC»Ä¤Æ§Þ³N¡A³o¼Ë´N¥i¥H©ú¥ÕÃĪ«¦b²ÓM¤ºªº°T¸¹¶Ç»¼¸ô®|¡]³o²o¯A¨ì²Ä¤G°T¸¹cAMP¡^¡A¶i¦Ó¶}µo¥X¾A·íÃĪ«¡CIntra-cellular¦bºë¯«¤ÀµõÁ{§É¹Lµ{«D±`ºëªö¡A¨â³Ó¤§«á¥X²{¤@±Ñ¡]ÀY¨â³Óªº¼Æ¾Ú¨S¦³«Ü«GÄR¡APanss totalªºES=0.3´NÅý³æ¤éªÑ»ùº¦100%¡^¡A¨º¤@±Ñ¬O±Ñ©ó¦w¼¢¾¯®ÄÀ³¡C¸ÜÁö¦p¦¹¡A¦ýES=0.3¥»¨Ó´N¼çÂõ۳Q¦w¼¢¾¯Â½½Lªº¥i¯à¡C³Ì«áFDA¦P·N¨Ã¤£·|¦]¬°¨º¤@±Ñ¦Ó±Æ°£Intra-cellular´£¥XNDAªº¾÷·|¡AIntra-cellular¹w¦ô¦b2018¦~¤¤°e¥óNDA¡C³o¤]¬O¤@®a«Ü¦³·N«äªºCNS¤½¥q¡A¤]¬O¾aµÛ¬ü°ê¸ê¥»¥«³õ·í±j¤O«á¬Þ¡A¤~¯à§Ö³t¶i¦æ¦h¶µÁ{§É¡C¥«È7.6»õ¬üª÷ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/9 ¤U¤È 12:35:51²Ä 196 ½g¦^À³
|
Cliff ¤j®¦¼w ÁÂÁ±zªº«ü¾É ±z«H¤â©à¨ÓªºÂIµû , º¡¬OºëµØ ; §Y¨Ï¤pªºªá¤W´X¦~¥\¤Ò , ®£¤´Ãø±æ¶µI ¨Ì±zªº±K½X ¡KfÀôµ²ºc¥i§U³q¹LBBB¡K ...¤]¶¶«K¥Ñ¦¹ª¾¹D¤j¼t¹ïDAAO§í¨î¾¯¬O«Ü¦³¿³½ìªº... ...±q¤@¨Ç²{¦³CNSÃĪ«¤Æ¾Ç¦¡¥hµo²{¡A¦ü¥G¨ã¦³fÀôµ²ºcªºÁÙ¯u¤£¤Ö... ÁÙ¦³±z¯S§Oªº´£¥Ü ...ÀH«K§ä¨ì¤@ӹϡA³o¤Ó¬ãµo¤¤ªºDAAO§í¨î¾¯´N¦³¤TӨ㦳fÀô... ...¤å¤º´£¨ìFig.2Hªºf¥ÒñQÓi(benzamide)¥]§t¤F²Ä¤@¥N¡B²Ä¤G¥N§Üºë¯«¯fÃĪ«¤§¥~¡AÁÙÅn¬A¤F±`¥Îªº¤î¦R¾¯metoclopramide(´N¬Oprimperan)¥H¤Î§Ü»RÁЯgÃÄTiapride... ¦Ó¤p§Ì¤]§ä¨ì¤F, f¥ÒñQÓi(benzamide)¬Of¥Ò»Äªºl¥Íª« ¦A¬Ý¬Ý§Ú̪ºf¥Ò»Ä¶u ; ¦hGªº¤À¤l , ¤]³£¬Of¥Ò»Ä¬ÛÃöªºl¥Íª« ³o¬O¥©¦X¶Ü? ÁÙ¬O½²±Ð±Â^©úªº¹BÄw±cØò ¥t¥~ , ASO57278 (5-methylpyrazole-3-carboxylic acid) ¤£ª¾¦óì¦],©|¥¼¦bÁ{§Éºôµn¿ý , ÁÙ¬O¤p§Ì²Â©å https://clinicaltrials.gov/ct2/results?cond=&term=ASO57278+%285-methylpyrazole-3-carboxylic+acid%29+&cntry1=&state1=&recrs= ¤j®aÀ³¸Ó³£«Ü·PÁ Cliff ¤j®¦¼w ¦Ñ¥v¤j¤j liaw6575 ¤j¤j ªº±Ð¾É ¦b¸£¤¤¦³ª¾ÃÑ ¤ß¤¤¦³©¯ºÖ¤§«á ©Î³\´N·|ì½Ì¤p§Ì¥u·|ÆxÄM¾Ç»y Cliff ¤j®¦¼w¥mÀ{ªº , ¦³½Ð¤j®a°O¦b¤ß¸Ì ¦Ü©ó¤p§Ì¤£ª¾¹ï¿ùªºµù°O , ¶È¨Ñ°Ñ¦Ò ,¨Ã½Ð«ü¥¿ ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2017/11/9 ¤W¤È 08:47:24²Ä 195 ½g¦^À³
|
²q·Q¤j¤j¡G n³q¹LBBB¡A¤À¤l¶q¤j¤£¬O°ÝÃD¡A¦³±K½X´N¥i³qÃö¡A½²¸³¦bªÑªF·|¤W´¿´£¥Ü¡A¡KfÀôµ²ºc¥i§U³q¹LBBB¡K¡C©Ò¥H§Ú·QfÀôµ²ºc¬O±K½X¤§¤@¡C ºô¯¸¤W¥i¥H·j´M¨ì¦p¦ó«P¶i³q¹LBBBªº¤èªk¡A¤]¦³¤H´¿¬ã¨s±´¸ß¤°»ò¯S©Ê¬O¯à³q¹LBBBªº±K½X¡Aµ²ªG±`³Q·Q¨ìªº¯×·»©Ê«o¤£¬On¥ó¡A½²¸³±sÁc¬°Â²ªº¤@¥y¸Ü¤Ï¦Ó¦n¥Î¡C ÀH«K§ä¨ì¤@ӹϡA³o¤Ó¬ãµo¤¤ªºDAAO§í¨î¾¯´N¦³¤TӨ㦳fÀô¡C¡]www.ncbi.nlm.nih.gov/pmc/articles/PMC2905773/figure/F1/ ¡^ ½s¸¹¡]1¡^¡GAS057278¡FMerckÃÙ§U¡FIC50¡G0.91£gM¡]«Ü§Cªº¼Æ¦r¡^¡F¤fªA¥ÍÅé§Q¥Î²v41¢H¡C ½s¸¹¡]2¡^¡GPfizer¡FIC50¡G4nM¡F¤fªA¥ÍÅé§Q¥Î²v¶È0.9¢H¡C¦³fÀô¡C ½s¸¹¡]3¡^¡GPfizer¡FIC50¡G4nM¡F¦³fÀô¡C ½s¸¹¡]4¡^¡GMerck¡FIC50¡G145nM ½s¸¹¡]5¡^¡GMGI pharma¡FIC50¡G188nM¡F¦³fÀô¡C ¤]¶¶«K¥Ñ¦¹ª¾¹D¤j¼t¹ïDAAO§í¨î¾¯¬O«Ü¦³¿³½ìªº¡C ¬O§_¥un¾Ö¦³fÀôµ²ºc´N¥i¥H³q¹LBBB¡H©ÎªÌÁÙ»Ýnªþ±a¨ä¥L¦bµ²ºc¤Wªº±ø¥ó¡A³oÓ°ÝÃD»Ýn»sÃĤƾDZM®a¤~¯à¸Ñµª¡AˬO±q¤@¨Ç²{¦³CNSÃĪ«¤Æ¾Ç¦¡¥hµo²{¡A¦ü¥G¨ã¦³fÀôµ²ºcªºÁÙ¯u¤£¤Ö¡C¬Ý³o½g2017-1¡uPerspectives on the Neurobiology of Antipsychotic Drugs in Psychiatric Disorders¡v¡]www.obm-pc.com/journals/neurobiology/neurobiology-01-01-001¡^ Fig.1¦C¤F²Ä¤@¥Nªº§Üºë¯«¯fÃĪ«¡A´£¨ì²Ä¤@¥NÃĪ«¤À§OÄÝ©ó³o¥|¤jµ²ºc¡CFig.2¦C¤F²Ä¤G¥Nªº§Üºë¯«¯fÃĪ«¡A¤å¤º´£¨ìFig.2Hªºf¥ÒñQÓi(benzamide)¥]§t¤F²Ä¤@¥N¡B²Ä¤G¥N§Üºë¯«¯fÃĪ«¤§¥~¡AÁÙÅn¬A¤F±`¥Îªº¤î¦R¾¯metoclopramide(´N¬Oprimperan)¥H¤Î§Ü»RÁЯgÃÄTiapride¡C ¡u¡KA special case is the benzamides group (Figure 2H), which encompasses not only FGAs (such as sulpiride) and SGAs (such as amisulpride), but also drugs used for other indications (such as the anti-emetic drug, metoclopramide, and the anti-dyskinetic drug, tiapride)¡K¡v Fig.1»PFig.2¤@²´±æ¥h¡A²M¤@¦â³£¦³¯QÀt´ßµ²ºc¡C |
|
|
·|û¡G·Q·Q10140340 µoªí®É¶¡:2017/11/8 ¤W¤È 07:08:58²Ä 194 ½g¦^À³
|
ÂI¥Û¦¨ª÷ ·í±z¦³»{ÃѦ³¦¹»Ýnªº¿ËªB¦n¤Í ±z·|¹ªÀy¥L¶Rxx¾¯¥B¤£ª¾¾¯¶q ÁÙ¬O¥h¬ÝÂå¥Í ®³µÛ³B¤èñ ¨ìÃĩлâÃÄ¡H ¥Í©Rªº»ùȬO¥µ¥ªº ¦Ó¥B¥ô¦ó¯fµhªº¶Ë®`³£¬O¤£¥i©Ù·Àªº ¤ß²z¤Wªº¤]¬O |
|
|
·|û¡Gº©¹CªÌ10144096 µoªí®É¶¡:2017/11/7 ¤U¤È 11:42:38²Ä 193 ½g¦^À³
|
¦Ñ¥v¥S´£¨ìªºAvanir¯u¬O¤Ó¦³½ì¤F èè¬d¤F¤@¤U¡A¤j®a«Ü¼ô±xªº´µ´µ·P«_½¦Ån¤]§t¦³¥k¬ü¨FªâDextromethorphan¦¨¤À³á www.ucpharm.com.tw/product_content_61 ´µ´µ«y¹Â½¦Ån¬°«D³Â¾K©ÊÂí«y¾¯¡AªvÀø¹L±Ó¡B®ðºÞª¢¡B·P«_¤Þ°_¤§«y¹Â¡AÃĮĩúÅã¡C ¡i¦¨¤À¡j ¨C½¦Ån¤¤§t¦³¡G Dextromethorphan HBr............................20mg dl-Methylephedrine HCI............................25mg [²¤] ·Q¨ì¤ß®®¦´Áªº¦Ò¥jÃD¡A¦³¤H½èºÃ¦pªGf¥Ò»Ä¶u¦³®Äªº¸Ü¡A¯f¤H¥h¦Y¨¾»G¾¯´N¦n¤F ¨ºÃø¹DPBAªº¯f¤H¨C¤Ñ¦Y´µ´µ´N·|¦n¶Ü¡H ¡]¦Ó¥B¡A¾¯¶q³£ÁÙ«Ü¥©ªº¬O20mg....^_^¡^ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/7 ¤U¤È 03:57:16²Ä 192 ½g¦^À³
|
ÁÂÁ¦ѥv¤j¤jÁ¿¾ú¥v Åý§Ú̪¾¹DÓ§O¤½¥q¬ãµoªº¨å¬G ³o¦ÑÃIJզX·s¥Îªº¨Ò¤l ¤]¤Ó¤Þ¤H¤J³Ó Y¦³½èºÃ¤ß®®ªºSND-1 ¥¿¦n¥i¸ê°Ñ¦Ò ¥un¦³±M§Q©M¨ä¥L¦UºØ«OÅ@ ´N¤£©È§O¤H¨Ó¬D¾Ô ¤j®a»¡ ¬O¶Ü?! ¤j®aÀ³¸Ó³£«Ü§Æ±æ ¦Ñ¥v¤j¤jÁ¿¬G¨Æ Åý¤j®aªø´¼¼z ©ç©ç¤â¨ÃÁÂÁ¦ѥv¤j¤j ¤]ÁÂÁ¤j®a! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/7 ¤U¤È 03:27:04²Ä 191 ½g¦^À³
|
2014¦~12¤ë¡A¤é¥»¤j¶ï»sÃĶ}»ù35»õ¬üª÷¶R¤UAvanir Pharmaceuticals¡A³o¬O«Ü¦³½ìªºcase¡A¥H¤U±¡¸`¦³»~½Ð±M®a«e½úÌ«üÂI¸É¥R¡C ¤§«e²á¹LAcadia¥u¾a¤@Ó¦å²M¯À5HT-6A¾÷Â઺Pimavanserin¥´³qÃö¡AAvanir«Ü¹³Acadia¡A¬Æ¦Ü¥i¥H»¡¤ñAcadia§ó¦³½ì¡A¦]¬°¥L¾aµÛ¨âÓ«Ü¥j¦ÑªºÃIJզX¦b¤@°_¡A¹B¥Î¦b¦h¶µCNSÁ{§É¤W¡A²Ä¤@Ó¦¨¤À¬O¤¤Q¦~¥N´N¤w¸g¥X²{ªº¤î«y¨}ÃÄ¥k¬ü¨FªâDextromethorphan hydrobromide¡AÅ¥¹L¡u¿Õ¤ñµÎ«y¡v§a¡A¦¨¥÷´N¬O³oÓ¡A²Ä¤GÓ¦¨¥÷¬O´£·Ò¦Ûª÷Âû¯Ç¾ð¥Ö¥Î©ó¤ß«ß¤£¾ãªº«¶¥§¤BQuinidine¡C³o¨âÓ´ê¦b¤@°_ªº¾÷Âà¬O¡Gdextromethorphan is a weak antagonist of NMDA receptors, and an agonist of sigma 1 receptors, quinidine in this combination increases the bioavailability of dextro-methorphan by slowing its oxidative metabolism by the liver enzyme cytochrome P450-2D6 and by inhibiting the blood-brain barrier protein pump P-glycoprotein¡A²³æ»¡¡A¤î«yÃħ@¥Î¦bCNS¡A¤ß«ß¤£¾ãÃÄ¥i´£°ª¥Íª«§Q¥Î«×¡C2004¦~°µ§¹°²©Ê©µÅè®ÄÀ³pseudobulbar affectÁ{§É¡]²ºÙPBA¡A¯f¤HµLªk±±¨î¤jú¤j¯º¡A©Î¸Óúªº®ÉÔ¤j¯º¡A¸Ó¯ºªº®ÉÔ¤jú¡^´£¥XNDA¡AFDA¹ï¦w¥þ©Ê«Ü¦³·N¨£¡A¦^ÂФ½¥qapprovable letter¡A¤]´N¬OÃþ¦ü²{¦bªº¡¨complete response letter¡¨¡CAvanirªá¤F«Ü¦h¥\¤Ò½Õ¾ã¾¯¶q¡A¨Ã¥B¥[°µ¤@Ó¤T´ÁÁ{§É¡A²×©ó¦b2010¦~11¤ëÀò±oapproval¡A¨ú¦W¬°Nuedexta¡C¥«³õ¹w¦ôpeak sales¤T»õ¬üª÷¡A2012¦~¾P°â3700¸U¡A2013¦~¾P°â7500¸U¡A2014¦~¾P°â1.1»õ¡A2015¦~¾P°â1.7»õ¡A2016¦~¾P°â2.18»õ¡A2017¦~H1¾P°â1.2»õ¡C 2011¦~Par Pharmaceuticals & Actavis ·Q¥HANDA¬D¾Ô±M§Q¡A2014¦~District Court»{¬°Avanir±M§Q¦³®Ä¡A2015¦~8¤ë¬ü°êÁp¨¹¨µ°j°Ï¤W¶Dªk°|Court of Appeals for the Federal Circuit½T»{U.S. Patent Nos. 7659282 and 8227484±M§Q¦Ü2026¦~µL»~¡Aconfirms patent protection for NUEDEXTA until 2026 in the United States.¡A¤]´N»¡Nuedextaªº¿W½æÅvexclusivity¥iºû«ù¨ì2026¦~¡C³oÓ±N¤î«y¦ÑÃĥΩó¡u°²©Ê©µÅè®ÄÀ³¡vªº±M§Q§ð¨¾¡AÀ³¸Ó¥i¥HÅý§ë¸ê¤HÁp·Q¨ì°ª¦å®ò¯g¦ÑÃĥΩó¦h¶µºë¯«¯e¯fªº±M§Q¡C¤j¶ï³£´±ªá¤j¿ú³Ü¡u¿Õ¤ñµÎ«y¡v¤F¡A§Ú̹ïf¥Ò»Ä¶u¬O§_¥i¥H§ó¥±`¤ß©O¡H 2014¦~12¤ëªºAvanir°£¤FNuedexta¤w¶}©l°^ÄmÀ禬¥~¡A·í®ÉpipelineÁÙ¦³¤°»ò§l¤Þ¤OÅý¤j¶ï¬Ý¤W²´¡H²¦³ºNuedexta¥Î¦bPBA¥u¬OÓ¤pÃÄ¡C2014¦~9¤ëÈÐpositive results from its phase II clinical trial evaluating the safety and efficacy for the treatment of agitation in patients with Alzheimer¡¦s diseaseÈСA·í¤éªÑ»ù¤jº¦85%¡A¥«È©è¹F30»õ¬üª÷¡A¸ê¥»¥«³õ¹ïªü¯÷®üÀq¬ÛÃö¯e¯f¬Û·í´Á«Ý¡C·í®É¤j¶ï¥¿±Á{Abilify±M§Q¦b2015¦~4¤ë¨ì´Áªº§xÂZ¡A¥²¶·n¦³·sªº²£«~±µ´À¡A©Ò¥H¤î«yÃÄ»P¤ß«ß¤£¾ãÃĪºµ´§®²Õ¦X³Õ±o¤j¶ïªº«C·ý¡C ²{¦bAvanir©xºô¤W»âÀYcompound¥s°µAVP-786¡]Nuedexta/AVP923¤G¥Nª©¡A¥HÉ÷deuterium´î½w¥NÁ¡^¡A¦³¨âÓP3Á{§É¶i¦æÈÐagitation in Alzheimer¡¦s diseaseÈСA³o¬O±µÄò2014¦~¤E¤ëªºP2¡C觹¦¨ºë¯«¤Àµõ2b¡A¦ýÁÙ¨S¬Ý¨ì¼Æ¾Ú¡APrimary Outcome¬Ot¦V¯gª¬µû¦ô16-Item Negative Symptom Assessment total score¡A¸ò«¥Ì¬Owhole syndromeªºBTD¦³®t²§¡C¥t¥~¡AAVP-825¬O±N°¾ÀYµhªº¾Ç¦WÃħאּ»ó¼Q¾¯«¬¦Ó¤w¡A²{¦b°¾ÀYµhªº¾Ô³õ¦bCGRP¡A¦³®a°µ±j¢¯g¡Bº¥á¤HÁ{§ÉªºCNS¤½¥q´N¦³¸ó¨¬CGRP»â°ì ¬Ý¾»{¬°«¥Ì¸òAvanir Pharmaceuticals¤ñ°_¨Ó¦p¦ó©O¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/7 ¤U¤È 01:31:07²Ä 190 ½g¦^À³
|
£¤£´ £¤£¹¨ì©³¬OÆg¬üµü ÁÙ¬O½|¤H¸Ü ¯u¯]»P¯u½Þ ¤pªºÁÙ¬O¶Ì¶Ì¦a¤À¤£²M§r? ·Q·Q¤j SND-12 ¬O ClozaBen |
|
|
·|û¡G·Q·Q10140340 µoªí®É¶¡:2017/11/7 ¤U¤È 01:16:54²Ä 189 ½g¦^À³
|
²q·Q¤j : ½Ð¸û¤@¤U...±K½X¤£´N¬ONaBen..«ç»ò¤@ª½µn³°¤£¶i¥h? >_< |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/7 ¤W¤È 08:07:43²Ä 188 ½g¦^À³
|
ÁÂÁ ¦Ñ¥v¤j¤j ¤ñ¸û¤ÀªR¦U®aªºÄvª§Àu¦H¡A¼W¥[§Ṳ́F¸ÑCNSÃĪ«»â°ìªº¥@¬É¤j¶Õ¡C ¦P®É¤]ÁÂÁ liaw6575 ¤j¤j ´N¨â®a¥«½Õ¤½¥q©Ò´£¥Xªº¤¤j¥«³õ¥¼º¡¨¬»Ý¨D »¡©ú¤ß®® SND¨t¦Cªº²£«~Àu¶Õ¡A¨Ã¤ÀªR¥æ©ö¥«³õªºª^³ò ¸Ô½Ð°Ñ http://liawbf.pixnet.net/blog/post/47623668-%E6%82%A8%E6%9C%89%E5%88%B0%E5%B8%82%E5%A0%B4%E6%AE%BA%E5%83%B9%E8%B2%B7%E9%81%8E%E6%9D%B1%E8%A5%BF%E5%97%8E%3F ¤p§Ì¤]ı±o¥æ©ö¥«³õ¯à°÷Åý³o¨ÇD ¶¤¤Í¤©¨ú¤©¨D ®Ú·½©Î¦b¥«³õ¹ï¤ß®®»ùȪº¤£¤F¸Ñ¡A¾ÉP¤í¯Ê¶R½Lªºµ²ªG ©Ò¥H¡A¤pªº¦b¦¹¹ï ¦Ñ¥v¤j¤j liaw6575 ¤j¤j ³£¬°´£¤É¥«³õ¹ï¤ß®®»{ÃѪº¨¯W¥I¥X¤Î§V¤O¡AP³Ì°ª·q·N ÁÂÁ¨â¦ì¡I ÁÂÁ¤j®a¡I |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/7 ¤W¤È 01:58:56²Ä 187 ½g¦^À³
|
¦A¬Ý¤@®a¤½¥q¡AOvid TherapeuticsÁöµMÄݩ󯫸g¬ì¡A¦ý¨«ªº¬OGABA¾÷Âà¡A²{¦b¤Wº¦9.8%¡A¥«È2.3»õ¬üª÷¡A2.3»õ¬üª÷ªºpipelineÀ³¸Óªø¤°»ò¼Ë¡H»âÀYªºOV-101¬O¤fªAªº£_-selective GABAA agonist¡A¶i®i³Ì§Öªº¬O¦¨¤H¤Ñ¨Ï¯gÔ¸sAngelman syndrome¡A¥Ø«e¦b¤G´Á¡A«C¤Ö¦~ªºAngelman syndrome¦b¤@´Á¡A«C¤Ö¦~ªºFragile X syndrome¤]¦b¤@´Á¡C¤Ñ¨Ï¯gÔ¸s¬O¨u¨£ªº¿ò¶Ç¯e¯f¡Aµo¥Í²v¤j¬ù2¸U¤H¤¤¦³¤@Ó¡AFragile X syndrome¤j·§¨C5000¤H¦³¤@¤H¡A¦]¦¹Ovid¦b³o¨âÓ¯e¯f§¡Àò±oorphan drug designation¡COvid©MªZ¥Ð¦³Ó¦X§@TAK-935/OV935¡A¥Î¦b¨u¨£Åöíwepileptic encephalopathies¡Aè¶}©l1b/2aÁ{§É 2.3»õ¬üª÷¦bCNS¤½¥q¬O¨u¨£¯e¯f¦Ó¥B¶È³B©ó¦´ÁÁ{§É |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/7 ¤W¤È 01:16:07²Ä 186 ½g¦^À³
|
¤µ¤ÑMinerva Neurosciences¤½¥¬©u³ø¡AQ3²b·l1130¸U¬üª÷¤ñ¹w´Á¦h¡A½L¤¤ªÑ»ù¤U¶^5%¡A³o¬O¤@®a¥«È2.5»õ¬üª÷ªº¤p¤½¥q¡A¥¿¦]¬°»ùÈ2.5»õ¬üª÷¡A©Ò¥Hȱo®³¥X¨Ó¬Ý¬Ýþ¸Ì¤ñ§Ú̱j¡C »âÀYªºMIN-101¬O5HT-2A antagonist¡BSigma2 antagonist¡A¥Î¦bºë¯«¤Àµõ¡A¡u12¶g¡vPhase 2bªºµ²ªG¦b2016¦~¤¤ë¤½§G¡A32mg²Õ¦bPANSS total score¡Bpositive score¡Bnegative score»P¦w¼¢¾¯²Õ¬Û¤ñªºES¤À§O¬O0.34¡B0.16¡B0.54¡APȤÀ§O¬O0.082¡B0.402¡B0.006¡A64mg²Õ¦bPANSS total score¡Bpositive score¡Bnegative score»P¦w¼¢¾¯²Õ¬Û¤ñªºES¤À§O¬O0.57¡B0.2¡B0.7¡APȤÀ§O¬O0.003¡B0.307¡B¤p©ó0.001¡A¨â²Õ§¡¦³¹F¨ì§ïµ½t¦V¯gª¬ªºprimary endpoint¡A¦ý¦b¥¿¦V¯gª¬ªº¤À¼Æ«o¬O¼W¥[ªº(¦ý¼W¥[´T«×¤ñ¦w¼¢¾¯²Õ¤Ö)¡A¤]´N¬O»¡MIN-101¹ï¥¿¦V¯gª¬¤£ºÞ¥Î¡C¦³¿³½ìªºªB¤Í¥i¥H½Õ¥XSND13ªº¡u6¶g¼Æ¾Ú¡v¡A´N¯à²z¸Ñ¬°¦ó±Ð±Âì¥ý¥u¥Ó½Ðt¦V¯gª¬ªºBTD¡Aµ²ªGFDA°eµ¹±Ð±Âwhole syndromeªº¤j§¡CMIN-101¬OMinerva¦b2007¦~8¤ë¦V¤é¥»¤TµÙ¥ÐÃä»sÃıÂÅv¤Þ¶iªº¡A¼Ú¬ücomposition of matterªº±M§Q«OÅ@±N¦b2021¦~¨ì´Á¡K¡K MIN-117¤]¬O±q¤é¥»¤TµÙ¥ÐÃä±ÂÅv¶i¨Óªº¡A¦å²M¯À»P¦h¤ÚÓi¾÷Âà¡A¥Î©ó««×¼~Æ{¯g¡A2018¦~·|¶i¤J2bÁ{§É¡A2016¦~¤¤ë2a¼Æ¾Ú¡G0.5mg²Õ¦bMADRS¸ò¦w¼¢¾¯²Õ¬Û¤ñªºES¬O0.23¡A2.5mg²ÕªºES¬O0.33¡A¤½¥q»¡MIN-117ªºES¬Ý°_¨Ó»P¥«°â§ÜÆ{¾¯Ãþ¦ü¡¨This magnitude of effect size is similar to those observed with currently marketed antidepressants.¡¨ ¡C«¥ÌSNG12¬Oª½±µ©M§ÜÆ{¾¯citalopram¤ñ¸û¡AES¬O0.95¡A°ª¤U¥ß§P¡CMIN-202¬O©MJ&J¦@¦P¦X§@ªº¡A§Ú¨S§ä¨ì1bªºMDD¼Æ¾Ú¡A²Ä¤@Ó2b¤w¸g¦¬¶i²Ä¤@Ó¯f¤H¡AÁÙ¦³¨âÓ2b trials¹wp¥»©u¶}©l¡C Minerva¤ñ«¥Ì¦h¤@Ó¥¢¯vªºÁ{§É¡A¦ý§ÚÌ«h¦h¤@Óªü¯÷®üÀqªºÁ{§É¡AþÓ¤ñ¸ûÈ¿ú¡H¦³¤@®a±Mªù«õ±¸¹Ó¸O©M¦Z¤g¸Oªº¡A¥«ÈÁÙ¦³6»õ¬üª÷¡AÁÙ¦³¤@®a¥u¦b¥¢´¼¤G´Áªº¡A¥Ø«e¤]¬O6»õ¬üª÷¡C Minerva¤ñ«¥Ì°ª©ú¡H§Ú·Q¥LÌÀ³¸Ó¦³ÓªZ¾¹¨S©ñ¤Wpipeline¡A¨º´N¬Oanti-hog cholera vaccine |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/4 ¤U¤È 08:33:35²Ä 185 ½g¦^À³
|
¨C·í®®Åª¦Ñ¥v¤j¤jªº¤j¤å , Á`¬O¾l¨ý²`»· ´N¦b¦Ñ¥v¤j¤j¶K¤W«e¤åªº«e«á , ªZ¥Ð§âTAK-831±À¦VP2 , ¦ý¾AÀ³¯g«o¬OFriedreich ataxia (FRDA) https://clinicaltrials.gov/ct2/results?cond=&term=TAK-831&cntry1=&state1=&recrs= "Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia Study Start : November 3, 2017 " ¤p§Ì·Q , ¬JµMTAK-831¬ODAAOi , ¬°¦ó¨S¥ý°µ«äı¥¢½Õµ¥¯«¸g¯e¯f? ¦Ó¬O¥ý¶i¦æFriedreich ataxia (FRDA) ¬O¤£¬O¥¦§¹¦¨¤F" Study to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration " ª¾¹DTAK-831 ³q¹LBBBªº®Ä²v¤£¨Î©Ò¾ÉP? ¦]¬°Friedreich ataxia (FRDA)ªº¯f²z "¯f²z¾Çªº¥Dn³¡¦ì¬O¯áÅè©M©P³ò¯«¸g¡CI®Ú¯«¸g¸`¡A¯áÅè¤p¸£§ô¡A¥~°¼¥Ö½è¯áÅè§ô©M«á¬Wªºµw¤Æ©MÅÜ©Ê" ©Ò¥H¦ü¥G²Å¦X³oºØ²q´ú ? ¤p§Ì²`ı¹³ªZ¥Ð³oºØ¦³°ò¦ªºÃļt , ¤£¥i¯à¦bÁ{§É«e¥u°µFRDAªº¸ÕÅç ,¦Ó¬O¦b½Ñ¦h¹êÅ礤§ä´M¥i¯àªº¤è¦V ¦ý¥Ø«e¥u§ä¨ì ªZ¥Ð©ó2017 ¤E¤ë¦b"°ê»Úataxia¬ã¨s·|ij"µoªíªº 187. DAO inhibitor preclinical therapeutic studies for FRDA ( P. 133 ) http://www.fagofar.org/wp-content/uploads/2017/10/IARC2017-ABSTRACT-AF1.pdf "The outcomes of this study encourage the continued study of TAK-831 as a potential therapy for FRDA." ¨ì©³¬OTAK-831¹L¤£¤FBBB ? ©Î¬O¸ÕÅ礴¦b¶i¦æ¤¤ , ³ø§i©|«Ýµoªí ? ¥BÅý§ÚÌÀRÆ[¨äÅÜ ¶È¨Ñ°Ñ¦Ò , ¨Ã½Ð¤j®a«ü¥¿¸É¥R ÁÂÁ¤j®a! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/4 ¤U¤È 03:07:57²Ä 184 ½g¦^À³
|
¬Q¤ÑSage¤½¥¬°]³ø¡AQ3²b·l7372¸U¬üª÷¡A§é¦X¨CªÑÁ«·l1.97¤¸¡A¸û¥h¦~¦P´ÁÁ«·l3780¸U¤j´T¼W¥[95%¡A²Öp«e¤T©u²b·l2.007»õ¬üª÷¡A¨CªÑÁ«·l5.37¤¸¡A¸û¥h¦~¦P´ÁÁ«·l1.03»õ¥ç¬Oªñ¥G¿¼W¡AµM¬Q¤éªÑ»ù¤Wº¦10.4%¡A¥«È25.9»õ¬üª÷¡A¦ü¥G¤wº¥Â\²æ¤E¤ëSRSE¤T´Á¨ü®Àªº§QªÅ¡C§Ú·Qì¦]¤£¥~¥GSage¦P¨B§ó·s¦h¶µÁ{§É¶i«×¡A³Ì¨üÆf¥Ø¥B¦³BTD¥[¨ªº²£«á¼~Æ{¯g觹¦¨¦¬®×¡]¤À¬°HAM-D>26ªº««×PPD»P20~25¤Àªº¤¤«×PPD¡^¡A¹wp¥»©u·|¤½¥¬µ²ªG¡AÀ°¤j®a½Æ²ß¤@¤U¡ABrexanolone ¡A¤]´N¬OSage-547¡A¬OÀR¯ßª`®g60¤p®É«á¶i¦æµû¦ô¡C¦¹¥~¤fªA«¬ªºSage-217¤]¤w§¹¦¨««×¼~Æ{MDDªº¤G´Á¦¬®×¡A¹wp¥»©u·|¤½¥¬µ²ªG¡CSage-217¹ï©ó©¬ª÷´Ë¤ó¯f¤]¨ã¦³§ïµ½Å¸§Ý¯gª¬¤§¥\®Ä¡A³o¬Oopen-label Phase 2 study¡Aas assessed by the MDS-UPDRS - Part II/III tremor score¡A±qbaseline 19.1¤À¥§¡¤U°7.7¤À¡CSage-217¥Î©óìµo©ÊŸ§Ý¤]¦³¤½¥¬³¡¤À¼Æ¾Ú¡C¥O§Úª`·NªºÁÙ¦³ì¥»©ñ¦bPre-clinicalªºSage-718¤w¸g¥¿¦¡¶i¤J¤@´ÁÁ{§É¡ASage-718¬ONMDA¾÷Âàpositive allosteric modulator of the NMDA receptor¡A觹¦¨single-ascending dose study ¡A¹wp©ú¦~¤U¥b¦~·|§¹¦¨multiple ascending dose trial¡C ¤µ¦~«e¤T©u¿N¤F2»õ¬üª÷¡A¦ý¤]ºÝ¥X¤£¤Ö¦¨ªG¡A¥B±b¤WÁÙ¦³2.43»õ¬üª÷¥iªá¥Î¡A©Î³\¤j®a·|«Ü¦n©_þ¨Ó³o»ò¦h¿ú¡H«Ü²³æ¡A¬ü°ê¸ê¥»¥«³õ¬O·sÃĶ}µo·~ªÌªº±j¤O«á¬Þ¡A2014¦~7¤ëSage¦bIPO¶Ò¨ì9000¸U¬üª÷¡A2015¦~4¤ë²{¼W1.38»õ¬üª÷¡A2016¦~1¤ë²{¼W1.5»õ¬üª÷¡A9¤ë¦A²{¼W1.75»õ¬üª÷¡Aµuµu¨â¦~¦h±q¸ê¥»¥«³õÀò±o5.53»õ¬üª÷ªºª÷´©¡A´«°µ¬O¥xÆW¿ì±o¨ì¶Ü¡H¯S§O¬O¤E¤ëSage¤~¦bSRSE±Ñ°}¡A´«¦b¥xÆWªÖ©w³Q¯¥ÅF¨ìÅéµL§¹½§¡C¦³¦nªºcompound¬O¤£°÷ªº¡AÁÙ¥²¶·¦³±j¤j°·¥þªº¸ê¥»¥«³õ¡A¦³¤ßºA¦¨¼ôªº§ë¸ê¤H»Pªk¤H¡]´«¥y¸Ü»¡¡A½Þ¶¤¤Í¬O«Ü¥i©Èªº¡^¡A¤~·|¦³½´«kµo®iªº·sÃIJ£·~ ¶¶¹D¤@´£¡ANMDA¾÷Âà°£¤FSage-718¥~¡A¥Ø«e§Ú¬d¨ìªºÁÙ¦³ªZ¥Ð»sÃĪºTAK-831¡A©M§Ṳ́@¼Ë¬ODAAOi¾÷Âà¡A¤£¹LÁÙ°±¯d¦bP1¡F½÷·çPF-04958242ªº¾÷Âà¬OPositive allosteric modulator of AMPAR¡BGlyT-1 inhibitor¡A¥h¦~P2¦¬¤F35¦ì¯f¤H«á¦Û¦æ¥s°±¡A»¡ªk¬O¡¨following an internal portfolio prioritization. It is not due to any safety concern or change in benefit:risk assessment¡¨¡A§Ú̬O¨«¦b«Ü«e±ªº |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/3 ¤U¤È 05:12:03²Ä 183 ½g¦^À³
|
¬Q¤ÑNeurocrine(NBIX)¤½¥¬©u³ø¡A³o¬OªvÀøTDÃĪ«Ingrezza¤W¥««á²Ä¤@Ó§¹¾ã¾P°â©u«×¡Aµ²ªGú¥X4600¸U¬üª÷ªº«G²´¼Æ¦r¡A»·¶W¹L¥«³õ¹w¦ôªº1100~1700¸U¬üª÷¡AÁöµM³oӼƦr¸òNeurocrine±Ä¥Îsell-inªº»{¦C¤è¦¡¦³Ãö(«ü½æ¨ì³q¸ô°Ó´N»{¦CÀ禬)¡A¦ý¤´Àò±o¥«³õªÖ©w¡AªÑ»ù¤jº¦19%³Ð·s°ª¡A¥«È¹F64»õ¬üª÷¡C®i±æ¥¼¨Ó´XÓ©u«×¡AÀ禬¦¨ªø¸}¨B¥i¯à·|¦³¨Ç¤£Ã©w¡A°£¦]sell-in»{¦C¤è¦¡¥~¡A¥i¯àÁÙ·|±Á{¨ìTeva¦b8/30®Öã¤W¥«ªºAustedoªºÄvª§¡AAustedo¬OTeva¶}»ù35»õ¬üª÷¶R¤UAuspex¨ú±oªº¡A·í®ÉAuspexªºTDÁ{§É觹¦¨¤T´Á¦¬®×¡AÂ÷¹w¦ô¸Ñª¼®É¶¡ÁÙn¤TÓ¤ë¡C§Úªº·P·Q·íµM¬O§Æ±æ«¥ÌªºÃĪ«¯à¦¨¥\¤W¥«¡A´N¦³¥i¯àºCºC´î¤Ö¤@¥NÃĪ«»P¤G¥NÃĪ«ªº¾¯¶q¡ATD³oÓ´o¤Hªº°Æ§@¥Î´N·|¶V¨Ó¶V¤Ö¡Cnª¾¹D¡AAbilify¤@¦~¯à¯}¤Ñ¯î½æ¨ì9ÓBillion¡A¨Ã«DÃĮĦ³¹L¤H¤§³B¡A¦Ó¬O°Æ§@¥Î¬Û¹ï¤Ö«Ü¦h¡Aºë¯«¤Àµõ¯f¤H¥»¨Ó´N·|ªø´Á±Á{t¦V¯gª¬ªº§xÂZ¡A¤@¥¹°Æ§@¥Î¥[¼@¡At¦V¯gª¬´N·|§óÄY«¡A¦]¦Ó§óÃø¦^´_¥¿±`¥Í¬¡ |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2017/11/1 ¤U¤È 01:49:19²Ä 182 ½g¦^À³
|
²q¤j~ ³Ìªñ®a¸Ì¨Æ±¡¤ñ¸û¦h ©Ò¥H¨S¤Ó¦h®É¶¡±M¬ã ·|¦A§ä®É¶¡¬Ý ÁÂÁÂ. ¤£¹L¤µ¤Ñ¥Í§Þ½æÀ£¨I« ¯uªº¬OµL¨¥... |
|
|
·|û¡G¤p¨k10143294 µoªí®É¶¡:2017/10/30 ¤U¤È 10:20:28²Ä 181 ½g¦^À³
|
ÁöµM¤£ª¾¹D¤°»ò¨Æ¡A¦ý§Æ±æ¤j¨Æ¤Æ¤p¡A¤p¨Æ¤ÆµL ²q·Q¤j¡AÄ@¥D¦uÅ@±z |
|
|
·|û¡Gseniorbbs10144999 µoªí®É¶¡:2017/10/30 ¤U¤È 07:50:18²Ä 180 ½g¦^À³
|
¬Ý¨Ó¨Æ±¡ÆZºò«æªº¡C¡C¡C¡C¡C¡C¡C ÁöµM¤£ª¾¹Dµo¥Í¤F¤°»ò¨Æ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/29 ¤W¤È 09:22:14²Ä 179 ½g¦^À³
|
½²±Ð±Â¹Î¶¤¥ÎSEMªº¬ã¨sµ²½× ºë¯«¤Àµõ¯gªºªvÀø¡Aº«§ïµ½t©Ê¯gª¬»P»{ª¾¥\¯à ¦ÓSND-1¨t¦C§ó¬OªvÀø¦¹ºØ¥¼³Qº¡¨¬»â°ìªº¹êÅ礤·sÃÄ liaw6575¤j¤j·s¥X¥Zªº±M¤å¡A´N¬O¹ï¦¹©Ò°µªº»¡©ú©M½×z http://liawbf.pixnet.net/blog/post/47604381-%E7%82%BA%E4%BD%95%E9%A6%96%E9%87%8D%E6%94%B9%E5%96%84%E8%B2%A0%E6%80%A7%E7%97%87%E7%8B%80-%E7%B5%90%E6%A7%8B%E6%96%B9%E7%A8%8B%E6%A8%A1%E5%BC%8F%E4%BE%86%E4%BA%86 ¦³¿³½ìªº®®¤Í¡A½Ð«e©¹®®Åª°Ñ¦Ò ¬Ý¤F³o»ò¦h±M¤å¡A±zªº«H¤ß«×¼W¦h¤F¶Ü¡H¡I ÁÂÁÂliaw6575¤j¤j¡I ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/28 ¤U¤È 03:18:23²Ä 178 ½g¦^À³
|
ºë¯«¤Àµõ¯gNMDA¯f²z»PªvÀøªº¤åÄm¦^ÅU¥v ¤p§Ì·P¨ØÆg¹Äliaw6575¤j¤jªá¤ß«ä§äÃD§÷®ø¤Æ¸ê®Æ¡A¦A¥Î©öÀ´ªº¤å¥yµL¨p¦a¤À¨É®®¤ÍÌ ®®¤Í̦³ ¦Ñ¥v¤j¤j liaw6575¤j¤j ªºª¾ÃÑ«ü¾É©M«H¤ß´£携 ¯u¬O¦A©¯ºÖ¤£¹L¤F ¤p§Ì¦b¦¹¦A¤@¦¸¦a¦V¨â¦ìP³Ì²`ªº·q·N ÁÂÁ±zÌ¡I ÁÂÁ¤j®a¡I ³Ì«á¦V³\¤j¤j»¡¡A³o½g±z¬Ý¤F¨S¡H¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/26 ¤U¤È 01:41:37²Ä 177 ½g¦^À³
|
³\¤j¤j ÁÂÁ±z! ©Î³\±z¥i¨ìliaw6575¤j¤jªºblog ¥J²Ó«ä¦Òliaw6575¤j¤j¨C½g¤å³¹©Òªí¹Fªº·N²[ ¬Û«H±z´Nª¾¹D¤p§Ìn»¡¬Æ»ò¤F ¨CÓ¤Hªºª¬ªp¤£¦P ©Î³\¦³¤£¦Pªº¨Mµ¦ ´N¦p¦P½²±Ð±Â©Ò¨¥ ¥Á¥D®É¥N¦U¦Ût³d§r ¤p§Ì¹ê¦b©êºp ¦R¤£¥X¶H¤ú¨Ó ÁÙ½Ðì½Ì ÁÂÁ±z! ¤]ÁÂÁ¤j®a! |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2017/10/26 ¤U¤È 12:49:49²Ä 176 ½g¦^À³
|
²q¤j~ ¨¯W¤F! ¤p§Ì¥i§_°½Ãiª½±µ½Ð±Ð²q¤j¬Ýªk ÁÂÁÂ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/25 ¤U¤È 06:51:40²Ä 175 ½g¦^À³
|
G ºô¤µ¤é¦³Ãö ªü¯÷®üÀq¯g ªº®É¨ÆÂIµû¤å³¹ << ªü¯÷®üÀq¯g>>«e³~µL¶q! Biogen... http://www.genetinfo.com/investment/featured/item/12154.html << ªü¯÷®üÀq¯g>>... AbbVie ... http://www.genetinfo.com/investment/featured/item/12168.html |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/25 ¤U¤È 06:35:12²Ä 174 ½g¦^À³
|
¤ß®®¤S¦b¼x¤~ ½Ð¸Ô°Ñ liaw6575¤j¤jªº±M¤å http://liawbf.pixnet.net/blog/post/47601084 ¦P¼Ë¨Ó¦Û liaw6575¤j¤jªº±M¤å http://liawbf.pixnet.net/blog/post/47601138-adis-insight%EF%BC%8Clet-there-be-light. Springer¶°¹Îªº¸ê®Æ®w¦³¤ß®®Á{§ÉÃĪ«¸ê®Æ http://adisinsight.springer.com/drugs/800041499 liaw6575¤j¤jµûz ³o¤Ï¬MSND-1³vº¥¦b¥þ²y¥«³õÃn¥ú |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/24 ¤U¤È 09:40:14²Ä 173 ½g¦^À³
|
liaw6575¤j¤j³o»ò¥Î¤ß¼gªº±M¤å ¡u NMDAR¼W®Ä¾¯ªvÀøºë¯«¤Àµõ¯gªº«á³]¤ÀªR¡]meta-analysis¡^¡v http://liawbf.pixnet.net/blog/post/47597388-nmdar%E5%A2%9E%E6%95%88%E5%8A%91%E6%B2%BB%E7%99%82%E7%B2%BE%E7%A5%9E%E5%88%86%E8%A3%82%E7%97%87%E7%9A%84%E5%BE%8C%E8%A8%AD%E5%88%86%E6%9E%90 ¤º®ez¤Î½²±Ð±Â©M°ª¶¯ªø©°Âå°|ªL³Õ¤h©ó2010¦~¼¶¼gªº«á³]¤ÀªR ¨Ã¦³liaw6575¤j¤jªº¤ß±o©Mµ²»y ¦³½Ð®®¤ÍÌ«e©¹®®Åª ÁÂÁÂliaw6575¤j¤j ÁÂÁ¤j®a¡I |
|
|
·|û¡G¤p¨k10143294 µoªí®É¶¡:2017/10/23 ¤U¤È 05:16:35²Ä 172 ½g¦^À³
|
¯uªº«Ü·PÁ liaw6575 ¤j¤j¡B¦Ñ¥v¤j¤j¡B¤Î²q·Q¤j¤j¡B¦b³o¥Í§ÞªÑ§C°gªº®ÉÔ¡BŪ¦U¦ì¤j¤jªº¤å³¹¡B¤ß¸ÌµÛ¹ê¦w©w«Ü¦h¡B¤]¹ï¤ß®®³oÀɪѲ¼§ó¥[¥Rº¡«H¤ß¡B¤]§ó¯à©ú¥Õ½²±Ð±ÂªºW¤ß¡B·P®¦¤£ºÉ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/22 ¤W¤È 06:56:20²Ä 171 ½g¦^À³
|
·PÁÂliaw6575¤j¤j ¨¯W¦aÄ묹°²´Á¡A¾ã²z²Î¦X¤åÄm¡AÁý¾i®®¤Íª¾ÃÑ¡B«H¤ß ³o¤@Ó·s½g³¹¬OÁ¿zSND-12ªºÁ{§É³ø§i ¬OClozaben»PClozapineÀø®Äªº¤ñ¸û µ²ªG½Ð°Ñ http://liawbf.pixnet.net/blog/post/47594838-snd-12%EF%BC%8C%E6%9B%B4%E5%A0%85%E5%AF%A6%E7%9A%84%E6%8C%91%E6%88%B0daoa ¦ýliaw6575¤j¤j¤]´£¤Î¡A³o½gì¤å³ø§i¦ü¥G¬O®ü³øª©¡A²¤¬°ºë² Y¦³®®¤Íª¾¥þ¤åª©¥»¡A¤]½Ð¤£§[¤À¨É SND-12, SND-13, SND-14, SNG-12, SNA-1 Ån¬A¦¨¦~«äı¥¢½Õ¯g¡BÃøªv«¬«äı¥¢½Õ¯g¡B¥¢´¼¯g¡B«Æ{¯g¡BÃøªv«¬¼~Æ{¯gµ¥ºë¯«¯e¯f ªºªvÀøª©¹Ï ÁÂÁ½²±Ð±Â¬°¯f¤Íªº§V¤O ¤]·PÁÂliaw6575¤j¤j¡A±z¨¯W¤F¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/21 ¤W¤È 08:56:02²Ä 170 ½g¦^À³
|
·PÁ liaw6575 ¤j¤j ¤Sµoªí¤j§@ http://liawbf.pixnet.net/blog/post/47593383-%E9%A1%9E%E4%BC%BCsna-1%E4%B9%8B%E4%BB%96%E5%B1%B1%E4%B9%8B%E7%9F%B3%EF%BC%8C%E5%8F%AF%E4%BB%A5%E6%94%BB%E9%8C%AF ³o¦¸¤À¨É§Ú̪º¬O SNA-1 ( D-cycloserine )¹ïÃøªv«¬¼~Æ{¯gªºÁ{§É³ø§i ³o¬O¥Ñ¥H¦â¦C¾ÇªÌ©Ò¬ã¨s ¬Oº~±Ú¥H¥~ªººØ±ÚªºÁ{§É®ÄªG °£¤F¹ï¹êÅç®ÄªGªº´yz¥~ liaw6575 ¤j¤j ¦P®É¤]¾ã¦X¨ä¥L¤åÄm ¨Ã±´°Q¥ÌÓi»Ä¿@«×¹ïSNA-1Àø®Äªº¼vÅT ºëªöµ´Û ¬O®®¤Í̦A«×¼W¥[«H¤ßªº¦n¾÷·| SND-13 SND-14 SNG-12 SNA-1 ªº¤HÅéÀø®Ä³ø§i ³£»ô¥þ¤F ÁöµM¼Ë¥»¼Æ¸û¤Ö ¦ý©Î¤]¥i±q¤¤±À±o¤@¤G ½²±Ð±Â±M·~ªº§PÂ_¥\¤O¤F ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! §óÁÂÁÂliaw6575 ¤j¤jªº¤À¨É ¨¯W±z¤F! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/18 ¤W¤È 08:47:24²Ä 169 ½g¦^À³
|
·PÁ liaw6575 ¤j ¹ï®ÄªG¶q ( effect size )ªº¸ÑÄÀ¤Î±Ð¾Ç http://liawbf.pixnet.net/blog/post/47586387-%E6%B0%A3%E6%B0%9B%E4%BD%8E%E8%BF%B7%EF%BC%8C%E6%9C%80%E5%AE%9C%E6%B2%89%E6%BD%9B%E5%9C%A8%E6%B7%B5-%E8%AB%96%E6%95%88%E6%9E%9C%E9%87%8F%E4%B9%8B%E8%A7%A3%E9%87%8B ÁÂÁÂliaw6575¤j ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/14 ¤U¤È 10:58:21²Ä 168 ½g¦^À³
|
·PÁ liaw6575¤j ªá¤j¶q®É¶¡ ¬°§Ú̾ã²z¨ÃµûªR SND-13 «e´ÁÁ{§É¸ÕÅç±M¤å " SND-13 , ¹³ª±13¤ä " http://liawbf.pixnet.net/blog/post/47579859-snd-13%EF%BC%8C%E5%83%8F%E7%8E%A913%E6%94%AF%EF%BC%8C%E6%89%8B%E6%8B%BF%E4%B8%80%E6%A2%9D%E9%BE%8D%EF%BC%8C%E9%9B%A3%E6%80%AAfda%E8%A6%81%E7%B5%A6btd ¶Wºë±m ½Ð®®¤Í°O±o¬Ý ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/11 ¤W¤È 08:33:31²Ä 167 ½g¦^À³
|
½Ð¤j®a¤@°_¨Ó²²¤»{ÃÑ ¤HÃþ¤j¸£ºc³y©M¥\¯à http://oneyearenglish.com/2012/04/17/%E4%BA%BA%E9%A1%9E%E5%A4%A7%E8%85%A6%E6%A7%8B%E9%80%A0%E5%92%8C%E5%8A%9F%E8%83%BD/ ¤j¸£¥Ö½è https://zh.wikipedia.org/wiki/%E5%A4%A7%E8%84%91%E7%9A%AE%E8%B4%A8 Brodmann areas https://zh.wikipedia.org/wiki/%E5%B8%83%E7%BD%97%E5%BE%B7%E6%9B%BC%E5%88%86%E5%8C%BA%E7%B3%BB%E7%BB%9F D-serine distribution within the human neocortex. Fig.3 http://pubmedcentralcanada.ca/pmcc/articles/PMC5470653/figure/fig3-1759091417713905/ (a¡Ve) D-serine content in the gray matter of cerebral neocortex was determined using 2D-HPLC. (a) Average of D-serine content was converted into a grayscale heat map and is shown on brain cartoon numbered with Brodmann areas (n = 5). D-serine level in the white area without numbers was not determined. Numbers with # indicate individuals. (b) Individual levels of D-serine are plotted with average ¡Ó SEM for each Brodmann area. ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/10 ¤U¤È 04:03:47²Ä 166 ½g¦^À³
|
·PÁÂliaw6575¤j ¤£Ã㨯³Ò ¤À¨É§Ṳ́߮®²£«~ªº¸ÕÅç³ø§i SNG-12 http://liawbf.pixnet.net/blog/post/47559201 ½w¸Ñ²v (½w¸Ñ¼Ð·Ç : HAMD-17 ¤p©óµ¥©ó 7 ) sarcosine²Õ vs. citalopram²Õ => 65 % : 5% SND-14 http://liawbf.pixnet.net/blog/post/47570421 ¾ãÅé¦Ó¨¥ , SND-14ªvÀø®ÄªG±q16¶g°_´N¥X²{©úÅã®t²§ , «ùÄòéw¨ì24¶gÀòµ²§ô¶g D-Serine ¦b¤j¸£ªº¤À¥¬ª¬ªp ¤é¥»¾ÇªÌ¦³³Ì·sªº¬ã¨s Heterogeneity of D-Serine Distribution in the Human Central Nervous System http://pubmedcentralcanada.ca/pmcc/articles/PMC5470653/ D-serine is an endogenous ligand for N-methyl-D-aspartate glutamate receptors. Accumulating evidence including genetic associations of D-serine metabolism with neurological or psychiatric diseases suggest that D-serine is crucial in human neurophysiology. D-Serine is Concentrated in the Human Cerebrum Heterogeneity of D-Serine Within Cerebral Neocortex is Associated With Brodmann and Functional Areas Expressional Difference of SR Does Not Affect D-Serine Level in the Neocortex Given that D-serine is a dominant ligand at glycine-site of synaptic NMDAR in human CNS, modulation of D-serine level in human CNS could be associated with NMDAR activity and regarded as a therapeutic target based on growing evidence of D-serine involvement in CNS diseases, such as stroke (Mustafa et al., 2010; Abe et al., 2014), epilepsy (Harai et al., 2012; Klatte et al., 2013), Alzheimer¡¦s disease (Hashimoto et al., 2004; Wu et al., 2004; Inoue et al., 2008), amyotrophic lateral sclerosis (Sasabe et al., 2007; Mitchell et al., 2010; Sasabe et al., 2012; Martinez et al., 2016), and schizophrenia (Balu et al., 2013; Balu and Coyle, 2015; Cho et al., 2016; Coyle et al., 2016)Although it is controversial if D-serine binding sites are saturated in the mammalian CNS, a number of studies suggest that the sites are not always saturated due to responsiveness by exogenous D-serine (Salt, 1989; Wood et al., 1989; Thiels et al., 1992; Tsai et al., 1998). Together with the fact that neocortical D-serine level is generally much lower in humans than in rodents, the heterogeneity of D-serine distribution in the human cerebral neocortex may influence physiological activity of NMDAR in the local areas. ½Ð¤j®a°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G«i©¹ª½«e10141841 µoªí®É¶¡:2017/10/9 ¤U¤È 10:49:18²Ä 165 ½g¦^À³
|
¦pªGSND5ÁÙ¯à¦bAdas-cog ±o¨ìÃÒ¾Ú, ¬Û«H±M©Þ¹Ó¸O©M¦Z¤g¸OªºBiogen ´N·|±·µÛ¥Õªáªáªº»È¤l¨Ó§ä½²±Ð±Â¤F! ¦³½Ð³¯ÀR«e½ú¦h«üÂISND5 |
|
|
·|û¡G³¯ÀR10141886 µoªí®É¶¡:2017/10/8 ¤W¤È 09:34:28²Ä 164 ½g¦^À³
|
¡u¥¢´¼¬ÛÃöªººë¯«²§±`¡vÅ¥°_¨Ó¹³S N D5 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/8 ¤W¤È 09:18:16²Ä 163 ½g¦^À³
|
ÁÂÁ ¦Ñ¥v¤j¤jªº«ü¥¿©M«ü¾É ¤pªº¯Ê¥FI´ºª¾ÃѦӦ³¶¾¨Ê°¨²Dªº»~ÂÕ ©¯±o¦Ñ¥v¤j¤jªº©ò¥¿¡A±o¦¬¥¿¥»²M·½ªº®ÄªG ¤Ó´Î¤F¡I¦³¤@Óºë³q¸g¥v¤l¶°¡A³ÕÄý¬ì¾Ç¸s½×ªº¦Ñ¥v¤j¤j§@§Y®Éªº±Ð¾É «ç¯à¤£·P¨ì·ÅÄÉ©M©¯ºÖ©O¡I «D±`·PÁ¦ѥv¤j¤jªº«üÂI ÁÂÁ¤j®a¡I |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/10/8 ¤W¤È 12:10:45²Ä 162 ½g¦^À³
|
²q·Q¤jô ¦Ñ¥v¥u¬O®ÑÂΡA¤Á¤Å¥[½Ñ¥ýª¾¤G¦r Acadia©xºô·s»D½Z¦³´£¨ì¡AFDAµ¹ªºBTD¬O¡u¥¢´¼¬ÛÃöºë¯«²§±`¡vªºBTD¡A¨Ã¤£©óªü¯÷®üÀq¥¢´¼¡A¡¨FDA has granted Breakthrough Therapy Designation to pimavanserin for dementia-related psychosis. Dementia-related psychosis includes psychosis in patients with Alzheimer¡¦s disease, dementia with Lewy bodies, Parkinson¡¦s disease dementia, vascular dementia, and frontotemporal dementia¡¨¡A©Ò¥HÀò±oBTDªºÁ{§É¸ê®Æ¤£¥u019study¡A¤]¥]¬A¤§«ePDPªº020study¡A¦]¬°020study¤¤25%¨ü¸ÕªÌ¤w¦³»´«×¥¢´¼¯gª¬¡AThe Breakthrough Therapy Designation for dementia-related psychosis was granted, in part, based on results of ACADIA¡¦s Phase II -019 Study with pimavanserin in Alzheimer¡¦s disease psychosis and results of the company¡¦s Phase III -020 Study with pimavanserin in Parkinson¡¦s disease psychosis. ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=2304720 ±z´£¨ì¡u¥BMini-Mental State Examination score ©M¦w¼¢¾¯²Õ¬Ûªñ¡A°²¦p¬O¥Î³oÓÁ{§É¼Æ¾Ú¦ÓÀòBTD¡K¡K¡v¡A¬Ý±z¤å·N¦n¹³¥H¬°pimavanserin¬Û¸û¹ï·Ó²ÕµL¼W¶iMMSE¤§¯à¡A«o¯à¥H¦¹¨ú±oBTD¡H¦^·Q¤@¤U¡u¥¢´¼¯g¤j·§¦³¤@¥bªº¯f¤H·|¦³¦X¨Öºë¯«¥¢±`¡A³o¬O¥Ø«e¨S¦³¥ô¦óÃĪ«¡A§Ú̥β{¦³ÃĪ«¥hªvÀø¬O§â¥¦¶V¥Î¶VÁV¡v¡A²{¦³ÃĪ««üªº³q±`¬O«D¨å«¬§Üºë¯«ÃĪ«¡A©Ò¥H¥h¦~Acadia¤½§G019study topline¬O³o¼Ë»¡ªº¡¨ Atypical antipsychotics have been associated with a statistically significant worsening of cognitive function in patients with Alzheimer¡¦s disease. In the -019 Study, over the course of 12 weeks of treatment, pimavanserin did not impair cognition as measured by the Mini-Mental State Examination (MMSE) score and was similar to placebo.¡¨¤½¥q¯S§O±j½Õpimavanserin¤£·|·l®`»{ª¾¥\¯à¡A¥Hªí©úÀu©óatypical antipsychotics¡C¹L¥h«Ü¦hÓPDPÁ{§É³ø§i¤]·|±j½Õ¡¨ did not impair cognition¡¨¡A¥]¬ASarcosine¤]¬O¡¨ Sarcosine temporally improved depression and neuropsychiatric symptoms in PD-D patients without exacerbating the motor or cognitive features |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/6 ¤U¤È 08:41:55²Ä 161 ½g¦^À³
|
¦A¨Ó¬Ý¬Ý liaw6575¤j¹ï¤ß®®²£«~½uªº³Ì·sµûªR http://liawbf.pixnet.net/blog/post/47564916-%E5%BF%83%E6%82%85%E7%94%A2%E5%93%81%E7%B7%9A%E7%9A%84%E5%88%97%E8%A1%A8%E6%AF%94%E8%BC%83 ÁÂÁÂliaw6575¤jªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/6 ¤U¤È 08:23:45²Ä 160 ½g¦^À³
|
¦Ñ¥v¤j¤j¬O¥ýª¾ µoªí±M¤å AcadiaªvÀøPDP¤À¨É(¤W)(¤U) http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-10-06&e=snoopychiang&t=.htm&j=2425&f=main&v=1 ªñ¨â¤ÑPimavanserin ´N¤SÀò±oAlzheimer¡¦s disease (AD) psychosis »â°ìªºBTD https://endpts.com/acadia-adopts-a-new-phiii-game-plan-for-breakthrough-med-dumps-alzheimers-phii/ ¦ý³ø¾É¤]ÂI¥XºÃ¼{ "On the plus side, FDA feedback awarding breakthrough designation and allowing for a single pivotal study is encouraging, especially with respect to how the agency views pimavanserin safety. Moreover, if the study succeeds, the addressable population could be very large, rendering how we currently model the ADP revenue oppty conservative. However, ACAD¡¦s ¡§basket¡¨ approach to this new ph3 may introduce additional challenges that are simply difficult to handicap: while the trial works to enrich the placebo-controlled portion for pimavanserin responders, we see the inclusion of such a heterogeneous population in a single pivotal as a risky strategy. µM¦Ó¤p§ÌÁÙ·d¤£²M·¡³oÓBTD¬O¥Î³oÓ¤G´ÁÁ{§É¥Ó½Ðªº¶Ü?!ÁÙ¬O¥t¦³¨ä¥L¸ÕÅç? "Promising Topline Results for Pimavanserin in AD " http://www.medscape.com/viewarticle/873624 " At week 6, patients taking pimavanserin had a 3.76-point improvement in the NPI-NH Psychosis score compared with a 1.93-point improvement for placebo, representing a statistically significant (P = .0451) comparative improvement. Baseline mean scores were 9.52 and 10.00 for the pimavanserin and placebo groups, respectively. Atypical antipsychotics have been associated with worsening of cognitive function in patients with AD. Over the course of 12 weeks of treatment in the current study, pimavanserin did not impair cognition as measured by the Mini-Mental State Examination score and was similar to placebo. On the secondary endpoint of mean change in NPI-NH Psychosis score at week 12, pimavanserin maintained the psychosis improvement seen at the week 6 primary endpoint. This, however, did not statistically separate from placebo." NPI-NH Psychosis score 6¶g®É©M¦w¼¢¾¯²Õ¦³ÅãµÛ®t²§ , ¦ý¦b12¶g®É«o¨S¦³ ¥BMini-Mental State Examination score ©M¦w¼¢¾¯²Õ¬Ûªñ °²¦p¬O¥Î³oÓÁ{§É¼Æ¾Ú¦ÓÀòBTD , §ó¥YÅãºë¯«¯«¸g¯e¯fÃĪ«ªº¯Ê¥F ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/10/1 ¤W¤È 09:20:04²Ä 159 ½g¦^À³
|
¦Ñ¥v¤j¤jªº±M¤å¤S¥XÀT¤F AcadiaªvÀøPDP¤À¨É(¤W) http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-09-30&e=snoopychiang&t=.htm&j=2424&f=main&v=1 ±M¤å¤¤±Ôz Acadia ªº Pimavanserin ¤@ÃÄ¥´³qÃö ¸ÓÃÄ 2014 ¦~¦b PDP (©¬ª÷´Ëºë¯«²§±`)»â°ìÀò BTD , 2016¦~¨ú±oÃÄÃÒ , ²{¦b Acadia Á`¥«È 46 »õ¬üª÷ ¦Ñ¥v¤j¤j¦b¤å¤¤¥ç»¡©ú sarcosine ¹ï PDP ªºÀø®Ä ¥B¦b³Ì«áµûz¹D Acadia ªº Pimavanserin ¤@ÃÄ¥´³qÃö «¥Ìªº SNG-12 Áö¿ð¥¼¤W°} ¦ý SND1 ªº¼ç¤O·|¤ñ¤£¤W Pimavanserin ¶Ü? ¥xÆW¸ê¥»¥«³õ«Ü¦³½ì , §ë¸êªB¤ÍºCºC«ä¦ÒÅo ÁÂÁ¦ѥv¤j¤jªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2017/9/28 ¤U¤È 09:59:12²Ä 158 ½g¦^À³
|
½²±Ð±Â¬O²Ä¤@¦ì¬ã¨sGyT-1 (SNG-12),¤]¬O²Ä¤@¦ì¥H¤HÅé¸ÕÅçÃÒ¹ê¨ä¼sªx¤§Àø®Ä¡C ¦ý¤p¤½¥q´N¬O¯Ê¿ú¡A¯Ê¤H¤~¡C |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2017/9/27 ¤U¤È 09:48:06²Ä 157 ½g¦^À³
|
Rapastinel ¤w¸g°µ§¹Phase II. ¤ß®®ªº SNG ¨t¦C«h©|¥¼±Ò°Ê¡C ²{¦b¥u¦³¸ê·½¥ý°µ SND ¨t¦CªºÃÄ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/9/27 ¤U¤È 03:25:43²Ä 156 ½g¦^À³
|
¦Ñ¥v¤j¤j¤Sµoªí·s§@ Rapastinel¡BSNG12»P««×¼~Æ{ http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-09-27&e=snoopychiang&t=.htm&j=2423&f=main&v=1 Rapastinel ¬O2016¦~¤¸¤ë®³¨ì BTD ÁÂÁ¦ѥv¤j¤jªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/9/25 ¤U¤È 05:07:28²Ä 155 ½g¦^À³
|
¦Ñ¥v¤j¤j¤S¥X·s½g³¹ ½²±Ð±Â½×¤å¤À¨É11---«Æ{©Mpartial agonist http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-09-25&e=snoopychiang&t=.htm&j=2422&f=main&v=1 ¹ï©ó¤pªº¨Ó»¡ ³o½g¯uªº¦nÃø®ø¤Æ ©Î³\¸Ó¦Y¨Ç®ø¤Æ¾¯ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/9/25 ¤W¤È 07:41:43²Ä 154 ½g¦^À³
|
º¥ý¡A¦Vliaw6575¤jPÁ¤ÎPºp PÁ¨ӦۤÀ¨É³o»ò´Îªº¤ÀªR¡APºp«h¦]¤pªº¤£§i¦Ó¤Þ¥Î¡A½Ðì½Ì SPCDªº¼ÒÀÀ¤§®È ¬Oliaw6575¤j¤Þ¥Î¾ÇªÌFava(2015) ªº¾ã²z²Îp µo²{¡A¦b±Æ°£¦w¼¢¾¯®ÄÀ³¤§¤U¡A¨â²ÕÀø®Ä«ü¼Ðªº´ú¶q§¡´î¤Ö¡A¥B¦w¼¢¾¯²Õ´î¤Öªº¤ñ¨Ò¤j©ó¹êÅç²Õ ¦]¦¹¡Aliaw6575¤j¹B¥Î²Îp¤ÀªR ±À±o¡A¥Ñ©óSPCD²Ä¤G¶¥¬q¤j´T°§C¦w¼¢¾¯®ÄÀ³ªº¤zÂZ ¦]¦¹¡A¥u»Ý¸û¤Öªº¼Ë¥»¤H¼Æ¡A´N¯à¾Ö¦³§ó¤pªº p È©M§ó°ªªº®ÄªG¶q¡A¨Ï¨â²Õ®t²§§óÅãµÛ ¦ýliaw6575¤j¤]´£¿ô¡A±À²z¥i¯à¦]¦³±ø¥ó³]¡A¥i¯à¦³»~¡A½Ð¤j®a©ú¹î§PÂ_ ¦A¦¸ÁÂÁÂliaw6575¤jªººë±m¸ÑªR ¸Ô½Ð°Ñ¨ä¤j§@ http://liawbf.pixnet.net/blog/post/47544627 ÁÂÁÂliaw6575¤j¡A¤] ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/9/20 ¤U¤È 07:57:40²Ä 153 ½g¦^À³
|
¦Ñ¥v¤j¤j³Ì·s¤j§@ Sage-547²£«á¼~Æ{³ø§i http://mychannel.pchome.com.tw/channel/class/class_paper_open.htm?d=2017-09-20&e=snoopychiang&t=.htm&j=2421&f=main&v=1 ¦Ñ¥v¤j¤j»¡ " §^«Dõ§O , ÃѦ¨¦N«ä¦½¨¬¨o " ¤p§Ì¸ò¦b«á±»¡ §^«D½²±Ð±Â , ÃѤ߮®¨¬¨o! «¢«¢! ¨£¯º¤F ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/9/15 ¤U¤È 03:04:17²Ä 152 ½g¦^À³
|
±M§Q¦WºÙ ¼W±j¯«¸gÃĤèÀø®Äªº¤s±ù»Ä»Pf¥Ò»Ä¤Î¨äl¥Íª« SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL http://twpat-simple.tipo.gov.tw/tipotwoc/tipotwkm?002F96220009070100000000000100A00000003E000000000^__ ¦b¬Y¨Ç¹ê¬I¡A¥»µo©ú¯A¤Î¨ìµo²{¥ô¦ó¨âөΤTÓ¨Ó¦Û¡G(i) NMDA(N-¥Ò°ò-D-¤Ñ¥V®ò»Ä)¨üÅé¼W±j¾¯¡A©M/©Î(ii)¥Ì®ò»Ä¦AÄá¨ú§í»s¾¯¡A©M/©Î(iii) D-®ò°ò»Ä®ñ¤Æ酶§í»s¾¯¡A¹ï²{¦³©Î¬O°ª·ÀIªº¯«¸gºë¯«¯fªº¤H¡A¤ñ¥H«e¤wª¾ªº³æÃĪvÀø¤èªk´£¨Ñ§ó¤jªº®Ä¯à¡A¤j¤j´î¤Ö©Î®ø°£¯e¯fªº¯gª¬¡C¦b¤£¦Pªº¹ê¬I¨Ò¤¤¡A¥»µo©úÁÙ´£¨Ñ¤F¨Ï¥Î³oºØ²Õ¦X°t¤è¡FÃIJz¦¨¤À¥]§t¥ô¦ó¨âөΤTÓÃľ¯ªºµ²¦X©M¤èªk¡C ¤£©ó¤@Ó¯S©wªº²z½×¡A®ò°ò»Ä®ñ¤Æ酶§í»s¾¯(DAAOI)¥i¥H¼W±jNMDA¨üÅé¿E°Ê¾¯(agonist)¦pD-µ·®ò»Ä©MD-¤þ®ò»Äªº¿@«×.µo©úªÌ¨Ã¤wÅã¥Ü¥X¹ïºë¯«¤Àµõ¯g±wªÌ¡A©M¨ä¥L¯e¯f¬O¦³¯qªº¡A¥¦¥i¥HÀ°§U¦UºØ¦U¼Ë»{ª¾¥\¯à»Ùê©M¦³¨ä¥Lºë¯«©Î¦æ¬°¯gª¬ªº±wªÌ¡C³oºØ¦X¨ÖªvÀø¤èªk¥i¥H´£¤ÉNMDA¨üÅé¡A©M/©Î¯«¸gÃĪ«§@¥Î¡A¨Ã¥B¤ñ³æ¤@¥ÎÃĮĪG§ó¨Î ¡yµ¹¤©¤è¦¡»P¾¯«¬¡z ¦b³\¦hªº±¡ªp¤U¡AÃĪ«²Õ¦¨ªºµ¹¤©¡A¥i¥H¥Ñ¥ô¦ó¤@ºØ©Î¦hºØ³~®|ªº²Õ¦X¡A¦p¸g¥Ñ¤f¡A¸gÀR¯ß¡A¸gÂH½¤¡A¸gªÍ¡A¸g¥Ö¡A¸g»ó¡A¸g²´¡A¸g¸|¡A¸g¦Þ¤U¡A¸g¸¡µÄª`®g¡A¸g¯á´Õª`¤J¡A¸g¦Ù¦×ª`®g¡A©Îªø´Á¾¯«¬¨ÓªvÀøÓ®×(¨Ò¦p¯f±w)¡C¦b¤@¨Ç¯S©wªº±¡ªp¤U¡A¸g¤fµ¹¤©ªº©TÅéºî¦X¾¯¥i¥H¥]§t¦X¾Aªº¸üÅé©Î»²®Æ¡A¦p¦p¥É¦Ì¾ý¯»¡A©ú½¦(gelatin),¨Å¿}¡A¨ëºi(acacia)¡A½©¿}¡A·L´¹ÅÖºû¯À¡A°ªÀ¤g(Kaolin)¡A¥ÌÅS¾J¡AÁC»Ä²B¶t¡AºÒ»Ä¶t¡A´â¤Æ¶u¡A¯×ªÕ¡A½ÅĦ»Ä¡A©Î±±¨îºC©ÊÄÀ©ñªº¦¨¤À¡C¤À¸Ñªº¦¨¤À¥i¨Ï¥Î¥]¬A¡A¦ý¤£©ó¡A·L´¹ÅÖºû¯À¡A¥É¦Ì¾ý¯»¡A¾ý¯»¶u¤A¾J»Ä©M®üĦ»Ä¡C¥i¥Îªº¤ù¾¯ÖߦX¾¯¥i¥]¬A¡A¦ý¤£¨ü©ó¡A¨ëºi(acacia)¡A·L´¹ÅÖºû¯À¡Aßn¥Ò°òÅÖºû¯À¶u(sodium carboxymethylcellulose)¡A»E¤A²mým«£ÖJà¬(»Eºûà¬)(polyvinylpyrrolidone(Povidone))¡Aßm¤þ°ò¥Ò°òÅÖºû¯À(hydroxypropyl methylcellulose)¡A½©¿}¡A¾ý¯»¡A»P¤A°òÅÖºû¯À(ethylcellulose)¡C ¦b³\¦h¨ãÅ骺±¡ªp¤U¡A¸g¤fªº³~®|ªº²GÅ龯«¬¡A¥]§t¤ô¾¯«¬©Î¨ä¥L²GÅ龯«¬¡A¥i¥H¥]¬A·»²G¡A¨Å¾¯¡A¿}¼ß¡A¤Î¥]§tÃÄ°s¡A»P¬¡©Êª«½è¡AÀã¼íª«½è¡A²¢¨ý¾¯¡AµÛ¦â¾¯¡A»P½Õ¨ý¾¯¡C¦hºØ²GÅé¤Î¯»¥½¡A¥i¥H¸g¨å«¬ªº¤è¦¡»s³Æ¦¨¥i¸g¥ÑªÍ³¡§l¤Jªº¾¯«¬¨ÓªvÀø¯f¤H¡C ¦b¤@¨Ç¯S©wªº±¡ªp¤U¡Aª`®g¾¯«¬¥i¥H¥]§t¦hºØ¸üÅé¦p´Óª«ªo¡A¤G¥Ò°ò¤A酰Ói(dimethylacetamide)¡A¤G¥Ò°ò¥Ò酰Ói(dimethylformamide)¡A¨Å»Ä¤Aà(ethyl lactate)¡AºÒ»Ä¤Aà(ethyl carbonate)¡A¦××^çM»Ä²§¤þà(isopropyl myristate)¡A¤A¾J¡A¦h¤¸¾J(polyols),(¥Ìªo¡A¤þ¤G¾J¡A»E¤A¤G¾J²GÅé¡A»P¨ä¥LÃþ¦üªºª«½è(glycerol¡Apropylene glycol¡Aliquid polyethylene,glycol and the like)¡C¸gÀR¯ß«¬ª`®g¡Aºî¦X¾¯¥i¥Hºwª`¤è¦¡µ¹¤©¡Aª`®gºî¦X¾¯¥]§t¬¡©Êª«½è©M¥Í²z¤W¥i±µ¨üªº½á§Î¾¯ªºª`¤J¡C¥i³Qª`¤Jªº½á§Î¾¯¥i¥]¬A¡A¨Ò¦p5%¸²µå¿}¡A0.9%¥Í²z¹ÆQ¤ô¡AªL®æ¤ó·»²G©Î¨ä¥L¦X¾Aªº»²®Æ¡C¦Ü©ó¸g¦Ù¦×ª`®gªº¾¯«¬¡A¬O¤@ÓµLµßºî¦X¾¯¡A¦s¦b©ó¥i·»©ÊÆQªº«¬ºA¡A¥i¥H³Q·»¸Ñ¨Ã»P¤@ºØÃĪ«½á§Î¾¯¦p¥iª`®g¤ô¡A0.9%¥Í²z¹ÆQ¤ô¡A©Î5%¸²µå¿}¡A©Îªø´Áª`®g¾¯«¬(¨Ò¦p¬Ñ»Ä(decanoate)¡A´ÄÃq»Ä(palmitate)¡A¤Q¤@²m»Ä(undecylenic)¡A©°»Ä(enanthate)),¥i¥H·»©ó»ªo¤@°_µ¹¤©¡C¥t¥~¡AÃĪ«ºî¦XÅé¤]¥i¥H»s³y¦¨¤f»¿}¡A´Î´Î¿}©Î¨ä¥LÃþ¦üªº¾¯«¬¡C ¦b¦UºØ²Õ¦X°t¤è³£¥J²Ó³Q¦Ò¼{¡C¦b¬Y¨Ç¹ê¬I°t¤è¡A¥H¤U¤TÃþ¬¡©ÊÃľ¯¦Ü¤Ö¥]§t¨âÓ¡G(i) NMDA(N-¥Ò°ò-D-¤Ñ¥VÓi»Ä)«P¶i¾¯¡A©M/©Î(ii)¥ÌÓi»Ä¦^¦¬§í¨î¾¯¡A©M/©Î(iii)D-Ói°ò»Ä®ñ¤Æ酶§í¨î¾¯(DAAOI)¡C¦b¬Y¨Ç¹ê¬I¤¤¡A©Ò¦³¤TÓ¬¡©ÊÃľ¯¬O¦s¦b©ó¤@Ó¦P¤@ªº°t¤è¡C¦b²Õ¦X°t¤è¤¤¡A¤£¦PÃľ¯²Õ¥ó¥i¥H³Q¤ÀÂ÷¡A¨Ò¦p¡A¦b¤£¦Pªº¤ù¼h¡A¦b¤£¦Pªº·L²y/·L½¦Ån¡Aµ¥µ¥¡C¦b¬Y¨Ç¹ê¬I¡A¨âÓ¥H¤Wªº¬¡©ÊÃľ¯²V¦X©M/©ÎÄa¯B¦b¤@°_¡A¨Ò¦p¡A¦b¤@Ó³æ¤@ªº½á§Î¾¯¤¤¡C³q±`¨C¤@Ó¤£¦Pªº¬¡©ÊÃľ¯³£±N´£¨Ñ¦³®ÄªvÀø¾¯¶q¡C ¡y½Æ¦X»s¾¯¡z µL½×¦P®É©Î«ö·Ó¶¶§Ç¡A¦b¬Y¨Ç¹ê¬I¤¤¡A¦¹³B©Ò´yzªºª«½è(¨Ò¦p¡Af¥Ò»Ä¡Af¥Ò»ÄÆQ¡A©Î¨äl¥Íª«¡A©M/©Î¤s±ù»Ä¡A¤s±ù»ÄÆQ¡A©Î¨äl¥Íª«)©M¯«¸gÃĪ«(¨Ò¦p¡A¦p¥»¤å©Òz)¥i¤À§O©Î¦P®Éµ¹¤©¡C µM¦Ó¦b¬Y¨Ç¹ê¬I¤¤¡A³o¨Çª«½è¡A¦p¡Gf¥Ò»Ä¡Af¥Ò»ÄÆQ¡Af¥Ò»Äà¡Af¥Ò»Ä¡A©Î¨ä¥Ll¥Íª«¡A¤Î/©Î¤s±ù»Ä¡A¤s±ù»ÄÆQ¡A¤s±ù»Äà¡A¤s±ù»Ä©Î¨ä¥Ll¥Íª«¡A©M¯«¸gÃĪ«(¦p§Ü¼~Æ{ÃÄ¡A§Üºë¯«¯fÃÄ¡Aºë¯«¿³¾ÄÃÄ¡A±¡ºüéw¾¯¡A§ÜµJ¼{¡A¹L°Ê¯gªvÀø¡A¦Ñ¦~è§b¯gªvÀø¡A©M¨ä¥Lºë¯«ÃĪ«µ¥)¬O¥H²Õ¦X°t¤è´£¨Ñªº¡A³z¹L¦UºØ¤è¦¡¡A¥]¬A¡A¦ý¤£©ó¡A¤fªAµ¹ÃÄ¡Aª½¸zµ¹ÃÄ¡Aª`®g¡A¸g¥Ö½§µ¹ÃÄ¡A¥Ö¤Uª`®g¡A»óµÄµ¹Ãĵ¥¡C ¡y®M¥ó(kit)¡z ¦b¥t¤@Ó¹ê¬I¤¤¡A¥»µo©ú´£¨Ñ®M¥ó¨ÓªvÀø¯«¸gºë¯«¯e¯f(¨Ò¦p¡A´î»´¤@өΦhÓ¯gª¬).µL½×¬O³æ¿Wªº°t¤è©Î§@¬°¤@Ó³æ¤@ªº¡§²Õ¦X¡§ªº°t¤è¡A³oÓ®M¥ó³Ì¦n¥]§t¤@өΦhÓ®e¾¹¡A©Î®e¾¹¤¤§t¦³¦b¦¹´yzªº¬¡©ÊÃľ¯ªº²Õ¦X¡C¦¹ª«½è¥i¥H´£¨Ñ¤@Ó³æ¦ì¾¯«¬(¦p®ê¾¯¡A¤ù¾¯¡A¾ò¶ê |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/9/13 ¤U¤È 07:17:27²Ä 151 ½g¦^À³
|
¤¤¬ã°|½²¥ß¼z°|¤hªº¬ã¨s ½²¥ß¼z¹Î¶¤¦³±æ§ä¦^±wªÌ¡§¥¢¥hªº°O¾Ð¡¨ (Blocking a key enzyme may reverse memory loss) http://med.sina.com/article_detail_103_1_33500.html Ãö¤ß¤@¤U ¥i¯à¦¨¬°¥¼¨ÓÄvª§ªº¹ï¤â ¥Ø«e¦s¦bªºHDAC§í¨î¾¯³q±`¦b§í¨îHDAC2ªº¦P®ÉÁÙ·|§í¨î¨ä¥¦HDACs¡A¥]¬A»PHDAC2 «D±`¬Û¦üªºHDAC1¡A³o·|¾ÉP¬r°Æ§@¥Î¡A¦]¬°HDAC1¦b²ÓM¼W¥Í¡A¯S§O¬O¥Õ²ÓM©M¬õ²ÓM¼W¥Í¤è±°_¨ì«n§@¥Î ...... ¸g¹êÅçµ²ªGªí©ú¡AY¹v¦VHDAC2ªºC¥½ºÝ¥i¯à¦¨¬°¤@ºØ±M¤@§í¨îHDAC2»PSP3µ²¦X¡A±q¦ÓªvÀøAD¾ÉPªº°O¾Ð¯Ê³´ªºµ¦²¤¡C ...... ¦ýHDAC2 C¥½ºÝ¤ù¬q¤´µM¥]§t¤F90Ó¥ª¥kªº®ò°ò»Ä¡A³oÓ³J¥Õ¤ù¬q§@¬°ÃĪ«¨Ó»¡ÁÙ¬O¤Ó¤j¤F¡C ¦]¦¹¬ã¨s¤Hû¤U¤@¨Bªº¬ã¨s¤è¦¡¬O¦A¶}µo¯à°÷°_¨ì¦P¼Ë®ÄªGªº§ó¤p¤ù¬q¡A©ÎªÌµo²{¤p¤À¤l¤Æ¦Xª«¯à°÷ªýÂ_HDAC2»PSP3¤§¶¡ªº¬Û¤¬§@¥Î¡C ³o©Î³\¦³±æ¯à±a¨Ó§ïµ½ªü¯÷®üÀq¯f±wªÌ¯gª¬ªº·sÃÄ¡C ¸g¥Ñ³o¬q±Ôz ¥»¬ã¨sÂ÷¦¨¼ô©Î©|»Ý®É¤é ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/9/8 ¤W¤È 08:13:10²Ä 150 ½g¦^À³
|
¹Ï¸Ñ SPCD SPCD for Trials with High Placebo Response by Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill https://www.turing-gateway.cam.ac.uk/sites/default/files/asset/doc/1606/Anastasia%20Ivanova.pdf |
|
|
|